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Résumé 
La prévalence de l’obésité, du diabète de type 2, et du syndrome métabolique, sont à la 
hausse chez les Cris d’Eeyou Istchee (CEI-Nord du Québec). Ces problèmes sont aggravés 
par leur diète non traditionnelle, leur sédentarité, ainsi que par une résistance culturelle aux 
produits pharmaceutiques. Afin de développer des traitements antidiabétiques 
culturellement adaptés, notre équipe a effectué une enquête ethnobotanique qui a identifié 
17 plantes provenant de la pharmacopée traditionnelle des CEI. À partir des études de 
criblage effectuées in vitro, deux plantes parmi les 17  ont attiré notre attention.   Populus 
balsamifera L. (Salicaceae) pour ses propriétés anti-obésité et  Larix laricina K. Koch 
(Pinaceae) pour ses propriétés antidiabétiques. P. balsamifera et son composé actif 
salicortin ont inhibé l’accumulation de triglycérides durant l’adipogénèse dans les 
adipocytes 3T3-L1. L. laricina a augmenté le transport de glucose et l’activation de 
l’AMPK dans les cellules musculaires C2C12, l’adipogénèse dans les 3T3-L1 et a 
démontré un fort potentiel découpleur (propriété anti-obésité). 
 Les objectifs de cette thèse sont d'évaluer les potentiels anti-obésité et antidiabétique et 
d’élucider les mécanismes d'action de P. balsamifera, salicortin, et L. laricina chez la  
souris C57BL/6 rendue obèse par une diète riche en gras (HFD). Les souris ont été 
soumises pendant huit (étude préventive) ou seize semaines (étude traitement) à une HFD, 
ou à une HFD dans laquelle P. balsamifera, salicortin, ou L. laricina a été incorporé soit 
dès le départ (prévention), ou dans les 8 dernières des 16 semaines d'administration de HFD 
(traitement).  
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Les résultats démontrent que P. balsamifera (dans les deux études) et salicortin (évalué 
dans l’étude traitement) diminuent: le poids corporel, le gras rétropéritonéal, la sévérité de 
la stéatose et l’accumulation de triglycérides hépatique (ERK impliqué), les niveaux de 
glycémie et d'insuline, et le ratio  leptine/adiponectine. Dans les deux études, P. 
balsamifera a  significativement réduit la consommation de nourriture mais cet effet coupe-
faim nécessite d’être approfondi. Dans l'étude préventive, P. balsamifera a augmenté la 
dépense énergétique (hausse de la température à la surface de la peau  et de l’activation de 
la protéine découplante-1; UCP-1). Les voies de signalisation activées par P. balsamifera et  
par salicortin (de façon plus modeste) sont impliquées dans:  la production de glucose 
hépatique (Akt), l’expression de Glut4 dans le muscle squelettique, la captation du glucose 
et du métabolisme des lipides (Akt dans le tissu adipeux), la différenciation des adipocytes 
(ERK et PPAR!), l’inflammation dans le foie (IKK!"), et l'oxydation des acides gras dans 
le muscle, le foie, ou le tissu adipeux (PPAR" et CPT-1). D’autre part, L. laricina a 
également diminué les niveaux  de glycémie et d’insuline, le ratio  leptine/adiponectine, le 
gras rétropéritonéal et le poids corporel. Ces effets ont été observés  en conjonction avec 
une augmentation  de la dépense énergétique: hausse de température à la surface de la peau 
(prévention) et  amélioration de la fonction mitochondriale et de la synthèse d'ATP 
(traitement). 
En conclusion, l’utilisation de P. balsamifera, salicortin et L. laricina comme des 
traitements alternatifs et culturellement adaptés aux CEI représente une contribution 
importante dans la prévention et le traitement de l’obésité et du diabète. 
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Mots-clés : anti-obésité, antidiabétique, adipokines, souris C57BL/6, Populus balsamifera 
L. (Salicaceae), Larix laricina K. Koch (Pinaceae), médecine traditionnelle des 
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Abstract 
The prevalence of obesity, insulin resistance, and the metabolic syndrome is 
increasing among the Cree of Eeyou Istchee (CEI - Northern Quebec). Non-traditional diet 
and sedentary lifestyle along with cultural disconnect of modern type 2 diabetes (T2D) 
therapies are involved. In order to establish culturally adapted antidiabetic treatments, our 
research team conducted an ethnobotanical survey, where 17 plants were identified from 
the CEI traditional pharmacopoeia. Based on data obtained from in vitro screening studies, 
two plant species out of 17 were of particular interest for their properties as antiobesity, 
namely Populus balsamifera L. (Salicaceae), and antidiabetic agents, namely Larix laricina 
K. Koch (Pinaceae). P. balsamifera and its active salicortin inhibited triglyceride 
accumulation during adipogenesis in 3T3-L1 adipocytes. L. laricina increased glucose 
uptake and AMPK activation in C2C12 myotubes, adipogenesis in the 3T3-L1 adipocyte 
cell line, and was observed as one of the strongest uncouplers, severely disrupting 
mitochondrial function (increasing fuel consumption/metabolic rate; antiobesity property).  
 The purpose of this PhD thesis is to evaluate the antiobesity and antidiabetic 
potential of P. balsamifera, salicortin, and L. laricina, in an in vivo model of diet-induced 
obese (DIO) C57BL/6 mice, as well as to investigate their possible mechanisms of action. 
Mice were subjected for eight (prevention study) or sixteen weeks (treatment study) to a 
high fat diet (HFD), or HFD to which P. balsamifera, salicortin, or L. laricina were 
incorporated either at onset (prevention), or in the last 8 of the 16 weeks of administration 
of the HFD (treatment). The results showed that P. balsamifera (in either study) and 
salicortin (incorporated in HFD only in treatment study) decreased the weight of whole 
  
vii
 
body, retroperitoneal fat pad, reduced the severity of hepatic macrovesicular steatosis and 
triglyceride accumulation (ERK pathway implicated). They also decreased glycemia and 
improved insulin sensitivity by diminishing insulin levels, and altering adipokine secretion 
whereby reducing the leptin/adiponectin ratio. In both studies, P. balsamifera significantly 
reduced food intake. This appetite-reducing effect needs to be investigated further. In the 
prevention study this was accompanied by an increase in energy expenditure (increase in 
skin temperature and tends to increase expression of uncoupling protein-1; UCP-1). The 
signaling pathways activated by P. balsamifera and slightly by salicortin are implicated in 
either controlling hepatic glucose output (Akt), skeletal muscle Glut4 expression, glucose 
uptake and lipid metabolism in adipose tissue (Akt), adipocyte differentiation (ERK 
pathway and PPAR!), decreasing the hepatic inflammatory state (IKK"#), and increasing 
muscular, hepatic, or adipose tissue fatty acid oxidation (PPAR", CPT-1). As for L. 
laricina, it effectively decreased glycemia levels, insulin levels and the leptin/adiponectin 
ratio, improved insulin sensitivity and slightly decreased abdominal fat pad and body 
weights. This occurred in conjunction with increased energy expenditure as demonstrated 
by elevated skin temperature in the prevention study, and tendency to improve 
mitochondrial function and ATP synthesis in the treatment protocol.  
In conclusion, these results represent a major contribution, identifying P. 
balsamifera, salicortin, and L. laricina, as promising alternative, and culturally adapted 
therapies for the prevention and treatment care of obesity and diabetes among the CEI.  
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Chapter 1: Introduction 
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1. Introduction 
Over the last few decades, obesity and type 2 diabetes (T2D) have been increasing at an 
alarming rate, becoming pandemic health problems.  The prevalence of obesity has more than 
tripled and currently affects more than 350 million people worldwide (WHO 2007a). As for T2D, 
it is projected that by 2030, there will be 366 million people affected on a worldwide scale, 
among which 3 million Canadians (WHO 2004a; Wild et al. 2004; WHO 2007b).   
Both these conditions are widespread among Canadian aboriginals, with obesity being 
present among 36% of the population as compared to 25% in non-aboriginal Canadians (PHAC 
2009; PHAC 2011b), and the incidence of T2D being three to five times higher than the rest of 
the Canadian population (Brassard et al. 1993; Légaré 2004a; Légaré 2004b; Kuzmina 2004 ). 
The incidence and prevalence rates of these diseases, as well as the complications that arise from 
them, are consistently higher in aboriginal women than men (Kuzmina 2009).   
The Cree of Eeyou Istchee (CEI) of the eastern James Bay area of Quebec, are a 
subpopulation (13 500) of the greater Cree Nation of Canada (72 000). They are spread out into 9 
communities across northern Quebec (Brassard et al. 1993). The CEI are particularly affected by 
T2D with an age-adjusted prevalence of 29% in 2009 among adults (>20 years) (Dannenbaum 
2008; Kuzmina 2009). The reasons behind these alarming incidences are their sedentary lifestyle, 
non-traditional diet, their difficulty of compliance to modern type 2 diabetes treatments, and 
genetic predisposition (Boston 1997; Young 2000; Hegele 2001). The Cree women also suffer 
from gestational diabetes with a rate that is twice as high as the rest of the North American 
population (Rodrigues 1999). This may be explained by excessive weight gain observed in young 
Cree mothers during pregnancy, and also by more aggressive screening for T2D during 
pregnancy (Kuzmina 2009). It is noteworthy that women with pre-existing T2D or gestational 
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diabetes have a much higher risk of developing maternal and neonatal complications (Kuzmina 
2009). Their children also have an increased predisposition to developing obesity and diabetes at 
a young age (Kuzmina 2009).  
In Canada, the increase in prevalence of obesity and T2D will create a major clinical and 
economical burden in the future. The estimated cost of obesity is $4.3 billion and this figure is 
said to be greatly underestimated since it does not include the cost of people who are overweight 
but not obese, and includes only adult obesity (PHAC 2009; PHAC 2011b). Concerning T2D, its 
economic burden has nearly doubled since 2000, reaching approximately $12.2 billion in 2010, 
and it is expected to rise by another $4.7 billion by 2020 (CDA 2009).  These numbers highlight 
the need to implement effective programs targeting the prevention of obesity and T2D, such as 
reinforcing existing clinical prevention practices involving, for instance, dietary intervention, 
reinforcing educational programs, and targeting physical inactivity (Young 2000; Kuzmina 
2009).  
Despite the availability of conventional T2D treatments and intervention programs, 
western medicine is failing to improve the health of aboriginal communities such as the CEI 
(NWAC 2007), and this may be due to cultural inappropriateness. Wherefrom emanates the need 
to find effective prevention and treatment options, that such populations can identify to in terms 
of culture and lifestyle (Boston 1997; Gray-Donald 2000; Young 2000; Légaré 2004b; Légaré 
2004a).  
For centuries prior to European colonization, the aboriginal population relied on 
traditional healing, a knowledge that was verbally taught and passed on from generation to 
generation.  Although with time some of this knowledge was lost, anthropologists nevertheless 
were able to document the use and administration of more than 500 plant species belonging to 
aboriginal medicine (Turner 1985; Blouin 2003). The plants were administered either alone or in 
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combination, and varied from herbal teas, to preparations to be chewed and swallowed, to 
poultices, or to inhaled vapors (Turner 1985).  
In order to respond to their primary health care needs, the CEI are now turning to their 
Elders and healers for treatments stemming from their vast traditional pharmacopoeia, reinforcing 
the importance to make these treatments more accessible and acceptable by proving their healing 
properties. Due to the high prevalence of T2D present among the CEI, our research team in 
collaboration with six CEI communities: Mistissini, Whapmagoostui, Nemaska, Waskaganish, 
Wemindji, and Oujé-Bougoumou conducted ethnobotanical surveys, based on 15 symptoms 
associated with T2D (Leduc et al. 2006; Fraser et al. 2007)(Figure 1).  
 
Figure 1: Map of Quebec showing the Cree communities that participated in the ethnobotanical 
study (adapted from: (AINC 2009)). 
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Over 30 plant species were identified. They were then classified and ranked by frequency 
of citation, number of symptoms, and the quality of symptoms (Leduc et al. 2006). A subset of 17 
of the more significant plants were then screened in vitro for their antidiabetic activity, revealing 
that roughly half of them possessed significant and varied antidiabetic activities (Spoor et al. 
2006; Harbilas et al. 2009). These studies also suggested, based on the in vitro mechanisms of 
action, that Populus balsamifera and its identified active salicortin (Harbilas et al. 2009; 
Martineau 2010a; Martineau 2010b), along with Larix laricina (Spoor et al. 2006; Martineau et 
al. 2010) possess antiobesity and antidiabetic potential.  
The purpose of this PhD thesis is to evaluate the antiobesity and antidiabetic potential of 
Populus balsamifera, its active salicortin, as well as that of Larix laricina in an in vivo model of 
diet-induced obesity, as well as to investigate their possible mechanisms of action. 
 
1.1 Energy homeostasis  
Energy homeostasis is maintained when energy intake equates energy output. Food 
consumption provides the body with all of the necessary macronutrients, such as carbohydrates, 
lipids, and proteins, and with most micronutrients such as minerals and vitamins (Woods 1998). 
Carbohydrates and lipids are the main source of energy/fuel for the body (Da Poian 2010). They 
are metabolized through anabolic (gluconeogenesis, glycogenesis, lipogenesis) and catabolic 
processes (glycolysis, glycogenolysis, lipolysis) (Dean 2004).  Lipids are considered a compact 
energy store (Ophardt 2003b), whereas proteins are mainly used as tissue building and 
maintenance, as well as building blocks for hormones and enzymes that regulate metabolism, 
support immune system, and other body functions (IOC 2010; Hermann). Proteins are used very 
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little for energy supply when caloric intake is sufficient (IOC 2010; Hermann). When 
metabolized, each one provides a different amount of food energy per gram of food consumed: 
lipids 9 kcal/g, carbohydrates 4 kcal/g, and proteins 4 kcal/g (Da Poian 2010; Insel 2011). 
Creating any positive imbalance between energy intake and output can eventually lead to obesity 
and T2D. 
 
1.2 Glucose homeostasis  
Glucose is metabolized through aerobic or anaerobic respiration yielding energy sources 
mainly in the form of adenosine triphosphate (ATP) (Widmaier 2004; Salway 2006). It is 
considered the key source of energy for the body, and especially for the brain (Fairclough and 
Houston 2004; Gailliot 2007; Gailliot and Baumeister 2007; Masicampo and Baumeister 2008).  
The body needs to maintain blood glucose within a narrow range, since either high  
(hyperglycemia) or low (hypoglycemia) levels of blood glucose lead to complications. The 
normal range of blood glucose is between 4 and 7 mmol/L fasting and below 11 mmol/L after 
having eaten. If a patient is consistently at a fasting blood glucose above 7 mmol/L, or above 11 
mmol/L after a meal, they are considered hyperglycemic (ADA 2006). In the long run 
hyperglycemia leads to the development of insulin resistance and T2D, and to the many 
secondary complications arising from T2D such as retinopathy, nephropathy, and peripheral 
nerve damage, just to name a few (Kumar 2003). On the other hand, if blood glucose levels are 
consistently below 4 mmol/L, they are considered hypoglycemic. Symptoms of hypoglycemia 
include lethargy, impaired mental functioning, irritability, shaking, weakness, loss of 
consciousness, and may even lead to brain damage (de Courten-Myers et al. 2000; NIDDK 
2008a; NIDDK 2008b). Tight regulation between intestinal absorption of glucose, disposal into 
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peripheral tissues, and glucose production by the liver, as well as catabolic and anabolic 
hormones are involved in glucose homeostasis. Catabolic hormones such as glucagon, cortisol 
and catecholamine are involved in increasing blood glucose levels, whereas insulin (discussed in 
detail in section 1.4), an anabolic hormone, is involved in decreasing blood glucose.  Glucagon is 
a pancreatic hormone released from alpha-cells of the islets of Langerhans in response to low 
blood glucose levels, or increased levels of catecholamines (epinephrine and norepinephrine). Its 
biological functions are antagonistic to those initiated by insulin. For example, insulin promotes 
glycolysis or glycogenesis, whereas glucagon once it binds to its receptors in the liver initiates 
gluconeogenic and glycogenolytic pathways, in order to promote glucose release into the 
bloodstream.   
 
1.2.1 Glycolysis 
This metabolic pathway consists in the conversion of glucose into pyruvate, in the process 
forming high-energy compounds such as ATP and nicotinamide adenine dinucleotide plus 
hydrogen (NADH) (Figure 2). It consists of two phases: a preparatory phase, where ATP is 
consumed and a pay-off phase where ATP is formed (Berg 2002; Nelson 2004). Three key 
enzymes regulate it: hexokinase or glucokinase, phosphofructokinase, and pyruvate kinase. 
Hexokinase converts glucose into glucose-6-phosphate (G6P). This step is the first step in 
glycolysis or glycogenesis. Glucokinase belongs to the family of hexokinases, and is found 
primarily in the liver, but also in the pancreas, gut and brain (Efanov et al. 2005).  Glucokinase 
has a lower affinity to glucose as compared to other hexokinases, thus enabling it to respond to 
high concentrations of glucose present after a meal, and favoring glycogen formation (Voet 
2004). At low glucose concentrations, the liver (low affinity glucokinases) does not compete with 
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other tissues, such as the brain (high affinity hexokinases) for critically dependent glucose supply 
(Voet 2004). When there is ample glucose available, after it has been converted to glycogen, the 
remainder gets converted into triglycerides (TG), and is exported and stored in adipose tissue 
(Voet 2004). G6P is isomerized to fructose-6-phosphate (F6P) by phosphoglucose isomerase, 
whereas phosphofructokinase converts F6P into fructose-1,6-biphosphate, which eventually leads 
to the formation of phosphoenolpyruvate (PEP)(Voet 2004). Pyruvate kinase then converts PEP 
into pyruvate (Voet 2004).  
 
Figure 2: Summary of the glycolytic pathway described in section 1.2.1, and of the 
gluconeogenesis pathway described in section 1.2.4 (adapted from:(Garrett 2010)).  
 
Pyruvate kinase 
 
 
 
Glucokinase/Hexokinase 
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Once pyruvate is formed, and if oxygen is present, the process continues into aerobic respiration, 
where pyruvate is further metabolized to acetyl-CoA (common breakdown product of 
carbohydrate, fatty acid, and amino acid) and CO2 within the mitochondria in a process called 
oxidative decarboxylation, facilitated by pyruvate dehydrogenase (Voet 2004) (Figure 3).  
 
Figure 3: Pyruvate metabolized to acetyl CoA, which then enters CAC (adapted from:(Garrett 
2010)).  
 
Acetyl-CoA then enters the citric acid cycle (CAC), also known as the Krebs cycle, and gets fully 
oxidized into CO2, water, NADH and FADH2. These are vital products of the CAC that are 
reoxidized in the presence of oxygen through the coupling of electron transport chain with 
Occurs in the mitochondria 
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oxidative phosphorylation, completing the breakdown process of metabolic fuel and driving ATP 
synthesis (Voet 2004; Miesfeld 2008). The final step is termed oxidative phosphorylation, where 
NADH and FADH2 are oxidized to NAD+ and FAD by the electron transport chain, oxygen 
being the final electron acceptor. This creates a hydrogen ion gradient across the inner 
mitochondrial membrane, which is used to produce a large amount of ATP through the ATP 
synthase proton pump (Figure 4). 
 
 
Figure 4: CAC products oxidized through coupling of electron transport chain with oxidative 
phosphorylation (in the presence of oxygen) driving ATP synthesis (adapted from:(Garrett 
2010)).  
 
If oxygen is not present, or when ATP demands are too high, such as during intense muscle 
activity when ATP is needed in a short time frame, then anaerobic glycolysis takes place. This 
leads to lactate formation, where pyruvate is converted to lactate, by lactate dehydrogenase. The 
Cori cycle shifts the metabolic burden from the muscle to the liver: lactate produced in muscle is 
taken up by the liver, initiating the Cori cycle, and is converted to pyruvate, then into glucose, 
which goes back into the bloodstream and returns to the muscle, as fuel for glycolysis, or to 
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replenish glycogen stores, if activity has decreased (Ophardt 2003a; Nelson 2004; Voet 
2004)(Figure 5). 
 
 Figure 5: The Cori cycle occurring in situations such as intense exercise, where oxygen 
concentrations are low and anaerobic glycolysis takes place, producing lactate (adapted 
from:(Garrett 2010)).  
 
1.2.2 Glycogenesis 
Glucose is metabolized to glucose-6-phosphate, and then converted by 
phosphoglucomutase to glucose-1-phosphate. There are then three important enzymes involved in 
catalyzing the glycogen synthesis pathway: UDP-glucose pyrophosphorylase, glycogen synthase, 
and glycogen branching enzyme. UDP-glucose pyrophosphorylase catalyzes the reaction of 
glucose-1-phosphate with UTP (uridine triphosphate) forming UDP-glucose. Glycogen synthase 
(GS) then catalyzes the reaction between UDP-glucose and an already existing glucan chain 
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(initiated by self-catalyzed attachment of a glucose residue to glycogenin, forming a primer), 
elongating it in the process. Then follows the action of glycogen branching enzyme that 
transforms the glucan chains into glycogen (Voet 2004)(Figure 6).  
 
Figure 6: Summary diagram representing glycogenolysis versus glycogen synthesis (taken 
from:(Bouche et al. 2004)).  
 
Glycogen synthase (GS) activity is modulated by phosphorylation (decrease in activity) and 
dephosphorylation, as well as by allosteric regulation by substrates such glucose-6-phosphate 
(Bouche et al. 2004). It can be phosphorylated at 9 different sites by protein kinases such as PKA 
(cAMP-dependent protein kinase A), calmodulin-dependent kinases, glycogen synthase kinase 3 
(GSK-3), protein kinase C (PKC) and others (Bouche et al. 2004) (Figure 7).  
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Figure 7: Examples of protein kinases regulating glycogen synthase activity (taken from:(King 
2012)). 
 
Glycogen synthesis is stimulated by insulin, glucose and depleting glycogen levels, and 
downregulated by hormones such as glucagon and adrenaline, which promote glycogen 
breakdown. Insulin activates the PI3K/Akt pathway, which phosphorylates GSK-3 whereby 
inhibiting its protein kinase activity. This enhances GS and promotes glycogen synthesis in the 
presence of ample amount of glucose in the blood (Bouche et al. 2004).  GSK-3 is a 
multifunctional serine/threonine kinase that is regulated, as mentioned, by insulin, as well as by 
PKC-mediated, or cAMP-dependent PKA phosphorylation. GSK-3 phosphorylates and inhibits 
glycogen synthase and the glycogen-associated form of phosphoprotein phosphatase-1 (PP1") 
(Figure 8).  
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Figure 8: Insulin inhibits GSK-3 mediated phosphorylation and enhances PP1 mediated 
dephosphorylation of GS thereby promoting glycogen synthesis (taken from:(Cohen and Goedert 
2004)).  
 
PP1 is also implicated in the control of glycogen metabolism, by catalyzing the 
dephosphorylation of GS, rendering it active. PP1 also dephosphorylates glycogen 
phosphorylase, rendering it inactive. Glycogen phosphorylase is an enzyme involved in glycogen 
breakdown (Bouche et al. 2004). Concerning the AMPK pathway, it enhances catabolic pathways 
in order to increase ATP synthesis, and inhibits anabolic pathways, such as glycogen synthesis, 
thereby reducing ATP utilization. AMPK activates GSK-3, which phosphorylates and inactivates 
GS (Saltiel and Kahn 2001; King et al. 2006; Cammisotto et al. 2008)(Figure 9).  
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Figure 9: AMPK signaling pathway and its downstream effectors (taken from: 
www.abcam.com/AMPKsignaling).  
 
1.2.3 Glycogenolysis 
This is the process by which glycogen is converted to glucose. This occurs in the presence 
of hormones such as glucagon or epinephrine, and in situations of low blood glucose 
concentrations. It can take place in the muscle or the liver. The first step is the conversion from 
glycogen to glucose-1-phosphate by glycogen phosphorylase, which is regulated/activated by 
phosphorylation (Johnson 1992; Voet 2004). Glucose-1-phosphate is then converted to glucose-
6-phosphate by phosphoglucomutase (Voet 2004) (see Figure 6). 
 At this stage, glucose-6-phosphate can either go through the process of glycolysis, or with the 
action of glucose-6-phosphatase release glucose into the blood for uptake by other tissues such as 
the muscle (Voet 2004). Glucose-6-phosphatase is regulated by transcription factors FOXO-1 and 
PGC-1" (Puigserver et al. 2003). It is to note that, in the muscle, there is very little presence of 
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glucose-6-phosphatase and therefore once glucose-6-phosphate is formed it is used in glycolysis 
(Berg 2002; Tischler 2008).  
 
1.2.4 Gluconeogenesis 
Gluconeogenesis is another pathway besides glycogenolysis that aims to maintain blood 
glucose levels (Voet 2004). This process occurs mainly in the liver but can also take place to a 
smaller extent in the kidney (Voet 2004). It is activated in situations of fasting or starvation, in 
situations where the person is on a low-carbohydrate diet, or is undergoing intense physical 
exercise. Many substrates can be used in the process of gluconeogenesis in the liver, such as 
lactate originating from the muscle (Voet 2004). Lactate dehydrogenase converts lactate to 
pyruvate in the Cori cycle (see Figure 5). Other non-carbohydrate precursors include pyruvate, 
citric acid cycle (CAC) intermediates, and amino acids formed during protein breakdown (Voet 
2004). Amino acids either enter the cycle as pyruvate, or oxaloacetate (OAA) or enter the CAC 
directly (as CAC intermediates), forming OAA, which is then converted to phosphoenolpyruvate 
(PEP) by phosphoenolpyruvate carboxykinase (PEPCK) (Voet 2004)(Figure 10). 
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Figure 10: Amino acids used in the process of gluconeogenesis (Champe 2008).  
 
PEP eventually leads to the formation of glucose-6-phosphate, which is transported to the 
endoplasmic reticulum (ER) by glucose-6-phosphate transport protein T1, and then converted to 
glucose by glucose-6-phosphatase (located in ER of liver, kidney, intestine, but not in muscle or 
adipose tissue) (Bhagavan 2002). Glucose is released from the ER into the cytoplasm. However, 
the exact mechanism by which it does so remains unknown. It was thought to occur through the 
presence of glucose transporter 7 (Glut7) present on the ER, however this hypothesis turned out 
to be an experimental artifact (Waddell et al. 1992; Burchell 1998). Theories currently under 
investigation include direct vesicular transport of glucose from the ER to the plasma membrane, 
where Glut2 then releases it into circulation (Fehr et al. 2005). 
Glycerol can also be used to form glucose de novo by being converted to glycerol-3-
phosphate by glycerol kinase, then to dihydroxyacetone phosphate by glycerol-3-phosphate 
dehydrogenase, to fructose-6-phosphate, glucose-6-phosphate and finally releasing glucose (Voet 
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2004) (summarized in Figure 2).  As mentioned, PEPCK and glucose-6-phosphatase are 
regulated by FOXO-1 and PGC-1" (Puigserver et al. 2003). In the presence of insulin the 
PI3K/Akt pathway is activated leading to phosphorylation of FOXO-1, which is no longer able to 
bind PGC-1", resulting in inhibition of gluconeogenesis by inhibiting enzymes such as PEPCK 
and glucose-6-phosphatase (Puigserver et al. 2003)(Figure 11).  
Figure 11: The effects of the insulin/PI3K/Akt pathway on FOXO-1 and gluconeogenesis 
enzymes (taken from:(Zhao et al. 2001; Nakae et al. 2002; Hirota et al. 2003; Puigserver et al. 
2003)).  
1.3 Glucose transporters 
 Glucose transporters allow the facilitated transport of glucose or related hexoses from the 
extracellular fluid into the cell (Zhao and Keating 2007) in order for it to be utilized in the 
production of cellular energy (glycolysis and ATP production) or as storage (glycogen or fatty 
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acids)(Roach 2002). There are two types of glucose transporters: facilitative glucose transporters 
(Glut), and sodium-dependent glucose co-transporters (SGLT).  
 
1.3.1 Glut transporters 
Glut transporters are composed of 12 membrane-spanning helices, where both the amino 
and carboxyl terminal are exposed to the cytoplasmic side of the plasma membrane (Olson and 
Pessin 1996; Wood and Trayhurn 2003; Thorens and Mueckler 2009; Augustin 2010). Once 
glucose binds to the transporter it induces a conformational change that allows the substrate to be 
transported into the cell and released into catabolic pathways, such as glycolysis or glycogenesis. 
There is an abundance of glucose transporters present, encoded by distinct genes, and their 
expression as well as regulation depends on tissue distribution. There have been 13 members of 
facilitated diffusion glucose transport (Glut) identified thus far, not including the 3 members 
belonging to the sodium-dependent glucose co-transporter (SGLT)(Zhao and Keating 
2007)(Table 1).  
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Table 1: Summary table of glucose transporters (Glut) and members of the sodium-dependent 
glucose co-transporter (SGLT)(taken from:(Zhao and Keating 2007)). 
 
The glucose transporters are divided into 3 subclasses: class I, II, III depending on sequence or 
structure similarities. Class I contains Glut1, Glut2, Glut3, Glut4, class II with Glut5, Glut7, 
Glut9, Glut11, and class III with Glut6, Glut8, Glut10, Glut12, Glut13 also known as 
H+/myoinositol transporter (HMIT). 
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1.3.2 Insulin and non-insulin responsive regulation of Glut translocation 
It is to note that among these only Glut4, 8 and 12 are responsive to insulin (Zhao and 
Keating 2007). Glut1 is ubiquitously distributed in all tissues. It is responsible for glucose uptake 
under basal conditions (Giorgino et al. 2000), and more modestly upon insulin stimulation 
(Pessin et al. 1999). The main insulin-responsive glucose transporter is Glut4, which is present in 
skeletal and cardiac muscle, as well as adipose tissue (James et al. 1989). In a resting state, Glut4 
is stored in intracellular vesicles with less than 5% being present at the cell surface (Brewer et al. 
2011). In the presence of insulin the PI3K/Akt or TC10 pathways are activated, which leads to 
increased translocation to the plasma membrane and activation of Glut4 (Funaki et al. 
2004)(Figure 12).  
 
Figure 12: PI3K/Akt and TC10 mediated Glut4 translocation and glucose uptake (taken 
from:(Milnar 2006)). 
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On the other hand, activation of the AMPK pathway results in a non-insulin dependent 
translocation and activation of Glut4 and Glut1 (Barnes et al. 2002)(Figure 13). It is to note that 
in an insulin resistant state there is either a decreased ability of insulin signaling, which translates 
to decreased Glut4 translocation and activity, or even decreased Glut4 expression (i.e. decreased 
levels of Glut4 protein) (Reaven 1999; Funaki et al. 2004). 
 
 
Figure 13: AMPK pathway modulates glucose and lipid metabolism (taken from:(Hardie and 
Sakamoto 2006)). 
 
1.3.3 SGLT transporters 
There are 3 types of SGLTs, which transport glucose against their concentration gradient 
using energy derived from co-transport of sodium down its electrochemical gradient (Shepherd 
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and Kahn 1999). SGLT-1 present in the small intestine and kidney and SGLT-2 found mainly in 
kidney are responsible for glucose absorption and reabsorption. Concerning SGLT-3, it is found 
in small intestine and skeletal muscle. Although it was thought to be a glucose transporter in the 
beginning, it is now considered to represent a glucose sensor involved in the depolarization of the 
cells in which it is present. The exact intracellular cascade initiated with SGLT3 is still being 
elucidated (Diez-Sampedro et al. 2003; Fairchild 2008).  
 
1.4 Insulin 
Insulin is a peptide hormone that plays an important role in carbohydrate and fat 
metabolism. Although glucose is the most potent stimulus of insulin release, other substances 
also modulate its pancreatic production, including dietary protein-derived amino acids, 
neurotransmitters, and gastrointestinal hormones such as glucose-dependent insulinotropic 
peptide (GIP) (Porte 2003; Kahn 2005). Insulin is composed of 51 amino acids (AA) consisting 
of an A chain (21 AA) and B chain (30 AA) joined together by two disulfide bonds (Katzung 
2004; Kahn 2005).  
 
1.4.1 Insulin synthesis 
It is synthesized, stored and secreted from #-cells of the pancreatic islets. Insulin is 
synthesized from preproinsulin (110 AA), a protein precursor for proinsulin that possesses a 
signal peptide (24 AA), rich in hydrophobic residues, allowing for translocation of the nascent 
protein into the rough endoplasmic reticulum (RER). The signal peptide is then removed by 
signal peptidases within the RER (Kumar 2003; Voet 2004; Kahn 2005), forming  proinsulin (84 
AA), which undergoes proper folding (aligning disulfide bonds between A and B chains) in the 
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RER (Figure 14) .  
 
Figure 14: Insulin synthesis from preproinsulin to insulin (taken from:(Kramer and Sauer 2010)).  
 
Properly folded proinsulin is then delivered to cis-Golgi in an ATP-dependent process and 
undergoes trafficking from the cis to the trans stacks of the Golgi apparatus. Proinsulin is then 
almost exclusively destined to the regulatory vesicular pathway, triggered in response to a 
secretagogue. However, very little if any also goes through the constitutive vesicular pathway, 
present in all cells and used for secretion (Kahn 2005). The regulatory pathway consists in 
packaging proinsulin into secretory granules followed by exocytosis in response to a stimulus, 
undergoing granule maturation in the process. It starts with a clathrin-coated vesicle containing 
proinsulin and involving a process of acidification. The cleavage of proinsulin is exerted by 
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proteolytic enzymes, such as prohormone convertase (PC1 and PC2) and the exoprotease 
carboxypeptidase E. Insulin and C-peptide are formed, resulting in insulin-rich mature uncoated 
granules (Steiner 1967; Kahn 2005; Sriram 2010)(Figure 15).  
 
 
Figure 15 : The secretory pathway in which proinsulin through a process of acidification, 
prohormone and converting enzymes, and granule maturation, results in the formation of insulin-
rich mature granules and C-peptide (taken from:(Steiner 2011)). 
 
 C-peptide is used clinically as an indicator of the insulin-secreting potential of #-cells of the 
pancreatic islets of Langerhans. C-peptide has also been shown to have effects on microvascular 
blood flow and tissue health (Forst et al. 2008; Nordquist and Johansson 2008). Concerning 
proinsulin, it is said to be predictive of non-insulin dependent diabetes mellitus (NIDDM), since 
it has been found that the ratio of proinsulin to insulin is increased in NIDDM and even in 
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insulin-dependent diabetes mellitus (IDDM). This observed increase may be the result of 
impairment in the enzymatic conversion of proinsulin to insulin, or even due to rapid granule 
turnover where proinsulin does not have enough time to be converted before it is released (Kahn 
2005).  
 
1.4.2 Insulin secretion 
The blood glucose threshold required to stimulate insulin secretion is 4-6 mM. In contrast, 
the one for insulin biosynthesis is even lower ranging from 2-4 mM, biosynthesis reaching its 
maximum peak at levels of 10-12 mM (Kahn 2005). When #-cells are exposed to glucose, there 
is a 20 minute lag period before an observed significant increase in proinsulin biosynthesis. After 
60 minutes, there is 10-20 fold increase in the rate of synthesis, and once the stimulus is removed 
it takes around 1 hour to return to normal levels (Kahn 2005).  
The following steps lead to insulin release: glucose enters the #-cells in the pancreas 
through Glut2 transporters. It is then metabolized (glycolysis) and goes through oxidative 
phosphorylation where high amounts of ATP are formed. This leads to the closing of ATP-
dependent K+ channels, triggering cell membrane depolarization and allowing for an influx of 
Ca2+ through voltage-controlled calcium channels (Figure 16). 
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Figure 16:  Insulin secretion (taken from:(Fauci 2008)). 
 
The increase in Ca2+ levels is also believed to activate phospholipase C, which cleaves 
phosphatidyl inositol 4,5-biphosphate (PIP2) into inositol 1, 4, 5-triphosphate (IP3) and 
diacylglycerol (DAG) (Thore 2005). IP3 binds to receptor proteins in the ER allowing Ca2+ to be 
released from ER via IP3-gated channels, increasing Ca2+ levels even more and causing 
previously formed and stored insulin to be released (Belfiore 2000; Thore 2005)(Figure 17).  
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Figure 17 : Other factors involved in stimulating insulin secretion such as IP3, DAG, PKC 
(adapted from:(Novak 2008)). 
 
Concerning DAG, it activates PKC, which is also known to stimulate insulin secretion. It does so 
probably by regulating proteins involved in the core machinery for vesicular docking on target 
membrane, thereby favoring membrane fusion (ex. SNARE, VAMP, SNAP25, syntaxin-1A) 
(Uchida et al. 2007). Other effector proteins involved in PKC action include granuphilin, Noc2, 
collectrin (Uchida et al. 2007; Gauthier and Wollheim 2008), or even myristoylated alanine rich 
PKC substrate (MARCKS). The latter binds actin and calcium-calmodulin, thus inducing insulin 
exocytosis (Calle et al. 1992; Donohoue 2008). 
Insulin release is pulsatile in nature and is considered either as basal or stimulated. Basal 
release occurs after absorption is complete in order to maintain glycemia at normal levels 
between meals. Stimulated release occurs postprandially in order to respond to increased glucose 
loads. In either case, insulin favors glucose disposal into peripheral tissues such as the muscle or 
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adipose tissue and inhibits hepatic glucose production. Moreover, stimulated insulin release is 
biphasic, with a first phase lasting 10 minutes where #-cells promptly release insulin, followed by 
a second, more steady and sustained, phase that lasts until normoglycemia is restored (Del Prato 
et al. 2002). Even though both phases are important in regulating glucose levels, it is the first 
phase that is weakened in patients with impaired glucose tolerance or in those with diabetes 
(Saltiel and Kahn 2001; Del Prato et al. 2002; Cavaghan 2004).  
 
1.5 Insulin signaling 
 The insulin receptor is a transmembrane receptor belonging to the family of tyrosine kinase 
receptors. It is composed of 2" extracellular binding domains, and 2# transmembrane subunits 
kept together by three disulfide bonds. The #-subunits contain extracellular and transmembrane 
portions, as well as an intracellular domain consisting of an ATP binding domain and a tyrosine 
kinase catalytic domain (Dorrestijn et al. 1998; Hunter and Garvey 1998; Perz and Torlinska 
2001). Binding of insulin to the "-subunits initiates a cascade of intracellular mechanisms. First, 
it creates a conformational change in the receptor, allowing ATP to bind to the intracellular 
domain of the #-subunit. This activates the tyrosine kinase domains residing on the intracellular 
portion of the #-subunits. Autophosphorylation ensues at the level of tyrosine residues found on 
the C-terminus of the #-subunit. This event enables the insulin receptor tyrosine kinase to 
phosphorylate the tyrosine residues found on the insulin receptor substrate (IRS-1/2) (Mantzoros 
2011).  
Once the insulin receptor is activated, the signal gets propagated to many downstream 
intracellular protein effectors and pathways, the two main ones being MAPk and PI3K (see 
Figure 12).  
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1.5.1 The MAPk pathway 
 The mitogen-activated protein kinase pathway (MAPk) regulates the transcription of genes 
implicated in the cell cycle, mediating insulin’s effects on growth and proliferation (Kido et al. 
2001; Mantzoros 2011). It is activated by a signaling cascade involving either the binding of 
growth factor binding protein 2 (Grb2) through the SH2 domain to phosphorylated IRS-1/2, or to 
phosphorylated Shc (src homologous and collagen protein). This allows SOS (son of sevenless; 
guanine nucleotide exchange factor) to bind to Grb2 through its Sh3 domain and to catalyze the 
exchange of GDP with GTP on Ras (small G protein) (Olefsky 2004). This leads to activation of 
Raf, Map kinase kinase (MEK or MAPKK), and MAPk Erk1/2, which goes on to phosphorylate 
a variety of transcription factors involved in cellular proliferation and differentiation (Saltiel and 
Kahn 2001; Capeau 2003)(see Figure 12). MAPk activation in the adipose tissue has been shown 
to inhibit adipocyte differentiation both in vitro and in vivo, mediating its effect by inhibiting 
PPAR! and activating SOX9, which decreases the expression of C/EBP# and $ (Finucane et al. 
2009; Sul 2009; Donzelli et al. 2010). It has also been associated with more intense pre-
replicative phases of hepatocyte proliferation, hyperplasia, leading to the development of non-
alcoholic fatty liver disease (NAFLD) (Chavez-Tapia et al. 2009).  
1.5.2 The PI3K pathway 
 Phosphorylated IRS-1/2 can also activate the phosphoinositol-3-kinase (PI3K) pathway, by 
recruiting PI3K through its regulatory subunit p85 SH2 domain. The p110 catalytic subunit of 
PI3K then phosphorylates phosphatidylinositol (4,5) biphosphate (PI(4,5)P2) generating 
phosphatidylinositol (PI(3,4,5)P3). Protein kinase 3-phosphoinositide dependent protein kinase-1 
(PDK-1) goes on to activate protein kinase (PKB)/Akt (containing a pleckstrin homology domain 
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(PH) that allows for binding to PIP3) or atypical PKC (both of which are serine/threonine 
kinases). Activation of both the Akt and atypical PKC (aPKC) kinases lead to the translocation of 
Glut4 to the membrane in order to increase glucose transport in tissues such as the muscle or 
adipose tissue (Czech and Corvera 1999; Tirosh et al. 2000). In the liver, activating aPKC 
stimulates storage pathways such as lipogenesis, which involves upregulating the expression of 
transcription factors such as SREBP1-c (Chattopadhyay et al.). Concerning hepatic Akt 
activation, it leads to mechanisms that promote glucose metabolism (glycolysis) and storage 
(glycogenesis), as well as lipogenesis, while inhibiting glucose production through 
gluconeogenesis or glycogenolysis. Therefore, Akt downregulates enzymes such as glucose-6-
phosphatase or PEPCK. It also phosphorylates GSK-3, thus allowing the activation of GS and 
promoting glycogen formation. Akt activation also phosphorylates FOXO-1. This prevents the 
latter from binding to PGC-1", resulting in the inhibition of gluconeogenesis pathways (see 
Figure 11). Without going into tissue specific regulation, Akt can also go on to modulate the 
mTOR (mammalian target of rapamycin) pathway. Akt phosphorylates and inactivates TSC2 of 
the tuberus sclerosis complex (TSC1/2) decreasing RHEB GTPase activity and increasing 
RHEB-GTP, resulting in mTOR activation (Pelengaris 2006). The mTOR pathway is involved in 
protein synthesis, cell size, survival (suppressing apoptotic pathways) and proliferation. It 
promotes ribosomal biogenesis, as well as transcription and translation, activating 40S ribosomal 
protein S6 kinase (p70s6k) and the eukaryotic initiation factor 4E-binding protein 1 
(EIF4E)(phosphorylation of EIF4EBP, a translation repressor protein, allows for EIF4E to 
dissociate and for translation to proceed) (Pelengaris 2006) (see Figure 12).  
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1.5.3 Downregulation of the PI3K/Akt/PKB pathway 
 The Akt pathway can be inactivated in many ways, such as receptor internalization, 
ubiquitination and subsequent degradation by proteasomes, or by dephosphorylation of 
phosphotyrosine residues of the insulin receptor by protein tyrosine phosphatases (PTP) such as 
PTP1B (Saltiel and Kahn 2001; Zinker et al. 2002). Downregulation of the insulin signaling 
pathway can also occur through dephosphorylation of PIP3 by 3-phosphoinositide phosphatase 
(PTEN) (Saltiel and Kahn 2001; Zinker et al. 2002). Other ways of halting activation of the 
insulin pathway include serine-threonine phosphorylation of the insulin receptor (Coba et al. 
2004), or of the IRS by PKC-# (inhibits catalytic activity of insulin receptor) (Aguirre et al. 2002; 
Ishizuka et al. 2004; Liberman et al. 2008). FFA metabolism is also involved in insulin signal 
impairment by increasing DAG levels and concomitantly activating conventional and novel PKC 
(Dey et al. 2006). In summary, different PKC isoforms, through different mechanisms, lead to 
insulin signaling impairment by acting either on the insulin receptor, IRS, or Akt, or even by 
activating pathways as the mTOR or MAPk, which can negatively regulate the pathway 
(feedback mechanism in situations of prolonged insulin stimulation) (Engelman et al. 2000; 
Tremblay et al. 2007; Fox et al. 2010).  
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Figure 18 : Examples of factors involved in negatively regulating the insulin pathway (taken 
from:(Clement et al. 2009; King 2012)).  
1.5.4 The TC10 pathway 
 The TC10 pathway functions in parallel but independently of the PI3K to stimulate Glut4 
translocation in response to insulin in tissues such as skeletal and cardiac muscle (Bernard et al. 
2006; Gupte and Mora 2006) as well as adipose tissue (Chiang et al. 2001) (see Figure 12). 
Tyrosine phosphorylation of the insulin receptor allows for Cbl (proto-oncogene)/CAP (Cbl-
associated adaptor protein) to be recruited to the receptor in the presence of APS (adaptor 
protein). Firstly, the phosphorylated tyrosine residues of the insulin receptor allow for APS 
binding via its SH2 domain. APS gets phosphorylated in the process, and recruits Cbl via its SH2 
domain. Cbl then interacts with CAP that belongs to the sorbin homology family  (SoHo) of 
adaptor proteins. The APS-Cbl-CAP complex, once phosphorylated dissociates and translocates 
to lipid rafts. Once there, CAP binds to flotillin through its SoHo domain, while Cbl via its SH2 
domain recruits the SH2/SH3 adaptor protein CrkII. CrkII via its SH3 domain forms a complex 
  
34
with C3G, a guanine nucleotide exchange protein that catalyzes the exchange from GTP to GDP 
on TC10 (Rho family of GTPase). TC10 is then activated and can interact with effector proteins 
such as Cdc42-interacting protein 4/2 (CIP4/2), located on intracellular compartments. Once 
activated they favor translocation of Glut4 containing vesicles to the plasma membrane 
(Baumann et al. 2000; Saltiel and Kahn 2001; Kimura et al. 2002; Chang et al. 2004).  
 
1.6 Other mechanistic pathways involved in glucose and lipid 
metabolism 
1.6.1 AMPK pathway 
 In general, AMPK activation stimulates energy producing pathways such as glycolysis and 
fatty acid oxidation. It inhibits energy-consuming pathways, for example lipogenesis, and steroid 
or protein synthesis (Hardie et al. 2003; Viollet et al. 2003). Even cell growth is inhibited, with 
AMPK activating and phosphorylating TSC2, and inhibiting mTOR activity (Hahn-Windgassen 
et al. 2005). The effects of AMPK on glucose and lipid metabolism can be beneficial in the 
treatment of diabetes, and obesity. It has been observed that the two commonly prescribed classes 
of antidiabetic medications, biguanides and thiazolidinediones, exert their beneficial effects 
through activation of this pathway (Viollet et al. 2003).  
 
1.6.1.1 AMPK pathway activation 
 The AMPK pathway is activated when the AMP/ATP ratio is increased. When the muscle 
is contracting ATP is broken down to ADP. In order to regenerate ATP, the formed ADP 
combines with another ADP creating ATP and increasing concentrations of AMP in the process. 
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This can occur in conditions of hypoxia, low glucose, exercise, and can even be activated by 
adipocytokines such as leptin and adiponectin, or substances such as AICAR, metformin, and 
mitochondrial uncouplers (Chen et al. 1999; Winder and Hardie 1999; Ruderman and Prentki 
2004; Fujii et al. 2006). There has even been recent evidence suggesting that long-chain fatty 
acids (LCFA) regulate AMPK/ACC activity (Kawaguchi et al. 2002; Clark et al. 2004; Taylor et 
al. 2005; Fediuc et al. 2006). There is no clear consensus on how LCFAs regulate AMPK/ACC 
activity (Fediuc et al. 2006). Some claim that LCFAs enhance the AMPK pathway, by increasing 
phosphorylation of AMPK and/or ACC (Kawaguchi et al. 2002; Clark et al. 2004; Fediuc et al. 
2006), while others report that they inhibit phosphorylation and activation of AMPK by its 
upstream kinase LKB1/STRAD/MO25 (Taylor et al. 2005). Other suggestions pertaining to the 
mode of activation by LCFAs include inhibition of dephosphorylation of Thr-172 on AMPK by 
protein phosphatases, or inhibition of dephosphorylation and activation of ACC once again by 
phosphatases (Winder 2001; Carling 2005; Fediuc et al. 2006). These findings clearly 
demonstrate that AMPK is more than just an energy sensor. It can also be considered as a 
mediator of extracellular signals and a metabolic sensor (Allard et al. 2007). Therefore, it is 
evident that many factors are involved in the regulation of AMPK activity and that of its 
downstream effectors (such as ACC). 
 AMPK, a stress-sensing protein kinase, is composed of 3 subunits. The " subunit 
containing a serine/threonine protein kinase catalytic domain, where upstream kinases 
phosphorylate Thr/172.   The # regulatory subunit has glycogen-binding domains that stabilize 
the interaction between " and ! subunits. The ! regulatory subunit has the ability to detect 
changes in the AMP/ATP ratio through four cystathionine beta synthase domains (CBS). The ! 
subunit binds both AMP and ATP in a competitive manner. If ATP displaces AMP then 
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activation of AMPK is reversed (Wong and Lodish 2006; Xiao et al. 2007; Garrett 2010). The 
four CBS domains create two AMP binding sites also referred to as Bateman domains. Once the 
first AMP binds to the Bateman domain, this increases binding affinity for the second AMP. This 
creates a conformation change in the ! subunit, which exposes the catalytic domain of the " 
subunit. It is in the " subunit that AMPK becomes activated through phosphorylation on 
threonine-172 by an upstream kinase termed AMPK kinase (AMPKK), such as liver kinase B1 
(LKB1/MO25/STRAD) (Hardie 2005). Calcium calmodulin dependent protein kinase-# 
(CaMKK#) has also been shown to activate AMPK (Shen et al. 2007). There have also been 
reports of other kinases that may exist upstream of AMPK and play a role in its activation and 
phosphorylation. One example is Tak1, a member of the MAPKKK family. However their 
physiological role and relevance are still being investigated (Shen et al. 2007; Carling et al. 2008) 
(Figure 19). 
 
Figure 19 : Kinases involved in activating and phosphorylating AMPK as well as the downstream 
effectors it regulates (taken from:(Gruzman et al. 2009)). 
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There has been evidence that allosteric modulators such as 3-phosphoglycerate, a glycolysis 
intermediate, can also influence AMPK activation. It can enhance AMPK activation by acting on 
AMPKK (LKB1-STRAD-MO25), or on AMPK itself, making it a better substrate for LKB1-
STRAD-MO25 (less accessible to phosphatases)(Ellingson et al. 2007).  
 
1.6.1.2 AMPK pathway on glucose metabolism  
 AMPK regulates glucose metabolism by increasing glucose transport and enhancing Glut4 
translocation to the plasma membrane through an insulin-independent pathway. AMPK has been 
shown to act on downstream effectors such as the Akt substrate 160 (AS-160), a Rab-GTPase 
activator protein and a key regulator of glucose trafficking (found predominantly in muscle and 
to some extent in adipose tissue) (Marette 2008). Once AS-160 is phosphorylated it inhibits Rab-
GTPase activator protein activity. Activated GTP-bound Rab can promote Glut4 translocation in 
the muscle and adipose tissue (Nascimento et al. 2006; Marette 2008; Nascimento 2010) (Figure 
20). AS-160 is a point of convergence of both the AMPK and Akt pathway, naturally implying its 
importance in regulating glucose transporter translocation (Treebak et al. 2006) (Figure 20).  
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Figure 20: This scheme is an example of how AMPK activates Glut4 translocation in muscle, 
through AS-160. AS-160 is a point of convergence between the Akt and AMPK pathway 
resulting in increased Glut4 translocation (taken from:(Sakamoto and Holman 2008)). 
 
AMPK may also upregulate Glut4 expression and transcription by acting on myocyte enhancer 
factor-2 (MEF2) and Glut4-enhancer factor (GEF; associates to MEF2), or even on PGC-1" 
(maybe binds and coactivates MEF2) (Karnieli and Armoni 2008) (Figure 21). AMPK can either 
directly activate Glut4 translocation, or it can interact with downstream activators. One such 
example is AMPK activation of MKK3/6, an upstream kinase that phosphorylates p38 MAPk. 
PGC-1" and MEF-2 are then activated, inducing mitochondrial biogenesis, as well as Glut4 
translocation (Karnieli and Armoni 2008).  P38 MAPk is activated in response to many of the 
same conditions that stimulate AMPK, including AICAR, and mitochondrial uncouplers. It is 
involved in the inflammatory process, cell growth, cell differentiation, cell cycle, cell death, and 
glucose transport (Xi et al. 2001; Lemieux et al. 2003; Pelletier et al. 2005; Ribe et al. 2005). In 
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the muscle, AMPK activation leads to inhibition of glycogen synthesis, and increased fatty acid 
oxidation (Winder and Hardie 1999; Hardie et al. 2003; Jorgensen et al. 2004; Andreelli 2005; 
Korbonits 2008; Grimaldi 2009).  
 
Figure 21: AMPK, in the muscle, acts on MEF2 and PGC-1" to increase Glut4, and activates 
fatty acid oxidation and mitochondrial biogenesis (taken from:(Czubryt and Olson 2004)). 
 
In the liver, AMPK inhibits hepatic glucose production (gluconeogenesis), lipogenic enzymes 
(FAS, ACC-1), and stimulates FA oxidation (Viollet et al. 2003). AMPK upregulates 
transcriptional factors such as PGC1-", modulating mitochondrial biogenesis and fatty acid 
oxidation (Steinberg and Kemp 2009; Lustig et al.).  
Hepatic glucose production is actually inhibited through the action of AMPK on PEPCK and G-
6-Pase. AMPK induces an orphan nuclear receptor called small heterodimer partner (SHP), 
which is a transcriptional repressor of many nuclear receptors and transcription factors. Some 
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examples include cAMP-response element binding protein (CREB), hepatocyte nuclear factor 4 
alpha (HNF-4"), and Foxo-1, all implicated in the expression of gluconeogenic enzymes PEPCK 
and G-6-Pase (Kim et al. 2008; Lee et al. 2010)(see Figure 19). 
 
1.6.1.3 AMPK pathway on lipid metabolism 
 In adipose tissue, the AMPK pathway increases fatty acid oxidation, while inhibiting 
energy-consuming pathways such us lipogenesis and lipolysis (Korbonits 2008; Gaidhu and 
Ceddia 2011). Lipolysis is increased during exercise. This activates the AMPK pathway in order 
to limiting further TG breakdown, while promoting fatty acid oxidation of the already present 
fatty acids. Fatty acids that are released need to be oxidized by adipose or other tissues, otherwise 
they will be reesterified into triglycerides creating an energy-futile consuming cycle (Gaidhu and 
Ceddia 2011).  
 AMPK plays a role in lipid metabolism by phosphorylating acetyl-CoA carboxylase (ACC) 
inactivating it in the process. There are two isoforms of ACC. ACC-1 is expressed in all tissues, 
mostly lipogenic ones, and is the prevalent isoform in the adipose tissue and liver. It is implicated 
in fatty acid synthesis. ACC-2, prevalent in cardiac and skeletal muscle, and to a lesser extent 
liver, is involved in mitochondrial fatty acid oxidation (Wakil and Abu-Elheiga 2009). AMPK 
phosphorylates ACC-1 on Serine (ser)-79, Ser-1200, and Ser-1215, and ACC2 on Ser-218. Once 
ACC is phosphorylated it does not allow the formation of malonyl-CoA, a building block of fatty 
acids. Malonyl-CoA inhibits the transfer of the fatty acyl group from acyl CoA to carnitine by 
inhibiting the activity of carnitine palmitoyl transferase (CPT-1). CPT-1 facilitates the transport 
of fatty acids to the mitochondria for beta-oxidation. In summary, by phosphorylating ACC and 
inactivating it, malonyl-CoA production is decreased allowing CPT-1 to function properly and 
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conduct fatty acids to beta-oxidation in the mitochondria. This process allows for decreased lipid 
accumulation in insulin sensitive tissues such as the muscle, liver, and adipose tissue contributing 
to the maintenance of insulin sensitivity (Winder and Hardie 1999; Zhou et al. 2009; Fogarty and 
Hardie 2010). AMPK also downregulates transcription factors involved in the synthesis of 
enzymes promoting fatty acid or cholesterol synthesis. Some examples include carbohydrate 
responsive element-binding protein (ChREBP), sterol regulatory element binding protein 
(SREBP-1c), and 3-hydroxy-methyl-glutaryl-CoA-reductase (HMGR; cholesterol synthesis). In 
the presence of insulin there is activation of phosphatases that remove the inhibitory effect on 
ACC and allow for fatty acid synthesis (Witters et al. 1988; Hansmannel et al. 2006)(see Figure 
9).  
AMPK is also said to act upstream of SIRT-1 (sirtuin-1), which is a NAD-dependent deacetylase. 
SIRT-1 has different roles depending on the tissue (liver, muscle, pancreas, adipose tissue) in 
which it is activated, and on different stimuli (i.e. whether fasted or fed state). SIRT-1 is said to 
be involved in a variety of metabolic processes (see Figure 9). It improves FA mobilization and 
oxidation, mitochondrial biogenesis, glucose uptake, insulin sensitivity  (represses PTP1B), and 
plays a role in insulin secretion (Fulco and Sartorelli 2008; Nunn et al. 2009; Valentino et al. 
2011).  
 
1.6.2 PPAR pathways 
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor proteins that 
function as transcription factors (Michalik et al. 2006). There are a variety of endogenous ligands 
that bind and activate PPARs. They include saturated or unsaturated FA, eicosanoids, 
leukotrienes (PPAR") or prostaglandins (PPAR!) (Tjokroprawiro 2006). When a ligand is bound 
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PPARs heterodimerize with retinoid X receptor (RXR). This complex then binds to DNA 
sequences termed peroxisome proliferator response elements (PPRE) of target genes involved in 
a variety of cellular processes. Examples include cell differentiation, adipocyte differentiation, 
metabolism of lipids, carbohydrates and proteins, tumorigenesis, and inflammation (Shi et al. 
2002; Tjokroprawiro 2006; Belfiore et al. 2009). There are three types of PPAR that have been 
identified each one having different functions and expressed in different tissues: PPAR", 
PPAR#/$, PPAR! (Berger and Moller 2002)(Figure 22).  
 
Figure 22: Summary of PPAR ", #, and ! activation and their functions (taken from:(Cho et al. 
2008)).  
 
PPAR" is expressed in liver, kidney, gut, heart, muscle, and adipose tissue 
(Tjokroprawiro 2006). PPAR" promotes lipid metabolism in tissues such as the liver and muscle. 
It activates genes implicated in fatty acid transport, and mitochondrial or peroxisome mediated 
fatty acid oxidation (Tjokroprawiro 2006; Wanders et al. 2011). It is also the target of fibrate 
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drugs, which aim to lower cholesterol and TG levels (Tjokroprawiro 2006), while improving 
insulin sensitivity (Fatehi-Hassanabad and Chan 2005).   
PPAR#/$ is found in many tissues including the brain, colon, liver, adipose tissue, and 
skin (Berger and Moller 2002; Shi et al. 2002; Tjokroprawiro 2006). Its function remains elusive. 
However there has been evidence that it may act as a potent inhibitor of ligand-induced 
transcription activity of PPAR" and ! by binding to PPREs. It interacts in the process with 
corepressor silencing mediator for retinoid or thyroid hormone receptors (SMRT) and SHARP 
(SMRT and histone deacetylase associated repressor protein) (Shi et al. 2002). Another function 
associated to PPAR#/$ was discovered with the use of an agonist GW501516. It consists in 
changing the body’s fuel preference from glucose to lipids (Stienstra et al. 2007; Adeghate et al. 
2011). This can be beneficial in reducing tissue lipid levels and the risks associated with 
hyperlipidemia (Adeghate et al. 2011). 
 PPAR! has three subtypes PPAR!1, PPAR!2, and PPAR!3, which are obtained through 
alternative splicing from a single gene (Tjokroprawiro 2006). In general, PPAR! activates genes 
that are implicated in lipid uptake (FATP and aP2/FABP4), fatty acid storage, and adipogenesis 
in fat cells (lipoprotein lipase and acyl-CoA). It even plays a role in glucose metabolism, 
modulating expression of genes for insulin receptor substrates, the p85 subunit of PI3K, and 
Glut4 (Picard and Auwerx 2002; Tjokroprawiro 2006)(Figure 23). 
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Figure 23 : PPAR! activates genes involved in adipocyte differentiation, glucose uptake, lipid 
metabolism  (taken from:(Brown and McIntosh 2003)). 
 
PPAR!1 is expressed in heart, muscle, colon, kidney, pancreas and spleen (Berger and Moller 
2002; Tjokroprawiro 2006). PPAR!2 is 30 amino acids longer than PPAR!1 and it is expressed in 
the adipose tissue (Berger and Moller 2002; Tjokroprawiro 2006). PPAR!3 is expressed in 
macrophages, large intestine, and white adipose tissue (WAT) (Berger and Moller 2002; 
Tjokroprawiro 2006). PPAR! modulators include insulin, which increases PPAR! mRNA 
expression, and SREBP1-c, which increases the production of lipophilic molecules with potent 
PPAR! ligand activity (Farmer 2005a). PPAR! is also the target of thiazolidinediones (Tzds), a 
class of oral hypoglycemic medications. PPAR! modulators are used to treat hyperlipidemia, by 
increasing ATP-binding cassette transporter (ABCA1). This increases the transport of cholesterol 
to HDL therefore increasing uptake and excretion from the liver (Adeghate et al. 2011). There 
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also exists a class of dual/pan-PPAR agonists. They are defined by non-selective action on 
PPARs by binding two or more of the PPAR isoforms, PPAR", $/#, !. PPAR" and PPAR! dual 
agonists are called glitazars and include aleglitazar, muraglitzar, tesaglitazar (Calkin and Thomas 
2008; Adeghate et al. 2011). Glitazars are being investigated for their use in treating a larger 
subset of symptoms of the metabolic syndrome since they have the lipid benefits of PPAR" 
agonists (fibrates), and the glycemic benefits of PPAR! agonists (Tzds) (Calkin and Thomas 
2008; Adeghate et al. 2011).  
 
1.6.3 Uncoupling proteins (UCPs) 
Uncoupling proteins (UCPs) are transmembrane proteins that are part of the larger family 
of mitochondrial anion carrier proteins (MACP) that uncouple oxidative phosphorylation from 
ATP synthesis. UCPs increase the permeability of the mitochondrial membrane, allowing protons 
from the intermembrane space to leak back in to the mitochondrial matrix without going through 
the ATP synthase complex (Figure 24). Therefore, this allows for fast substrate oxidation with 
low ATP production. There have been 5 subtypes identified thus far (UCP-1 to 5), with UCP-1 to 
3 more extensively studied. UCP-1, termed thermogenin, has been identified in brown adipose 
tissue (BAT), and has been associated with non-shivering thermogenesis (Krauss et al. 2005).  
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Figure 24 : UCPs increase permeability of mitochondrial membrane, allowing protons to be 
pumped back in to the mitochondrial matrix without going through the ATP synthase complex 
(taken from:(Krauss et al. 2005)). 
 
The sympathetic nervous system increases the transport, mobilization, and oxidation of fuel, 
increasing the production of NADH, and FADH2, essential for UCP-1 mediated proton leak. It 
stimulates #3-adrenergic receptors activating a cAMP/PKA mediated signaling cascade. This 
leads to phosphorylation and activation of lipases transforming TG into FFAs. FFAs can be 
metabolized for example through #-oxidation and subsequent entering into the CAC, serving as 
substrate for mitochondrial oxidative respiration (Krauss et al. 2005). FFAs can also directly 
activate UCP-1. However, the exact mechanism is unknown. Two mechanisms have been 
proposed (Krauss et al. 2005). In the first hypothesis, it is thought that FFAs act as a prosthetic 
group within the UCP-1 translocation channel donating protons to proton-buffering amino acids 
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that aid in the translocation of protons through the channel (Krauss et al. 2005)(Figure 25 a). The 
second hypothesis is termed the fatty-acid cycling model (Krauss et al. 2005). Without a carrier 
protein, the fatty-acid anion remains in the mitochondrial matrix. It binds to UCP-1, which brings 
it to inner mitochondrial membrane. This exposes it to the intermembrane space where it accepts 
a proton (Krauss et al. 2005). It then flips back across the inner mitochondrial membrane toward 
the matrix where it releases the proton. The cycle then starts over again with UCP-1 transporting 
the fatty-acid anion back across the inner mitochondrial membrane and exposing to 
intermembrane space and protons (Krauss et al. 2005) (Figure 25 b).  
a)      b) 
  
 
 
 
 
 
Figure 25 :  FFA can activate UCP-1 through two distinct mechanisms detailed above (taken 
from:(Krauss et al. 2005)). 
 
UCP-2 is found in skeletal muscle and liver and controls the generation of mitochondria-derived 
reactive oxygen species (ROS) (Krauss et al. 2005). ROS formation is highly dependent on 
proton-motive force, therefore promoting proton leak through UCP-2 expression can limit it 
(Krauss et al. 2005). UCP-3, predominant in BAT and skeletal muscle, is thought to play a role in 
the handling of lipids as fuel, having important implications in obesity (Krauss et al. 2005). Fatty 
acids can accumulate in the mitochondria due to increased lipid metabolism, and this can produce 
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toxicity (Krauss et al. 2005). It has been reported that mutations in UCP3 have led to increased 
respiratory quotients indicative of decreased fatty acid oxidation. This suggests that UCP3 
expression and function is important in lipid metabolism. An increase in UCP3 expression is 
associated with increased fat metabolism seen in fasting or high-fat diet animals (Krauss et al. 
2005).   
 
1.7 Lipid metabolism 
1.7.1 Lipogenesis 
There are three major sources of fatty acids (FA): from dietary components (glycerides, 
phospholipids, sterols), from peripheral lipolysis, or from de novo lipogenesis. Fatty acids can 
then either be oxidized through beta-oxidation, lipolytic pathways, or ketosis, or they can form 
TG through esterifcation of FA with glycerol. Lipid accumulation therefore occurs when there is 
an imbalance between the amount of FA being formed and stored as TG, and the amount that is 
being used as fuel. This imbalance can lead to the development of obesity, insulin resistance, type 
2 diabetes, and cardiovascular disease (Saltiel and Kahn 2001). The main sites of lipogenesis 
comprise the liver, adipose tissue and intestinal mucosa (Vernon et al. 1999). The liver has a 
central clearing role, taking up and esterifying FA. It can also synthesize FA de novo from acetyl-
CoA derived from the metabolism of carbohydrates, and to a lesser extent of amino acids 
(Vernon et al. 1999; Ramesh and Sanyal 2004; Patel 2011; King 2012). An abundance in dietary 
carbohydrates leads to TG formation. Indeed the action of acetyl CoA carboxylase (ACC) on the 
glycolytic end-product acetyl-CoA forms malonyl-CoA and activates FAS. Alternatively, the 
glycolysis intermediate glyceraldehyde-3-phosphate is used to form glycerol-3-phosphate 
(esterification leads to TG) (Neville and Picciano 1997)(Figure 26).  
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Figure 26: Summary of different pathways that lead up to TG formation (taken from:(Neville and 
Picciano 1997)). 
 
Very little de novo lipogenesis occurs in individuals on a high-fat diet. Excess FA is converted to 
TG in the liver. Alternatively it can also be stored in the adipose tissue through the action of 
lipoprotein lipase on the chylomicrons or VLDL particles carrying them. The adipose tissue 
obtains FA through the action of lipoprotein lipase. This enzyme hydrolyses TG coming from the 
liver or intestine and is also implicated in de novo FA synthesis (Vernon et al. 1999). On the 
other hand, the intestinal mucosa is involved in handling FAs that are absorbed from diet. It is to 
note that the synthesized TG are exported into circulation either as chylomicrons, coming from 
the intestine, or as VLDL, coming from liver (Vernon et al. 1999)(Figure 27). Fatty acid 
synthesis occurs in the cytoplasm as compared to fatty acid oxidation occurring in mitochondria.  
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Figure 27 : Action of lipoprotein lipase on chylomicron and VLDL leads to FA release followed 
by TG esterification destined to secretion by the liver or storage into adipose tissue (taken 
from:(Vernon et al. 1999)). 
The presence of insulin is indicative of a fed state, promoting pathways of storage, such as 
lipogenesis and FA synthesis. Insulin induces lipogenesis in the liver, while inhibiting hormone-
sensitive lipase and therefore lipolysis in the adipose tissue. Consequently, this limits the release 
of fatty acids and glycerol, while promoting TG storage (Sakakura et al. 2001; Kraemer and Shen 
2002; Postic et al. 2004). Insulin induces sterol-regulatory-element binding protein (SREBP1-c), 
which regulates the transcription of genes involved in cholesterol and FA biosynthesis. 
Activation of SREBP1-c by insulin or chREBP/Mlx by high blood glucose levels can also 
modulate the transcriptional effects of insulin on lipogenic or glycolytic enzymes. Examples 
include fatty acid synthase (FAS), ACC, pyruvate kinase and glycerol-3-phosphate 
acyltransferase (first step in process of TG formation from glycerol-3-phosphate) (Shimano 2001; 
Bildirici et al. 2003; Clement et al. 2009). PPAR! is also known to regulate fatty acid storage by 
stimulating lipid uptake and adipogenesis in adipose tissue (Bildirici et al. 2003).  
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1.7.2 Lipolysis  
Hormones such as glucagon, norepinephrine, epinephrine, growth hormone, testosterone, 
cortisol, and leptin, as well as the AMPK pathway stimulate lipolysis. The latter occurs when 
energy stores need to be mobilized. It is the process by which TG are converted to FA, by lipases 
such as hormone-sensitive lipase (in adipose tissue) or other lipoprotein lipases. FA then go 
through #-oxidation producing acetyl-CoA, which can then enter the CAC (ATP production) or 
go into the gluconeogenic pathway (Lass et al. 2011). Fatty acids arrive in the cell, and in the 
cytoplasm they get linked to coenzyme A, forming fatty acyl coenzyme A. The latter is then 
transported by CPT-1 into the mitochondria, where it undergoes cycles of #-oxidation. Each 
cycle releases a molecule of acetyl-CoA and a fatty acyl-CoA shortened by 2 carbon atoms. This 
process continues until all is converted to acetyl-CoA, which proceeds into the CAC (Lodish 
2000). Beta-oxidation occurs in the mitochondria of the cells in question, or it can also occur in 
peroxisome when the fatty acid chains are too long to be processed by mitochondria. The 
difference between #-oxidation in the peroxisome as compared to the mitochondria is that it is 
not coupled to ATP synthesis. More specifically, the electrons transferred on O2 yield H2O2. 
Catalase, present in peroxisomes, converts H2O2 to water and oxygen (Lodish 2000). It is also 
believed that these long chain fatty acids may undergo initial oxidation in the peroxisomes 
followed by mitochondrial oxidation.  
In addition, medium chain fatty acids can undergo CYP4A mediated %-oxidation that 
takes place in the endoplasmic reticulum of the liver or kidney (Reddy and Hashimoto 2001). It 
involves oxidation on the %-carbon, the most distant carboxyl group of the fatty acid, instead of 
the #-carbon, involved in #-oxidation. First step in omega-oxidation, FA go through a process of 
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hydroxylation by mixed function oxidases (members of CYP450 family). This is followed by 
oxidation of the hydroxylated FA, with alcohol dehydrogenase and aldehyde dehydrogenase 
(Kundu et al. 1991). At the end of this cycle, the formed dicarboxylic acid can enter mitochondria 
or peroxisome as a CoA-ester. It undergoes #-oxidation, producing succinic acid as an end 
product, which can then enter CAC or the gluconeogenic pathway (Hunt and Alexson 2008; 
Wanders et al. 2011). Omega-oxidation represents a minor pathway, responsible for 5-10% of FA 
oxidation. However, during starvation or diabetes it gains importance. Alpha-oxidation occurs in 
peroxisome and only its end products go on in mitochondria for full oxidation. Alpha and omega-
oxidation occur when carbon-3 of the fatty acid has a methyl or other functional group attached 
to it (Kundu et al. 1991; Wanders et al. 2011).  
TGs are transported in the blood through the means of chylomicrons or lipoproteins to 
tissues such as the muscle and adipose tissue. Once they reach these tissues the cellular 
lipoprotein lipases (LPL), found in the endothelial cells of the capillary beds of the adipose, 
muscle and cardiac tissues, lyse the TG from the chylomicrons or lipoproteins into glycerol and 
FFA. The FFA are then either taken up by the cell or transported by binding to albumin to tissues 
requiring energy (Brody 1999; Lodish 2000). Concerning glycerol it is absorbed by the liver and 
kidney. Through the action of glycerol kinase it is converted to glycerol-3-phosphate. In the liver, 
glycerol-3-phosphate is converted to dihydroxyacetonephosphate (DHAP) and then isomerized to 
glyceraldehyde-3-phosphate (GA3P). The latter can be used for glycolysis or gluconeogenesis 
(Berg 2002). 
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1.7.3 Lipoproteins 
Chylomicrons belong to the family of lipoproteins, which also include very low density 
lipoprotein (VLDL), low density lipoprotein (LDL), high-density lipoprotein (HDL), and 
intermediate density lipoprotein (IDL). Chylomicrons are composed of nascent TG synthesized 
from absorbed FFA and monoacylglycerol along with other lipids and apolipoprotein B48 
(Wasan et al. 2008). Chylomicrons are produced in absorptive cells of small intestine, more 
specifically in epithelial cells within the villi of the duodenum. Their purpose is to transport 
exogenous (i.e. dietary source) fats to appropriate tissues in order to be used for fuel or storage if 
in excess (Widmaier 2004; Wasan et al. 2008). VLDL is assembled in the liver from TG, 
cholesterol and apolipoproteins (B100, C1, E), transporting endogenous fats and cholesterol to 
tissues (Wasan et al. 2008). VLDL is converted to LDL in the blood. VLDL comes into contact 
with lipoprotein lipase, which removes TG from VLDL for storage or energy production. As TG 
get removed from VLDL its composition changes, and it becomes an IDL. 50% of IDL is 
endocytosed by liver through ApoB-100 and ApoE, and the remaining 50% lose ApoE and 
become LDL (cholesterol content greater than TG). LDL can then be endocytosed. Its contents 
are either stored, used for membrane structure, or converted to steroid hormones or bile acids. 
HDL has the highest protein to cholesterol ratio of all lipoproteins. The main apolipoprotein in 
HDL is ApoA. It is cleared from the blood by scavenger receptor B1 (SRB1), which is present on 
hepatocytes (Wasan et al. 2008). The role of HDL is to transport cholesterol back to the liver. It is 
then excreted into bile and intestine directly, or indirectly after conversion to bile acids. HDL can 
also be delivered to steroidogenic organs such as ovary and testes (Kingsbury and Bondy 2003) 
(Figure 28). 
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Figure 28: Summary of the formation and fate of chylomicrons and lipoproteins (Kwan et al. 
2007). 
  
1.7.4 Alternative fuel through ketogenesis 
Ketogenesis occurs mainly in the mitochondria of hepatocytes under conditions of 
starvation, overnight fast (increased glucagon and decreased insulin secretion), low blood glucose 
levels and after exhaustion of glycogen stores (Voet 2004; Soeters et al. 2009). During starvation, 
gluconeogenesis can take place for several days. It promotes TG breakdown forming glycerol and 
dihydroxyacetone phosphate in the process, or increases proteolytic degradation of proteins, the 
major source being muscle mass (Voet 2004). There is also mobilization of FA stores from 
adipose tissue, where FA are broken down into acetyl-CoA through #-oxidation. All these 
mechanisms have the objective of restoring energy production, and eventually leading to alternate 
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pathways, such as ketone body formation (Voet 2004). The CAC can get overwhelmed due to 
large amounts of acetyl-CoA produced by #-oxidation. In addition, CAC activity can be 
decreased due to lack of intermediates, such as oxaloacetate used in pathways of 
gluconeogenesis. Therefore, this leads to acetyl-CoA being used in the biosynthesis of ketone 
bodies. Two molecules of acetyl-CoA through the action of thiolase form acetoacyl-CoA, which 
interacts with a third molecule of acetyl-CoA forming #-hydroxy-#-methylglutaryl-CoA (HMG-
CoA; precursor of cholesterol biosynthesis) by HMG-CoA synthase. This leads up to the 
formation of ketone bodies such as acetoacetate (action of HMG-CoA lyase on HMG-CoA), and 
#-hydroxybutyrate (action of #-hydroxybutyrate dehydrogenase on acetoacetate)(Voet 
2004)(Figure 29).  
 
Figure 29: The pathway leading up to the formation of ketone bodies (taken from:(King 2012)).  
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The liver releases these ketone bodies into circulation, in order to be used as fuel in 
peripheral tissues, such as heart and skeletal muscle. The brain’s main source of energy is 
glucose. However during prolonged periods of starvation, since fatty acids cannot penetrate the 
blood-brain barrier, the main source of fuel become the ketone bodies (Voet 2004). Once the 
ketone bodies have reached the peripheral tissues, they are converted by a series of enzymes to 
acetyl-CoA. Acetoacetate, a #-keto acid, can undergo non-enzymatic decarboxylation, forming 
acetone and CO2. When it is produced faster than it is metabolized, it can lead to 
ketosis/ketoacidosis, giving individuals acetone-smelling breath (Voet 2004; Soeters et al. 2009). 
In healthy individuals, the ketogenesis pathways is kept under control. However, in patients with 
type 1 diabetes (lacking the presence of insulin which inhibits ketogenesis), this pathway can lead 
to increased amounts of acetoacetate ketone body formation, causing ketoacidosis, and a pH drop 
in the blood. Symptoms of ketoacidosis include vomiting, dehydration, confusion and can lead to 
coma.  Ketoacidosis can also be present among type 2 diabetic patients, where it is termed 
ketosis-proned type 2 diabetes. This occurs in T2D patients, since the amount of insulin produced 
is insufficient, or its action on target tissues is impaired due to established state of insulin 
resistance, leading to decreased glucose uptake, and enhancement of the ketogenesis pathway 
(Voet 2004)(Figure 30). 
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Figure 30: Ketone bodies used as a source of fuel and energy production in tissues such as the 
brain and the heart (taken from:(Rabinowitz and White 2010)).  
 
1.8 The metabolic syndrome and  obesity 
1.8.1 The metabolic syndrome 
The metabolic syndrome, also known as syndrome X, is characterized by the presence of 
3 out of these 5 symptoms: central obesity defined by waist circumference or waist-to-hip ratio of 
respectively over 102 cm and 0.90 for males, and of over 88 cm and 0.85 for females; elevated 
circulating triglycerides levels (over 150 mg/dL or 1.7 mmol/L); decreased HDL (good 
cholesterol) levels (under 40 mg/dL or 1.03 mmol/L in males, and 50 mg/dL or 1.29 mmol/L in 
females); increased blood pressure (over 130/85 mmHg); and increased fasting blood glucose 
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levels (varies according to guidelines followed, but in general over 5.6 mmol/L) or use of 
medications for hyperglycemia (Alberti 2006). There are a variety of factors that are involved in 
the development of the metabolic syndrome. These include a sedentary lifestyle with decreased 
physical activity and increased caloric intake, body weight, genetics, age, and stress, which is 
said to increase cortisol levels, which in turn increase glucose and as a result insulin levels 
(Bouchard 1995; Groop 2000; Poulsen et al. 2001; Tsigos and Chrousos 2002; Grundy et al. 
2004; Pollex and Hegele 2006). Hyperinsulinemia has been associated with raising blood 
pressure by increasing the sympathetic nervous system and release of catecholamine levels 
(Abdulla et al. 2011).  
 
1.8.2 Obesity 
The body mass index (BMI), which takes into account the weight and height of an 
individual, is used as a tool to determine the degree of obesity: between 25-30 kg/m2 an 
individual is considered overweight and pre-obese, over 30 kg/m2 they are considered obese, and 
with a BMI over 35 kg/m2 they are morbidly obese. Obesity is defined by an excess in fat 
accumulation not only in the adipose tissue, but also ectopically in the liver and muscle. An 
imbalance in the liver either of fatty acid uptake, endogenous FA synthesis, TG synthesis, FA 
oxidation, or TG export, increases the chances of developing non-alcoholic fatty liver disease 
(NAFLD) (Stienstra et al. 2007).  Obesity, more specifically central, i.e. visceral adipose tissue, 
increases the risk of developing the many metabolic and systemic disorders that characterize or 
originate from the metabolic syndrome. These include T2D, dyslipidemia, and cardiovascular 
health problems, the latter being a major cause of mortality in these patients. Obesity is linked to 
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a state of chronic low-grade inflammation, initiated by morphological changes in adipose tissue. 
This contributes to the development of insulin resistance (Figure 31).  
 
Figure 31: Summary of factors leading to obesity and its associated metabolic disturbances (taken 
from:(Bays 2011)). 
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1.8.3 Obesity and inflammation 
Obesity leads to adipose tissue/adipocyte hypertrophy, stimulating necrotic and apoptotic 
pathways (Cinti et al. 2005; Sun et al. 2011). This upregulates the phagocytic stimuli involved in 
macrophage infiltration, inducing chemokines (MCP-1, CXCL14, MIP1", MCP-2 and MCP-3), 
T-lymphocytes, neutrophils. Secretion of proinflammatory cytokines (TNF-", IL-6, MCP-1, etc.) 
is also increased (Figure 32).   
 
Figure 32 : Obesity lead to hypertrophy and hypoxia leading to increased secretion of pro-
inflammatory cytokines and macrophage infiltration (taken from:(Morton 2009)).  
 
Whereas, anti-inflammatory cytokines, such as adiponectin and IL-10 are down-regulated 
(Suganami and Ogawa 2010; Mandal et al. 2011; Sun et al. 2011)(Table 2).   
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Table 2: Summary of factors that are upregulated and released during obesity (taken from:(Ouchi 
et al. 2011)).  
The observed hypertrophy also leads to poorly oxygenated adipose tissue and therefore 
hypoxia. This upregulates factors such as macrophage migration inhibitory factor (MIF), matrix 
metalloproteinases MMP2 and MMP9, IL-6, ANGPTL4, PAI-1, VEGF and leptin. The two latter 
are directly regulated by the hypoxia inducible factor (HIF) (Sun et al. 2011). VEGF and 
ANGPTL4 are involved in angiogenesis. They are said to be the target of peroxisome proliferator 
activators, such as the PPAR! agonists thiazolidinediones, and to promote insulin sensitivity 
(regulating glucose and lipid metabolism) (Gealekman et al. 2008). PAI-1 is an inhibitor of 
fibrinolysis/degradation of blood clots. Its high levels in obese patients have been linked with a 
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higher incidence of fibrosis, arterial remodeling, hypertension, and atherothrombotic events 
(Vaughan 2011). PAI-1 is also reportedly high in type 2 diabetics, and can be used as a predictor 
of the development of this disease. However the exact causality relationship is under 
investigation (Vaughan 2011). Treatment with metformin or thiazolidinediones in diabetic 
patients effectively reduces circulating PAI-1 levels (Vaughan 2011).  
 
1.8.4 Adipose tissue as an endocrine organ 
The adipose tissue acts as an endocrine organ, able to release cytokines, also known as 
adipokines, into the bloodstream. This allows it to communicate with the other insulin-sensitive 
organs, i.e. the muscle and the liver. These adipokines, which include leptin, adiponectin, resistin 
and TNF-", are secreted from the adipose tissue and function in an endocrine (regulating energy 
homeostasis), autocrine or paracrine manner (regulating adipocyte metabolism).  Palmitoleate or 
palmitoleic acid (C16:1 n-7) is a monounsaturated fatty acid derived from plant and marine 
sources. Current studies have classified palmitoleate as an adipose tissue-derived lipid hormone, 
termed as lipokine (Cao et al. 2008; Lodhi et al. 2010; Mozaffarian et al. 2010; Zhang and Zhang 
2010; Fabbrini et al. 2011; Fernandez et al. 2011; Yang et al. 2011; Zechner et al. 2012). This 
lipokine is produced during de novo lipogenesis in the adipose tissue (through the action of SCD-
1 on palmitic acid/palmitate). It is a circulating factor that in animal models is involved in 
improving insulin sensitivity, as well as regulating glucose and lipid metabolism in insulin-
sensitive tissues such as the liver and muscle. It has been associated with preventing #-cell 
apoptosis, promoting #-cell proliferation, and improving the circulating lipid profile (Cao et al. 
2008; Lodhi et al. 2010; Mozaffarian et al. 2010; Zhang and Zhang 2010; Fabbrini et al. 2011; 
Fernandez et al. 2011; Yang et al. 2011; Zechner et al. 2012). It has been reported to alter the 
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adipocytokine profile, for example decreasing circulating levels of TNF-" and resistin, which are 
associated with insulin resistance. Other beneficial effects include reducing lipid accumulation in 
the liver. This is achieved by decreasing expression of enzymes or transcription factors involved 
in de novo lipogenesis and triglyceride synthesis, such as fatty acid synthase (FAS), SCD-1 
(stearoyl-CoA desaturase-1), and SREBP-1. It has also been suggested that palmitoleate modifies 
food intake, however its exact mechanism remains unresolved (Cao et al. 2008; Lodhi et al. 2010; 
Mozaffarian et al. 2010; Zhang and Zhang 2010; Fabbrini et al. 2011; Fernandez et al. 2011; 
Yang et al. 2011; Zechner et al. 2012). The next important step is validating the aforementioned 
metabolic benefits of palmitoleate in humans.  
 
1.8.4.1 Leptin 
Leptin is a hormone secreted primarily from white adipose tissue (WAT). Other sources 
include brown adipose tissue (BAT), placenta, ovaries, skeletal muscle, stomach, gastric mucosa, 
bone marrow, pituitary and liver. It is secreted in levels proportional to body fat, making it a 
biomarker for adiposity. Its action on the hypothalamus allows for regulation of energy intake 
and expenditure, body temperature, body weight, and reproductive function (acting on 
gonadotropin-releasing hormone, luteinizing and follicle stimulating hormone) (Matarese et al. 
2002; Meli et al. 2004; Hafeezullah 2006). Leptin binds to neuropeptide Y (NPY) and agouti-
related protein (AgRP) neurons in the arcuate nucleus of the hypothalamus. This decreases the 
activity of these neurons, signaling to the body that satiety has been reached. In return, it 
increases expression of anorexigenic peptides POMC (proopiomelanocortin) and CART (cocaine 
and amphetamine regulated transcript). Orexigenic peptides, both NPY and AgRP, are involved 
in the regulation and stimulation of appetite. Leptin also acts on and increases the activity of "-
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melanocyte-stimulating hormone ("-MSH) neurons signaling satiety. In obese individuals, leptin 
circulates in high concentrations in the plasma leading to leptin-receptor desensitization, 
consequently not allowing the body to properly perceive signals of satiety (Zimmet et al. 1996). 
Leptin has also been shown to activate the AMPK pathway, promoting glucose uptake, fatty-acid 
oxidation, inhibiting lipogenesis and ectopic fat storage in non-adipose tissues, thereby enhancing 
insulin sensitivity (Margetic et al. 2002; Castracane 2006; Hardie 2008)(Figure 33).  
 
 
Figure 33 : Summary of the actions of leptin on peripheral tissues (taken from:(Maiorana et al. 
2007)).  
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1.8.4.2 Adiponectin 
Adiponectin is secreted into the bloodstream where it accounts for 0.01% of total serum 
protein. Its concentrations range from 5-10 µg/ml, being higher in females than in males (Trujillo 
and Scherer 2005). It was thought to be exclusively secreted from adipose tissue. However recent 
evidence supports that it is also expressed and secreted from cardiomyocytes and vascular smooth 
muscle cells, which also express adiponectin receptors (Pineiro et al. 2005; Ding et al. 2007). 
Adiponectin has antidiabetic, anti-atherogenic, anti-hypertensive, insulin-sensitizing properties, 
as well as anti-inflammatory ones. It is also involved in modulating a number of metabolic 
processes implicated in glucose regulation and fatty acid metabolism. As opposed to leptin, it is 
inversely correlated to the percentage of body fat (Ding et al. 2012). Diabetes and obesity lead to 
decreased circulating adiponectin levels, whereas weight loss promotes its secretion. Its 
expression is up-regulated during adipogenesis (Trujillo and Scherer 2005), and also by 
antidiabetic medications, such as the thiazolidinediones (Lindsay et al. 2002). It stimulates the 
AMPK pathway. This promotes glucose and fatty acid uptake (Liu et al. 2010), increases fatty 
acid oxidation in tissues such as the muscle and adipose tissue, and inhibits hepatic glucose 
production (Figure 34). Therefore, in obese individuals the low circulating adiponectin levels 
further contribute to the development of insulin resistance by a reduction of the beneficial effects 
of AMPK pathway activation (Kadowaki et al. 2008).  
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Figure 34: Adiponectin stimulates the AMPK pathway in both the liver and skeletal muscle, 
decreasing glucose production, promoting lipid oxidation and glucose uptake (taken from:(Long 
and Zierath 2006)).  
 
1.8.4.3 Pro-inflammatory cytokines, particularly TNF-"  
Increased visceral fat and adipocyte hypertrophy increase the degree of inflammation, 
through macrophage infiltration into WAT. This leads to production of pro-inflammatory 
cytokines (Stienstra et al. 2007). Examples include interleukins 1b, 6, and 8 (IL-1#, IL-6, IL-8), 
and monocyte-chemoattractant protein-1 (MCP-1), MIF (proinflammatory process), MIP 
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(regulates leukocyte migration and infiltration in inflammatory process), as well as C-reactive 
protein (biomarker of system inflammation)(Fruhbeck 2008). MCP-1 is similar to resistin in that 
it is secreted by the adipose tissue, increases with obesity, and has immune modulating functions 
(Stienstra et al. 2007).  
The most important cytokine, however, is called tumor necrosis factor-alpha (TNF-"). It 
is secreted in levels proportional to adipose tissue size, while also regulating cell size. This means 
that as adipocytes get bigger, TNF-" levels increase. This in turn initiate changes to limit 
adipocyte size or induce apoptosis (Coppack 2001). Hence it is implicated in regulating its own 
expression, while increasing the synthesis of other cytokines such as IL-6. TNF-" and IL-6 
decrease lipid accumulation in adipose tissue. This is achieved through the inhibition of 
lipoprotein lipase and stimulation of hormone-sensitive lipase, which induces uncoupling protein 
expression (Coppack 2001). TNF-" contributes to the development of insulin resistance by 
downregulating insulin-stimulated glucose uptake. This occurs through a reduction of Glut4 
expression, or through effects on insulin receptor or IRS-1 (Coppack 2001). Its actions on the 
insulin signaling pathway include lowering tyrosine phosphorylation of the insulin receptor, and 
increasing serine phosphorylation at 307 through phosphorylated IKK# (well-known downstream 
kinase of TNF-") or even JNK, or by phosphorylating other serine or threonine residues of IRS-1 
(Coppack 2001; Jiang et al. 2003; Gual et al. 2005; Huang et al. 2009). IKK# can also be 
activated by PKC isoforms, which are involved in IRS-1 ser/thr phosphorylation in response to 
FFA concentrations. FFA activate PKC, which goes on to stimulate IKK, or they can directly act 
on JNK, with the end result being serine phosphorylation (Ser307) on IRS-1 (Gual et al. 2005). It 
is to note, that salicylates (found in Populus balsamifera, one of the plant extracts studied in this 
thesis) inhibit IKK#. This can lead to an improvement in glucose tolerance by preventing the 
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decrease in tyrosine phosphorylation (Gual et al. 2005). TNF-" has also been reported to inhibit 
CCAAT-enhancer binding protein and PPAR!, which in turn decrease the expression of genes 
such as FABP, FAS, ACC, glucose-6-phosphate dehydrogenase, as well as lipoprotein lipase and 
Glut4 (Coppack 2001). The inflammatory cytokine increases the mobilization of lipids by 
activating hormone sensitive lipase, thereby increasing lipolysis of TG in the adipose tissue and 
releasing FFAs into circulation. This promotes ectopic fat storage. IL-1 and IL-6 are also 
involved in increasing lipolysis and inhibiting lipoprotein lipase (Coppack 2001)(Figure 35).  
 
Figure 35 : TNF-" leads to insulin resistance by acting on various downstream effectors (taken 
from:(Cawthorn and Sethi 2008))).  
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1.8.4.4 Resistin 
Resistin is produced and released by adipose tissue, as well as mammary gland, heart, 
brain, lungs, and gastrointestinal tract (Pantsulaia et al. 2007). It is said to play a role in 
inflammation, energy homeostasis (not completely well-defined), and insulin resistance 
(Vasudevan 2011). There have also been studies that have revealed that resistin induces #-cell 
apoptosis in rat insulinoma RINmF5 cells, whereas in many cell lines it can lead to a reduction of 
Akt phosphorylation and attenuation of insulin signal (Gao et al. 2009). There are many 
contradictory studies on the role of resistin on obesity and T2D. However, in many cases, there 
have been reported increased levels present in obese patients (particularly with central obesity), 
associated with increased insulin resistance. It is also said to be implicated in the transcriptional 
events that lead up to increased expression of pro-inflammatory cytokines, such as TNF-", IL-1, 
and IL-6 (Calabro et al. 2009). 
  
Figure 36: Resistin leads to insulin resistance and increases expression of pro-inflammatory 
cytokines (taken from:(Flier 2001)).  
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In addition, transcription of the resistin gene is decreased in subjects treated with agonists of 
PPAR!, such as the antidiabetic Tzd medications, thereby contributing to increase the action of 
insulin (Kumar 2003; Calabro et al. 2009)(Figure 36).  
 
1.8.4.5 Newly identified inflammatory cytokines 
There are many other newly identified inflammatory cytokines that are being investigated 
for their role in obesity and type 2 diabetes. Retinol binding protein 4 (RBP4), a hepatocyte-
secreted factor that transports retinol (vitamin A) throughout the body, has also been reported to 
be released from adipocytes and macrophages (Ouchi et al. 2011). Its expression is inversely 
correlated with that of Glut4. Its presence inhibits insulin-induced IRS-1 phosphorylation. 
Therefore increased RBP4 serum concentrations are associated with features of the metabolic 
syndrome: increased blood pressure, low HDL levels, increased cholesterol and triglyceride 
levels, and increased body mass index/BMI (Ouchi et al. 2011). Mostly produced by visceral 
adipose tissue in states of obesity and insulin resistance, RBP4 can be used as a marker of intra-
abdominal adipose tissue expansion and subclinical inflammation (Ouchi et al. 2011). Lipocalin 2 
is also known as neutrophil gelatinase associated lipocalin or 24p3. It belongs to the lipocalin 
protein family, which also includes RBP4. It is expressed abundantly in adipose tissue, is induced 
by inflammatory stimuli, and positively correlates to the degree of obesity and adiposity, 
hyperglycemia, insulin resistance and C-reactive protein (Ouchi et al. 2011).  
ANGPTL2 is also a marker that is positively associated with adiposity, markers of insulin 
resistance and C-reactive protein levels, and it activates inflammatory and phagocytic (monocytes 
and macrophages) responses (Ouchi et al. 2011).  
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CXCL5 is associated with obesity, insulin resistance, and inflammation. It is expressed at 
high levels in adipose tissue. It decreases insulin-induced glucose transport in the muscle by 
activating the JAK/STAT pathway and increasing expression of SOCS2, which inhibits insulin 
signaling cascade (Chavey et al. 2009).  
NAMPT, also known as pre-B cell colony enhancing factor or visfatin, is expressed by 
adipose tissue. It circulates in high levels in patients with obesity and type 2 diabetes. Its serum 
levels positively correlate to IL-6 and C-reactive protein levels(Ouchi et al. 2011). However, 
there have been conflicting results regarding its physiological role, since some studies report that 
it has glucose-lowering properties and promotes insulin secretion from pancreatic #-cells 
(Revollo et al. 2007). 
 
1.8.4.6 Obesity treatments 
The best way to prevent or even treat obesity is through diet and exercise. In extreme 
cases of obesity, bariatric surgery may be recommended or even necessary. However, many 
antiobesity treatments are available on the market or currently under investigation in clinical 
trials. They are geared to control or decrease body weight, by altering either appetite, 
metabolism, or interfering with the body’s ability to absorb certain nutrients (Melnikova and 
Wages 2006).  Throughout history, mankind has focused on finding the ultimate solution to 
weight loss, these included the use of laxatives, purgatives, thyroid hormone in euthyroid 
individuals, dinitrophenol (DNP), amphetamines, Fen-phen, and ephedra. Many of these 
treatments were removed from the market due to their serious adverse effects (Valentino et al. 
2011). For example, DNP, which uncouples oxidative phosphorylation from ATP production 
producing heat instead, lead to warmth and frequent sweating, and in some cases to fatal 
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hyperthermia (Valentino et al. 2011). It can even cause agranulocytosis (leucopenia where 
individuals lack major class of infection-fighting white blood cells), dermatitis, and cataracts 
(Valentino et al. 2011). Those taking thyroid hormone had hyperthyroid-like symptoms such as 
palpitations, and difficulty sleeping. Amphetamines (enhance release of neurotransmitters) used 
for their appetite-suppressing effects and increased alertness were very popular and eventually 
became a part of the ‘rainbow pill regime’, which included amphetamines, thyroid hormone, 
diuretics, digitalis, laxatives and barbiturates (to suppress the stimulant effects of the 
amphetamines) (Valentino et al. 2011). Fen-phen, a combination of fenfluramine and 
phentermine, was very popular in the 90’s, but was removed from the market in 1997 due to 
reports of valvular heart disease (Valentino et al. 2011). Ephedra was removed because of 
concerns that it increased blood pressure and the risk of stroke and death (Valentino et al. 2011).  
More recent antiobesity treatments include Orlistat, sibutramine, rimonabant, and 
exenatide (Valentino et al. 2011). Orlistat (Xenical®), a lipase inhibitor, acts by inhibiting 
intestinal fat absorption through the inhibition of pancreatic lipase. This treatment comes with 
undesirable side-effects such as oily bowl movements (can be decreased if dietary fat content is 
reduced), stomach pain, and flatulence (Bays 2004; Valentino et al. 2011). Sibutramine 
(Meridia®) is a neurotransmitter reuptake inhibitor, increasing concentrations of serotonin, 
norepinephrine and dopamine in the synapse, resulting in decreased appetite (satiety), and 
increased thermogenesis (Li and Cheung 2009). It has been pulled off the market because its risks 
outweigh the benefits. Indeed, it increases blood pressure, and can cause myocardial infarction, 
stroke, dry mouth, constipation, headache and insomnia (Li and Cheung 2009). Rimonabant is a 
CB1 receptor antagonist, acting centrally in the brain by decreasing appetite, and peripherally by 
increasing thermogenesis and energy expenditure (Li and Cheung 2009; Verty et al. 2009). It has 
not been approved for use in Canada or USA due to serious psychiatric adverse effects (ex. 
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depression and suicide) (Valentino et al. 2011).  TM38837 is in clinical trials, and is an inverse 
agonist of the CB1 receptor (acts in periphery) (Sink et al. 2009). Exenatide (Byetta®) is a long-
acting GLP-1 analogue. GLP-1 is secreted by the intestine L-cells in the presence of food, 
delaying gastric emptying and promoting the feeling of satiety (Bays 2004; Hainer 2011; 
Valentino et al. 2011). The disadvantage of this treatment is that it needs to be injected twice a 
day and causes severe nausea, and gastrointestinal symptoms.  
There are numerous treatments that are being researched and are undergoing clinical trial 
for their antiobesity potential. These include pramlintide (symlin), ZGN-433, lorcaserin, new 
combinations of selective serotonin reuptake inhibitors (SSRIs) with phentermine, and other 
lipase inhibitors such as GT 389-255 (without the oily stools side-effect as seen with Orlistat). 
Pramlintide is administered subcutaneously and is a synthetic analogue of the hormone amylin, 
secreted by the pancreas in response to food intake, delaying gastric emptying while promoting 
satiety (Bays 2004; Li and Cheung 2009; Valentino et al. 2011). Although it is approved for use 
in combination with insulin for the treatment of T1D and T2D, it is now being evaluated for its 
antiobesity potential (Bays 2004; Pullman et al. 2006; Li and Cheung 2009; Valentino et al. 
2011). ZGN-433, also known as beloranib, an analog of the natural compound fumagillin (known 
for its anti-angiogenic properties), is an inhibitor of methionine aminopeptidase (METAP2; 
binding to its active site). Through a mechanism that remains unclear at this point, it re-
establishes the balance in the metabolism of fat, decreasing body weight and retroperitoneal fat 
pad weight, while restoring glycemia in the process (Powell et al.). Lorcaserin is a selective 
agonist of the 5-HT2c receptor, found exclusively in the brain in regions such as the 
hypothalamus. Activation of these receptors leads to increased production of POMC increasing 
satiety and promoting weight loss (Bays 2009). FDA did not approve the use of lorcaserin due to 
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cancer promoting properties that could not be ruled out, and for its marginal effect on weight loss 
(Alavi 2010; Colman 2010; Valentino et al. 2011).   
There are many potential treatment avenues currently being investigated for their use 
against obesity. There have been studies that demonstrate the importance of studying the 
interactions between nuclear hormone receptors and regulatory cofactors. For example, when the 
interaction between SMRT (nuclear hormone corepressor) and the nuclear hormone receptor 
proteins was inhibited, this lead to increased adiposity and decreased metabolic rate (Nofsinger et 
al. 2008). Another interesting venue is the use of ribonucleic interference (RNAi), in silencing 
genes implicated in fat metabolism. One gene that has been explored in mouse models is the 
RIP140 gene, a nuclear hormone corepressor, which regulates fat accumulation. Genetically 
manipulated mice devoid of RIP140 exhibited a lean profile, were resistant to diet-induced 
obesity, and increased metabolic rate (Leonardsson et al. 2004; Christian et al. 2006; Kiskinis et 
al. 2007).  
 
1.9 Diabetes classifications and antidiabetic treatments 
1.9.1 Diabetes prevalence, symptoms, diagnosis 
Diabetes mellitus, generally referred to as diabetes, currently affects 346 million people 
worldwide (WHO 2011a). It is defined by increased blood glucose levels due either to inadequate 
insulin secretion or to the lack of response by the cells to the insulin produced. Individuals 
experience symptoms such as polyuria (increase urination), polydypsia (increase thirst), 
polyphagia (increased appetite), and weight loss, as well as vision changes, and fatigue (WHO 
2011a).  
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A person is diagnosed as diabetic when they have a fasting blood glucose concentration of 
7 mmol/L (126 mg/dL) or more, or when their glycemia during random testing is 11 mmol/L 
(200 mg/dL) or more (WHO 2006). Glycated hemoglobin (HbA1C) is also used in the diagnosis 
of diabetes, giving an index of average blood glucose levels over a period of 120 days (lifespan 
of erythrocytes) (Fourlanos et al. 2006).  Individuals with an HbA1C of over 6.5% are considered 
diabetic (ADA 2010b). An oral glucose tolerance test (OGTT) consists in the administration of an 
oral glucose load of 75g after an overnight fast followed by measuring blood glucose levels after 
2h. If glycemia levels are over 11 mmol/L (200 mg/dL) two hours after an OGTT, the individual 
is considered diabetic (WHO 1999; WHO 2006; Goldstein 2008; Vijan 2010). If, however, they 
are between 7.8 mmol/L (140 mg/dL) and 11 mmol/L (200 mg/dL) the individuals are considered 
as having impaired glucose tolerance (IGT) (WHO 1999; WHO 2006; Goldstein 2008; Vijan 
2010). On the other hand, if fasting levels range from 5.6 to 6.9 mmol/L (100 to 125 mg/dL), they 
are considered as having impaired fasting glucose (IFG) (WHO 1999; WHO 2006; Goldstein 
2008; Vijan 2010). Both IGT and IFG are considered prediabetic conditions, yet only individuals 
with impaired glucose tolerance have a higher risk of developing full-blown diabetes and the 
complications that arise from it (WHO 1999; WHO 2006; Goldstein 2008; Vijan 2010).  
1.9.2 Type 1 diabetes 
Type 1 diabetes (T1D), also known as insulin-dependent diabetes mellitus (IDDM) or 
juvenile diabetes, results in increased blood and urine glucose levels, and in some cases 
ketoacidosis. This is due to a lack of insulin, caused either by autoimmune or idiopathic 
destruction of #-cells of the islets of Langerhans in the pancreas. T1D corresponds to 5-10% of 
all cases of diabetes, and is divided into two subtypes: type 1A, corresponding to autoimmune 
destruction of #-cells, and type 1B idiopathic, of unknown origin (Imagawa et al. 2000; ADA 
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2004; ADA 2009). Genetics and environmental factors are implicated in the development of 
T1D.  There are many genes (polygenic) involved in the onset, for example HLA-DQ or DR gene 
mutations, HLA being cell surface receptor on antigen presenting cells and involved in antigen 
presentation. In terms of environmental factors, they include viral infections (Fairweather and 
Rose 2002), where the immune system attacks the virus and the #-cells in the pancreas. Dietary 
components influencing the gut flora, intestinal permeability and immune function of the gut, 
may lead to #-cell autoimmunity and to the progression of T1D (Knip 2009). Chemicals (toxins) 
such as streptozotocin (zanosar), used as an antibiotic and antineoplastic agent (chemotherapy for 
pancreatic cancer), kills #-cells resulting in decreased insulin production(Bolzan 2002). Other 
factors that may lead to diabetes are diseases of the exocrine pancreas, where damage to the 
pancreas is extensive. Examples of such problems include trauma to the pancreas, pancreatitis, 
and tumors (malignant or benign) (ADA 2004; ADA 2010a). It is to note that autoantibodies can 
be detected prior to the onset of hyperglycemia, and can be present for 5-10 years before the 
development of T1D (Knip et al. 2005). The antibodies can target islet cells, insulin, the 65 kDa 
glutamic acid decarboxylase (GAD; responsible for pancreatic GABA synthesis with a role on 
the endocrine function of pancreas)(Franklin and Wollheim 2004), tyrosine phosphatase IA-1 and 
IA-2b (suggested role in pancreatic development and insulin secretion), and other antigens. 
(Roberts et al. 2001; ADA 2010a). Within this time frame, some individuals may develop T1D as 
adults, often misdiagnosed as T2D because of their age, creating another subtype of diabetes 
termed latent autoimmune diabetes of adults (LADA). LADA appears after age 35 and is 
associated with other autoimmune diseases, such as autoimmune thyroid, celiac disease, 
rheumatoid arthritis, pernicious anemia, and autoimmune hepatitis (Fourlanos et al. 2006; Dib 
and Gomes 2009). Even though T1D is not preventable, there exist many treatments to control 
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hyperglycemia and to minimize the long-term complications associated with it. These include the 
utilization of immunosuppressive drugs, insulin therapy, pancreas transplantation, and islet cell 
transplantation (Shapiro et al. 2000). There have even been reports that breastfeeding (affecting 
microbial flora), as well as administration of vitamin D (acts as immunosuppressive) in early 
childhood decreases the risk of developing T1D (Akerblom et al. 2005; Wahlberg et al. 2006; 
Holmberg et al. 2007; Rosenbauer et al. 2008; Siljander 2010).   
 
1.9.3 Type 2 diabetes 
Type 2 diabetes (T2D), also referred to as non-insulin-dependent diabetes mellitus 
(NIDDM) or adult-onset diabetes, accounts for 90-95% of all cases of diabetes. It is characterized 
by hyperglycemia, insulin resistance, and relative insulin deficiency (Patel and Macerollo 2010). 
An individual is diagnosed with T2D if they have a single raised glycemia level along with 
presence of symptoms (similar to those observed with T1D), or if they have increased blood 
glucose levels on two separate occasions (fasting over 7 mmol/L and OGTT over 11 
mmol/L)(Patel and Macerollo 2010).  
There are many culprits that lead to the development of T2D. These include lifestyle 
(high-caloric diet and physical inactivity) changes, and environmental factors (epidemiological, 
industrialized countries or those with recent increased wealth as seen in Asia) (Caterson et al. 
2004; Scholl 2012). Genetic mutations (polygenic) are also involved. Examples include 
mutations in the TCF7L2 gene, involved in regulating expression of proglucagon and glucagon 
like peptide-1 (GLP-1), or in the KCNJ11 gene, which encodes islet ATP-sensing K+ channel 
Kir6.2 (Kirkpatrick et al. 2010). Other culprits include medications, and certain medical 
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conditions, such as the metabolic syndrome, chronic pancreatitis, cancer (NDIC 2008; NIDDK 
2011).  
Many factors lead to #-cell dysfunction, and therefore to insulin deficiency in T2D. These 
include: increased demands of insulin secretion induced by insulin resistance, or age-related 
impairment, or deposition of the islet amyloid polypeptide (IAPP or amylin). IAPP leads to #-
cells becoming refractory to the glucose signals or even to #-cell apoptosis (Hoppener and Lips 
2006; Ritzel et al. 2007). IAPP is a neuroendocrine hormone and member of the calcitonin family 
of polypeptide hormones. Under normal conditions, amylin (produced by #-cells) is secreted 
along with insulin in response to meal ingestion. However hyperinsulinemia leads to increased 
IAPP production which deposits as amyloid fibrils in #-cells and is toxic to them (Marzban et al. 
2003; Marzban 2004; Valentino et al. 2011). Glucotoxicity and lipotoxicity of the #-cell also lead 
to decreased glucose-induced insulin secretion, impaired insulin gene expression, and increased 
#-cell death (Robertson et al. 2004).  Since obesity leads to 55% of observed cases of T2D, 
increasing physical activity, reducing consumption of saturated or trans fats and replacing them 
with unsaturated fats, helps prevent or treat T2D (Eberhardt 2004). In extreme cases, even gastric 
bypass surgery proves to be extremely beneficial. There are also many antidiabetic therapies 
available that can be administered in combination with insulin, to help manage hyperglycemia.  
T2D was also known as adult-onset diabetes, since it was more common among those of 
middle age or older (due to decreased lean mass, increased accumulation of abdominal fat, and 
decreased tissue sensitivity to insulin). However, it is now being seen more frequently in children 
and young adults due to the increased prevalence of obesity in this demographic group (CDC 
2001; Copeland et al. 2005; Snijder et al. 2006). Lean individuals may also develop diabetes and 
this may be due to genetics, fatty liver disease, inflammation, or autoimmunity (more likely 
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qualified as LADA and often misdiagnosed as T2D). Even stress, during which time excessive 
amounts of cortisol are released, increases blood sugar. Cortisol release is beneficial in times of 
fight or flight, but detrimental when secreted chronically, eventually leading to T2D.  
 
1.9.3.1 Insulin resistance and diabetes 
Insulin resistance is characterized by an inability of normal levels of insulin to maintain 
blood glucose levels in check, leading to impaired glucose tolerance expressed as postprandial 
hyperglycemia. This stimulates #-cells to secrete more insulin, causing hyperinsulinemia, which 
compensates for the decrease in insulin sensitivity (Leslie 1993; Kumar 2003). As diabetes 
progresses, the #-cells are no longer able to produce enough insulin, due to #-cell exhaustion, 
intrinsic #-cell defect (lose glucose-recognition ability), and loss of 20-50% in #-cell mass 
(Bonner-Weir 2000; Porte and Kahn 2001; Kumar 2003). Insulin resistance consists in a 
diminished response of insulin-sensitive tissues, such as liver, muscle and adipose tissue, to 
physiological concentrations of insulin. This may be due to a variety of qualitative or quantitative 
defects. Examples include changes in insulin receptor content or function, or at the level of 
certain intracellular mechanisms (ex. phosphorylation on serine instead of tyrosine residues on 
targets downstream of insulin receptor activation) (Kumar 2003), or as mentioned can occur at 
the level of the #-cell (affecting insulin production or release). Environmental factors such as age, 
obesity and level of exercise are involved in the development of insulin resistance and T2D. 
 Obesity, especially central obesity, is linked to a state of low-grade inflammation. This 
implies that there is dysregulation of a variety of adipokines and inflammatory cytokines that are 
implicated in the development of insulin resistance and T2D (Zimmet 1982; Manson 1991; 
Shimokata 1991; Leslie 1993). Obesity also gives rise to an atherogenic lipoprotein profile, 
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increased TG in circulation, and increased FFA (result of increased lipolysis from the adipose 
tissue), as well as increased LDL and decreased HDL (van de Woestijne et al. 2011). All these 
metabolic abnormalities favor increased ectopic fat storage in organs such as the liver, muscle, 
and #-cells. The process downregulates crucial intracellular mechanisms, involved in glucose 
production (liver), glucose uptake (muscle), or glucose-sensing (pancreas)(Yaney 2003).  It is to 
note that the inflammatory cytokines such as TNF-", along with FFA activate either JNK/SAPK 
(Prada et al. 2005), IKK"#, or PKC pathways (Kim et al. 2004), that are all implicated in 
phosphorylating serine residues on the IRS, in turn downregulating the insulin pathway (Cusi 
2010).  
It is to note that branched-chain amino acids (BCAA) and their related metabolites are 
also strongly associated with the incidence, progression, and remission of insulin resistance, 
diabetes, and cardiovascular disease (Newgard 2012). BCAA, which include leucine, isoleucine, 
and valine, are essential amino acids acquired by the body through the ingestion of specific foods 
or as supplements. Amino acids, the building blocks of proteins, are required for normal growth, 
tissue repair and maintenance, hormone production, immune function, as an energy source 
(during starvation). BCAA metabolism is strongly linked to circulating levels of insulin, as well 
as to the action of insulin on tissues (liver, muscle, adipose tissue) (Adeva et al. 2011). In healthy 
individuals, insulin facilitates disposal of amino acids into peripheral tissues. Whereas in 
diabetics and obese individuals, where there is presence of insulin deficiency or resistance to 
insulin action, BCAA metabolism is disturbed and their plasma concentrations are increased 
(Pereira et al. 2008; Adeva et al. 2011). BCAA act similarly to FA in that they both interfere with 
insulin signaling and secretion, promoting the development of insulin resistance. There have been 
reports that BCAA chronically activate mTOR, p70-S6K-1, c-Jun N-terminal kinase (JNK), and 
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phosphorylate Ser307 on IRS-1, all leading to the downregulation of the insulin receptor pathway 
(Ha and Zemel 2003; Adeva et al. 2011; Newgard 2012). Excess of BCAA and FA can also clog 
#-oxidative pathways, filling the TCA cycle in a process called anaplerosis. This can lead to 
decreased glucose utilization and eventually glucose intolerance. It has also been stated that 
chronically elevated levels of BCAA and its related metabolites may synergize with increased 
levels of FA to promote chronic hyperinsulinemia. This leads to increased secretory pressure on 
#-cells and may contribute to #-cell dysfunction, observed in T2D (Newgard 2012). BCAA 
concentrations can also be strongly influenced either from ones diet, genetic variations in 
catabolic enzymes, as well as variations in gut microbiome (bacterial species are capable of de 
novo BCAA synthesis) (Newgard 2012). There has been evidence suggesting that increased 
plasma BCAA levels occur years before diabetes is diagnosed, reinforcing their predictive value 
(Adeva et al. 2011; Valerio et al. 2011). In addition, plasma concentrations of BCAA and their 
metabolites are highly responsive to intervention outcomes, which are reported to enhance the 
BCAA catabolic pathway. Such examples include antidiabetic medications (for example 
thiazolidinediones) or even gastric bypass surgery (Adeva et al. 2011; Newgard 2012).  
 
1.9.3.2 Complications arising from T2D 
If left unmanaged or if managed improperly, T2D gives rise to long-term complications, 
such as retinopathy, neuropathy, nephropathy, loss in cognitive ability, and to cardiovascular 
complications (ADA 2010b; ADA 2010a). These microvascular complications can be the result 
of the activation of the polyol pathway, advanced glycation end product formation (AGEP), PKC 
activation, VEGF, reactive oxygen species (ROS) production, and the hexosamine pathway.  
Hyperglycemia leads to activation of the polyol pathway, activating aldose reductase and 
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consuming NADPH, which leads to decreased glutathione reductase activity, and therefore 
increased oxidative stress and likelihood of developing cellular damage (Nathan 1993; Cumbie 
and Hermayer 2007).  This pathway’s derived intermediates, along with non-enzymatic reactions 
(Maillard) between amino groups and glucose or highly reactive glucose derivatives 
(dicarbonyls), can also lead to the production of AGEP. AGEPs are heterogeneous group of 
modified proteins, lipids and nucleic acids, which alter intracellular and extracellular proteins and 
their function. They are implicated in the aging process and in diabetes. AGEPs bind to receptors 
of AGEP, and lead to NF-k# mediated production of pro-coagulatory and pro-inflammatory 
cytokines, and to increased vascular permeability (Nathan 1993; Cumbie and Hermayer 2007). 
Hyperglycemia can also lead to increased de novo DAG formation (from glyceraldehyde-3-
phosphate), which is an upstream activator of the majority of PKC isoforms, such as PKC# and $. 
PKC can also be stimulated by AGEP and hyperglycemia-induced superoxides. PKC# and $ 
activation are responsible for the deleterious effects observed in the retinal, neural and renal 
tissues. They do so by impairing blood flow, increasing vascular permeability, and increasing 
inflammatory cytokine production (Nathan 1993; Cumbie and Hermayer 2007). The PKC 
pathway can also lead to increased production of vascular endothelial growth factor (VEGF), 
which is implicated in retinopathy (increased VEGF levels in vitreous humor), through its action 
on VEGF-1 and VEGF-2 tyrosine kinase receptors, stimulating angiogenesis, capillary 
permeability and leakage. Increased VEGF levels may also be implicated in the development of 
nephropathy (Nathan 1993; Cumbie and Hermayer 2007). Hyperglycemia leads to mitochondrial 
electron transport chain overload, which induces mitochondrial superoxide overproduction, 
possibly activating all four pathways involved in hyperglycemia damage, i.e. the polyol pathway, 
hexosamine pathway, PKC isoform activation, and AGEP formation (Nathan 1993; Cumbie and 
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Hermayer 2007). In the presence of high concentrations of glucose, some of it gets diverted from 
the glycolytic pathway to that of hexosamine. In the hexosamine pathway, fructose-6-phosphate 
(from glycolysis) is converted to glucosamine-6-phosphate and UDP-N-acetyl-glucosamine by 
fructose-6-phosphate amidotransferase (Brownlee 2005). The end products of the hexosamine 
pathway can lead to pathologic changes in gene expression, for example increasing expression of 
PAI-1, leading to vascular complications in diabetics (Brownlee 2005). Macrovascular 
complications associated with T2D include peripheral arterial disease, stroke (increase risk by 
150-400%), and coronary artery disease. There is also an increased incidence of myocardial 
infarction due to the context in which T2D occurs, i.e. abdominal obesity, hypertension, 
hyperlipidemia, and increased coagulability, all defining parameters of the metabolic syndrome 
(Fowler 2008)(Figure 37).  
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Figure 37: Summary of macrovascular and microvascular complications associated with 
diabetes/hyperglycemia (taken from:(Cefalu 2006b)).  
 
1.9.4 Gestational diabetes 
Gestational diabetes refers to increased blood glucose levels detected during pregnancy, 
without necessarily having any previous history of diabetes. It affects around 4% of pregnancies 
worldwide, but this varies greatly depending on the population (Bose 2005). For instance, the 
prevalence of gestational diabetes among the Cree is 12.8%, which is twice as high as the rest of 
the North American population, and the second highest among aboriginal populations worldwide 
(Rodrigues 1999). Gestational diabetes can be categorized into two groups. The first group 
consists in mothers developing diabetes during pregnancy. The second group refers to a state 
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where diabetes was present prior to pregnancy. Group 1 is further divided into two subtypes. In 
type A1, pregnant mothers have an abnormal OGTT with normal fasting blood glucose levels. 
This can be controlled with diet. Type A2, consists in abnormal OGTT and fasting glucose levels. 
This type needs antidiabetic medication or insulin. Group 2 is subdivided into many more types 
(B, C, D, E, F, R, RF, H, T) depending on the age of onset and duration of diabetes, and the 
complications that may have arisen from it (the earlier the onset the greater the health risks) 
(White 1949; Gabbe 2007; Rahman 2009). There are many identifiable risk factors involved in 
the development of gestational diabetes. These include previous diagnosis of gestational diabetes, 
or prediabetes, impaired glucose tolerance, impaired fasting glycemia, women of 35 years of age 
and over, ethnic background, overweight, obese or severely obese, just to name a few (Ross 
2006). The symptoms associated to it resemble those of T1D or T2D: increased thirst, urination, 
fatigue, nausea, bladder infections, yeast infection, and blurred vision (WHO 2011a). Gestational 
diabetes incurs many potential health concerns for both mother and child, during pregnancy (pre-
eclampsia and caesarian section) or after birth. It increases the likelihood for both to develop 
T2D. It even leads to babies with high birth weights (chance of developing childhood obesity 
later on in life), and low blood glucose levels (hypoglycemia shortly after birth). It can be treated 
with diet and exercise, and if necessary with antidiabetic medication or insulin (Donovan 2010; 
CDC 2011c)(Figure 38).   
  
86
 
Figure 38: Gestational diabetes and the problems it incurs on mother and child (taken from: 
http://www.tree.com/health/diabetes-types-gestational.aspx) 
 
 
1.9.5 Maturity onset diabetes of the young 
Maturity onset diabetes of the young (MODY) corresponds to 5% of cases presumed to be 
T1D or T2D. It produces mild to moderate hyperglycemia at an early age (before 25), with 
ineffective insulin production and release from pancreatic beta-cells, with minimal or inexistent 
effects on insulin action(ADA 2004). It is a hereditary form of diabetes, with mutations occurring 
in an autosomal dominant gene (sex-independent), and it is also qualified as monogenic, affecting 
one gene (ADA 2004). An example of one of the most common forms of MODY is mutation in 
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the glucokinase gene, glucokinase being implicated in the conversion of glucose to glucose-6-
phosphate, the metabolism of which triggers insulin secretion from the #-cell(ADA 2004). 
Therefore, a mutation in glucokinase, which is considered a glucose sensor for the beta-cell, 
requires increased plasma glucose levels in order to elicit insulin secretion (ADA 2004). Other 
types of MODY include gene mutations in hepatocyte nuclear factors (HNF-1a, HNF-1b, HNF-
4a; regulate transcription of genes involved in glucose, fatty acid, and cholesterol transport and 
metabolism), or in the insulin promoter factor (IPF-1; necessary for pancreatic development and 
#-cell maturation)(ADA 2004).  Treatments for MODY are similar to those for T1D and T2D, 
and include diet, exercise, antidiabetic medications and insulin injections.  
 
1.9.6 Treatments for diabetes 
Lifestyle changes alone or in combination with pharmacological agents can help manage 
T2D and minimize its complications. Weight loss through diet, decreasing saturated or trans fats, 
increasing fiber and polyunsaturated fat intake, and exercise reduce the risk of developing T2D or 
at least help in the treatment of it (Widmaier 2004; Bantle et al. 2008). Difficulty of sustainable 
implementation of lifestyle changes requires the use of antidiabetic medications. Those available 
include insulin secretagogues (sulfonylureas, and rapid-acting secretagogues such as 
meglitinides), insulin sensitizers (biguanides, and thiazolidinediones), inhibitors of intestinal 
carbohydrate absorption and digestion ("-glucosidase inhibitors), and the new class of incretin-
based therapies (incretin mimetics, and DPPIV inhibitors).  
1.9.6.1 Sulfonylureas 
Sulfonylureas bind and close ATP-sensitive potassium (KATP) channels, binding with 
high affinity to sulfonylurea receptors (SUR-1) and increasing insulin secretion. SUR belong to 
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the family of ATP-binding cassette transporters and are subunits of the KATP channel. The 
KATP channel is a hetero-octameric complex composed of two different types of protein 
subunits: four inward-rectifier K+ ion channels Kir6.x (6.1 and 6.2) (ATP binding to this tetramer 
closes the channel), associated with four SUR subunits.  KATP channels are also found in heart, 
skeletal and smooth muscle, with different SUR subunits, giving different drug sensitivities. For 
example tolbutamide and gliclazide bind and block SUR-1 containing channels in #-cells but not 
SUR-2 found in cardiac and smooth muscle. In contrast, glibenclamide, glimepiride, repaglinide, 
meglitinide bind and block both SUR-1 and SUR-2 containing channels (Proks et al. 2002). The 
binding of sulfonylureas to SUR-1 blocks ATP-dependent K+ channels, depolarizes the 
membrane and opens voltage-gated calcium channels, allowing for a calcium influx. The rise in 
intracellular calcium levels promotes exocytosis of insulin from storage granules. There are first 
and second-generation sulfonylureas available on the market. Although both increase insulin 
secretion from pancreatic #-cells, they vary in terms of their potency and adverse effects 
(Katzung 2004)(Figure 39). 
 
Figure 39 : Mechanism of action of sulfonylureas (taken from:(Brady and Terzic 1998)).   
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Examples of first-generation sulfonylureas include tolbutamide, chlopropamide, and tolazamide 
are. Whereas glyburide, glipizide, and glimepiride belong to the second-generation and have 
fewer side-effects and drug interactions. The main adverse effects of sulfonylureas include 
hypoglycemia, weight gain, and potential cardiovascular implications. It is noteworthy that 
sulfonylureas are associated with primary and secondary failure. Primary failure is characterized 
by the patient not responding to the highest dose of medication. Whereas during secondary 
failure, the patient initially responds but fails to as time goes on. Therefore, secondary failure 
may be the consequence of #-cell exhaustion caused by the treatment. Other factors that promote 
secondary failure include decreased #-cell mass, reduction in physical activity, decline in lean 
body mass and increase in ectopic fat deposition; the latter caused in part by progression of 
chronic type 2 diabetes (Wilson Rodger 1999; Katzung 2004; Moran 2010).  
 
1.9.6.2 Meglitinides (rapid-acting insulin secretagogues) 
Meglitinides or glinides, such as the carbamoyl methyl benzoic acid derivative 
repaglinide, or the d-phenylalanine derivative nateglinide, are rapid in onset and improve 
postprandial glycemic control. They can be used by diabetics who are allergic to sulfurs or 
sulfonylureas. Repaglinide reaches its peak effect 1hour after ingestion and its duration of action 
is 5-8 hours. In contrast, nateglinide is absorbed within 20 minutes, reaches its peak after 1 hour, 
and its effect lasts less than 4 hours (Katzung 2004). They bind to SUR1 in the plasma membrane 
of the #-pancreatic cells, but on a different binding site than that of sulfonylureas. Nateglinide has 
also been reported to partially restore initial insulin release (partially lost in T2D which results in 
increased postprandial glucose) (Katzung 2004). Both repaglinide and nateglinide can be used 
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effectively either alone or in combination therapy with non-secretagogue antidiabetic agents, 
such as biguanides or thiazolidinediones (Katzung 2004; Shigeto et al. 2007)(Figure 40).  
 
Figure 40 : Mechanism of action of meglitinides (taken from:(Dornhorst 2001)). 
 
1.9.6.3 Biguanides 
Biguanides do not depend on functioning pancreatic #-cells in order to mediate their 
effects (Katzung 2004). They act by potentiating the effects of insulin on its target tissues. They 
inhibit gluconeogenesis in the liver, and increase glucose uptake, through increased Glut4 
translocation, in the muscle and adipose tissue. They also stimulate glycolysis (Katzung 2004). 
Since hepatic and renal gluconeogenesis are inhibited by biguanides, there is a greater risk of 
developing lactic acidosis, especially in patients with renal insufficiency (Katzung 2004). This is 
one of the main reasons that phenformin and buformin were removed from the market since they 
were more prone to cause acidosis, with the former being associated with sometimes fatal lactic 
acidosis (Fisman and Tenenbaum 2009). Metformin has a better safety profile, and as a result is 
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still used today as pharmacotherapy toward diabetes. Some of its adverse side effects include 
nausea, diarrhea, dyspepsia, anorexia, and although uncommon, hypoglycemia, especially if 
taken with other oral antidiabetic medication (Katzung 2004). It is reported that, through the 
insulin-independent AMPK pathway, metformin induces fatty acid oxidation, suppresses 
expression of lipogenic enzymes, and decreases circulating TG levels (Zhou et al. 2001; Krentz 
and Bailey 2005)(Figure 41).  
 
Figure 41: Mechanism of action of biguanides, such as Metformin (taken from:(Zhou et al. 
2001)). 
 
1.9.6.4 Thiazolidinediones 
Thiazolidinediones (Tzds), also known as glitazones, are ligands of the peroxisome 
proliferator activated receptor gamma (PPAR!). PPAR! is a nuclear receptor, involved in the 
regulation of genes implicated in glucose and lipid metabolism, insulin signaling, adipocyte 
differentiation (pre-adipocyte to adipocyte accompanied with fat accumulation). PPAR! is also 
involved in modulating the synthesis of adipokines (increasing adiponectin levels) and inhibiting 
pro-inflammatory cytokines (ex. TNF-")(Katzung 2004; Yki-Jarvinen 2004)(Figure 42). 
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Glitazones have been shown to activate the AMPK pathway in the liver, muscle, and adipose 
tissue (Fryer et al. 2002; Hardie et al. 2006). There are three drugs that belong to this family of 
medications, namely troglitazone, pioglitazone, and rosiglitazone. Although they have all been 
associated with serious adverse effects, only troglitazone has been completely removed from the 
market for its increased risk of causing drug-induced hepatitis (Cluxton et al. 2005). Both 
pioglitazone and rosiglitazone have been suspended in Europe due to potential risks of causing 
bladder cancer and cardiovascular complications respectively (McCulloch 2011).   
 
Figure 42: Mechanism of action of thiazolidinediones on peripheral tissues such as liver, muscle, 
and adipose tissue (taken from:(Singh 2008)). 
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1.9.6.5 Alpha-glucosidase inhibitors 
Alpha-glucosidase inhibitors, which include acarbose, miglitol, and voglibose (newest in 
its class), help in lowering postprandial hyperglycemia while having an insulin-sparing effect 
(Katzung 2004). They act as inhibitors of "-glucosidases such as sucrase, maltase, glycoamylase, 
and dextranase. These are enteric enzymes found on the brush border membrane of the intestinal 
cells. These enzymes aid in the digestion of complex starches such as oligosaccharides and 
convert disaccharides into monosaccharides, allowing them to be absorbed in the duodenum and 
upper jejunum (Katzung 2004)(Figure 43).  
 
Figure 43: Mechanism of action of "-glucosidase inhibitors (taken from:(Arungarinathan 2011)). 
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By inhibiting these enzymes, carbohydrates will not be digested in the upper small intestine and 
instead will undergo bacterial digestion/fermentation in the colon, causing undesirable side 
effects such as bloating, flatulence and diarrhea. Other adverse effects of "-glucosidase inhibitors 
include nausea, vomiting, and hepatic injury (Hanefeld 1998; Harrigan 2001; Rodes 2007). In 
situations where a patient taking "-glucosidase inhibitors goes into hypoglycemia, it is advised 
for them to eat something containing monosaccharides such as glucose tablets. Indeed food 
containing complex starches will not be digested and will not relieve low blood glucose levels. 
Treatment with these medications can also lead to decreased glucose-insulinotropic polypeptide 
(GIP). The latter responds to rate of nutrient absorption rather than presence of nutrients as is the 
case with glucagon-like peptide-1 (GLP-1), which is increased during treatment (Moritoh et al. 
2009). 
 
1.9.6.6 Incretins 
Glucagon like peptide-1 (GLP-1) and gastric inhibitor protein, also known as glucose-
dependent insulinotropic polypeptide (GIP), belong to the group of gastrointestinal hormones 
termed incretins. They are both secreted within minutes of food intake and are degraded almost 
as quickly by the enzyme dipeptidyl peptidase-4 (DPP-4) (Baggio and Drucker 2007). GLP-1 is 
secreted from L-cells of the distal gut (ileum and colon) and GIP from K-cells of the proximal 
intestine (duodenum and jejunum)(Baggio and Drucker 2007). They both exert their effects on 
pancreatic # cells by promoting glucose-dependent insulin secretion, inducing #-cell proliferation 
and enhancing resistance to apoptosis (Bouwens and Rooman 2005; Baggio and Drucker 2007; 
Moritoh et al. 2009). GLP-1 slows down gastric emptying and increases satiety. Sustained GLP-1 
receptor activation potentially results in weight loss (Baggio and Drucker 2007). It is also 
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implicated in glucose-dependent inhibition of glucagon secretion, consequently decreasing 
hepatic glucose output (Baggio and Drucker 2007). GIP is reported to modulate energy storage 
pathways, in part by increasing glucose uptake and storage in muscle and adipose tissue. It also 
stimulates components involved in fatty acid metabolism, such as lipoprotein lipase and fatty acid 
synthesis (Gallwitz 2006; McClean et al. 2007; Kim and Egan 2008). Regardless of their 
individual functions, they work together to keep blood glucose levels under control. The potential 
of these hormones as novel antidiabetic medications has led to the development of two new 
classes of oral hypoglycemic drugs. Exenatide and liraglutide are GLP-1 mimetics/analogs that 
are resistant to the action of DPP-4. The second class comprises DPP-4 inhibitors such as 
sitagliptin, vildagliptin, saxagliptin, linagliptin, with many more under clinical development 
(dutogliptin, gemigliptin) (Baggio and Drucker 2007; Seewoodhary and Bain 2011)(Figure 44). 
a)      b) 
  
 
Figure 44: a) Mechanism of action of incretin mimetics, b) DPP-IV inhibitors (taken 
from:(Abrahamson 2006; Pratley and Gilbert 2008)). 
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1.10 Complementary and alternative medicine 
Despite the availability of modern medicine and of educational programs on lifestyle 
intervention, proper treatment and management of T2D, obesity, and even other ailments is not 
always achieved. This has encouraged many to consider the use of complementary and 
alternative medicine. Until the middle of the 20th century and the advent of the so called modern 
medicines, traditional medicine were the only means widely used and available (Robinson 2011). 
Whether it be in developing countries, such as Asia, Africa, Latin America and the Middle East, 
or in industrialized nations such as Canada, France, Germany, and Italy, around 70-95% of the 
citizens use traditional medicines (complementary, alternative, non-conventional) to respond to 
their primary health care needs and concerns (Robinson 2011). This growing popularity has 
created a worldwide annual market of 60 billion US dollars. It has therefore prompted a growing 
interest among government bodies, and pharmaceutical industries, which are now investing more 
money in order to identify promising medicinal herbs and novel chemical compounds (Tilburt 
and Kaptchuk 2008).  
There are many plant species that have been identified throughout the world as having 
antidiabetic potential. Some of these plants have even lead to the development of pharmaceutical 
drugs, such as Metformin, which is derived from the naturally occurring compound guanidine, 
found in Galega officinalis (French Lilac, or goat’s rue) (Oubré 1997; Yeh et al. 2003). Other 
examples of some widely used herbal medicines for treating diabetes are Trigonella foenum 
graecum (Fenugreek) (Haddad et al. 2001; Broca 2004), used in North Africa, India and Middle 
East, Gymnema sylvestre (gur-mar; sugar destroyer) (Haddad et al. 2001; Ananthan et al. 2004) 
originating from an ancient Indian healing system, and Momordica charantia (bitter melon) 
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(Basch et al. 2003; Yeh et al. 2003; Grover and Yadav 2004) used in Asia, Africa, India, and 
South America.  
1.10.1 Ethnobotanical survey and identification of plant species with 
antidiabetic potential within the CEI traditional pharmacopoeia 
As mentioned, an extensive ethnobotanical survey was conducted in 6 communities of 
northern Quebec, that identified over 30 plants from the CEI traditional pharmacopoeia, as 
having potential to treat diabetes and its associated symptoms (Leduc et al. 2006). The CEI have 
witnessed a soaring prevalence of T2D, which can in part be explained from lifestyle changes 
(decreased physical activity and adoption of western diet), accompanied by a cultural disconnect 
to modern medicine. This reinforces the need in identifying effective treatment options that the 
CEI can identify to in terms of culture and lifestyle. Therefore, validating the culturally 
acceptable use of plant species stemming from the CEI traditional pharmacopoeia as antidiabetic 
treatments is of primary importance. There were a number of in vitro screening studies that were 
carried out, in order to bring forth the plant species portraying the strongest antidiabetic activities 
(Spoor et al. 2006; Harbilas et al. 2009). The assays used assessed the plants abilities to increase 
glucose uptake in muscle cells and adipocytes in the presence or absence of insulin while 
comparing them to the commonly used antidiabetic drug Metformin. Their effects on 
adipogenesis (compared to the Tzd Rosiglitazone), and insulin secretion, as well as their 
neuroprotective and anti-oxidant capacities were also evaluated. Based on the results of these 
studies, further experiments were conducted in order to identify the signalling pathways 
implicated (Eid et al. 2010a; Eid et al. 2010b; Martineau 2010a; Martineau 2010b; Martineau et 
al. 2010; Nistor Baldea et al. 2010). Although roughly half of the plants exhibited a strong 
antidiabetic potential, there were 2 in particular out of 17 plant species, namely P. balsamifera 
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and L. laricina that became of interest based on their potential of being both antiobesity and 
antidiabetic agents.  
 
1.10.2 Populus balsamifera L. (Salicaceae): traditional uses 
Populus balsamifera L. (P. balsamifera), also known as balsam poplar, belongs to the 
family of Salicaceae (Figure 45). It is a deciduous tree that needs full sun and a moist rich soil. It 
can grow on average up to 30m in height in many regions of North America, up to the arctic 
slope of Alaska (Rook.org 2006; PFAF 2008b). Different parts of the species have been used as 
various concoctions for many years by North American Indian tribes, such as the CEI, for their 
medicinal properties. Leaf buds have antiscorbutic, antiseptic, diuretic, expectorant, stimulant and 
tonic properties (Uphof 1968; Grieve 1971; Usher 1974; Mills 1985; Schofield 2003). The resin 
from the leaf buds can be used as salve and wash for sores, rheumatism, and wounds (Moerman 
1998; Foster 1999), or made into a tea that can be used as a wash topically for inflammation, 
muscle pain, or ingested to help in lung ailments and coughs (Foster 1999). Leaf buds in hot 
water can be inhaled to decongest nasal passages (Weiner 1990). Concerning the bark, it contains 
salicin, a glycoside that breaks down into salicylic acid in the body during metabolism. This 
compound has anodyne (pain reliever), anti-inflammatory, and febrifuge (decreases fever) 
properties (Weiner 1990; Bown 2001). Tea from inner bark can be used for colds, coughs, lung 
problems, rheumatism, kidney and urinary problems (Erichsen-Brown 1989; Moerman 1998).  
  
99 
 
Figure 45: Populus balsamifera L. (Salicaceae) 
(taken from : http://www.rook.org/earl/bwca/nature/trees/populusbal.html) 
 
 
1.10.2.1 In vitro screening studies using P. balsamifera demonstrate antiobesity potential 
The inner bark of P. balsamifera was used in the in vitro screening assays as well as in the 
in vivo studies of the present thesis. The phytochemical markers found in this part of the plant 
species, include salicins, salicortin, salireposide, and populosides (Harbilas et al. 2009), which 
are phenolic acid glycosides (Si et al. 2009). Once they are ingested, these compounds are 
eventually broken down into salicylic acid (Bown 2001; Kar 2003; Boeckler et al. 2011). There 
are two classes of phenolic acids, derivatives of benzoic acid to which the markers found in 
balsam poplar belong to, and derivatives of hydroxycinnamic acid.  
Balsam poplar demonstrated a strong antiobesity potential in the in vitro screening studies 
(Harbilas et al. 2009; Martineau 2010a; Martineau 2010b). In fact, it completely inhibited 
triglyceride accumulation during adipogenesis in 3T3-L1 adipocytes (where cells undergo 
differentiation from pre-adipocyte into adipocytes accumulating TG in the process). The cells 
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treated with the plant species retained pre-adipocyte fibroblastic morphology and there was total 
absence of any visible lipid droplets (Martineau 2010a). This may, in part, be attributable to its 
PPAR! antagonist effect, as determined in an independent gene-reporter assay.  
Using bioassay-guided fractionation, salicortin was identified as being the active principle 
responsible for the observed effects of balsam poplar on adipogenesis. Although it has been 
documented as having antiproliferative effects (cancer studies), its antiobesity potential is newly 
ascribed (Subramanian et al. 2006; Martineau 2010b). This compound is abundant in poplar, 
willow bark, and throughout the salicaceae family. Salicylates are well known for having anti-
inflammatory properties, and for improving insulin sensitivity. Salicortin, which composes 10% 
of the whole plant extract, was produced through fractionation, isolation, purification of the 
plants' crude extract as previously described (Martineau 2010b; Martineau 2010a)(Figure 46). 
The structure of the purified compound was identified and confirmed by 1H and 13C NMR and by 
comparison with previously reported data. 
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Figure 46: Fractionation, isolation and purification of salicortin from P. balsamifera crude extract 
(taken from:(Martineau 2010b)).  
1.10.3 Larix laricina K. Koch (Pinaceae): traditional uses 
Larix Laricina K. Koch, also referred to as tamarack, belongs to the family Pinaceae 
(Figure 47). It is a deciduous conifer tree, that needs full sun and moist to wet rich soil. It can 
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grow up to 18m mainly in the northern part of North America (from Labrador to Alaska, and 
North Eastern United States), up to the Arctic tree line (PFAF 2008a).  
 
 
Figure 47: Larix laricina K. Koch (Pinaceae) 
(taken from : http://wisplants.uwsp.edu/scripts/detail.asp?SpCode=LARLAR) 
 
The branches, needles and bark have been used for many years by North American tribes, such as 
the CEI, under different preparation forms to treat a wide array of diseases. When the bark is 
prepared in tea form, it can be used as an alterative, diuretic, laxative, and tonic (Grieve 1971; 
Foster 1999), or in the treatment of jaundice, anaemia, rheumatism, colds and skin ailments 
(Moerman 1998; Foster 1999). It is useful for sore throats when gargled, and indicated as a 
poultice for infections stemming from wounds, sores, swellings and burns (Moerman 1998; 
Foster 1999). When bark is infused with buds, it is an expectorant (Moerman 1998), and with 
needles it can either be considered cough medicine, or as a disinfectant if applied as a poultice 
(Moerman 1998). The resin is chewed and used to treat indigestion (Foster 1999), or can even be 
beneficial for kidney or lung ailments, or as dressing for ulcers and burns (Lauriault 1989).  
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1.10.3.1 In vitro screening studies using L. laricina demonstrate antiobesity and antidiabetic 
potential 
The inner bark of L. laricina was used in the in vitro screening assays (Spoor et al. 2006; 
Martineau et al. 2010) as well as in the in vivo assays of the present thesis. The phytochemical 
markers found in this part of the plant species include taxifolin, a flavanonol (type of flavanoid), 
and hydroxystilbenes (stilbenes). Compounds of these two phytochemical classes have been 
reported to have antiobesity and antidiabetic properties, as well as to protect against the 
associated complications (cardiovascular, peripheral nerve damage, etc.) (Haraguchi et al. 1997; 
Baur et al. 2006; Baur and Sinclair 2006; Peluso 2006; Kundu and Surh 2008; Pearson et al. 
2008; Shabrova et al. 2011).   
L. laricina demonstrated antidiabetic potential in vitro by increasing glucose uptake in 
C2C12 myotubes (Spoor et al. 2006), by acting on the AMPK pathway (no Akt activation) and 
increasing ACC phosphorylation (involved in FA oxidation)(Martineau et al. 2010). It also 
upregulated adipogenesis in the 3T3-L1 adipocyte cell line. The effects of the plant species were 
comparable to their positive controls, commonly used antidiabetic medications, i.e. Metformin 
for the glucose uptake assay and Rosiglitazone for the adipogenesis assay. L. laricina was 
observed to be one of the strongest uncouplers, disrupting mitochondrial function. Uncouplers are 
being closely studied in the scientific literature for their potential use as antiobesity agents, since 
fuel consumption/metabolic rate is increased to try and compensate for low ATP formation. 
During uncoupling, heat is produced instead of ATP formation. If this becomes excessive, fatal 
hyperthermia can arise. Uncoupling can also lead to lactic acidosis by promoting anaerobic 
glycolysis in order to compensate for decreased ATP production (Martineau et al. 2010). 
However, the safety profile of the plant extract was confirmed in an in vitro screening study 
(Martineau et al. 2010).  
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1.11 Animal models of obesity and diabetes 
There are many animal models that are available to study diabetes and/or obesity: ob/ob 
and db/db mice, KKAy, streptozotocin models, pancreatectomy in mice or rats, Zucker diabetic 
fatty rats, transgenic or knockout models, or diet-induced obesity and diabetes in desert rats or 
C57BL/6 mice. The ob/ob (leptin deficiency) and db/db mice (leptin receptor defect), lead to 
hyperphagia, hyperinsulinemia, and insulin resistance (Sima 2005; Cefalu 2006a; Wolf 2006). 
KKAy mice are a cross between black KK glucose intolerant mice and yellow Ay mice. The Ay 
gene encodes agouti peptide, which is an antagonist of melanocortin 4 receptor (MC4R) in the 
hypothalamic melanocortin system inhibiting leptin activity (Barsh et al. 2000).  Streptozotocin 
models lead to destruction of pancreatic #-cells in mice or rats, and therefore to impaired 
pancreatic function, insulin deficiency, hyperglycemia, and the development of diabetes (Cefalu 
2006a). Pancreatectomy corresponds to a surgical removal of 90% of the pancreas, leading to 
hyperglycemia and diabetes (Rossetti et al. 1987). Zucker diabetic fatty rats are a model of type 2 
diabetes that have a mutation in the leptin receptor. They become obese, hyperglycaemic and 
have an inability to increase #-cell mass. This results in insufficient insulin secretion to 
compensate for the state of obesity-induced insulin resistance (Cefalu 2006a). There also exists 
transgenic and knockout models, in which there are mutations in genes needed for insulin action 
or secretion (Glut4, Glut2, insulin receptor, IRS, etc.)(Nandi et al. 2004).  Models that assess the 
impact of increased energy intake on type 2 diabetes include the spiny mice (Acomys chirinus), 
the desert gerbil (Psammomys obesus) as well as the diet-induced obese C57BL/6 mouse model 
(Cefalu 2006a).  
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In humans, the prevalence of T2D is closely related to lifestyle and caloric intake, with 
obesity being a major contributor to the development of T2D and the metabolic syndrome. It has 
been proven that the percentage of fat in the diet is positively correlated with percentage of body 
fat, is predictive of the subsequent increase in body mass index, and is independent of total 
energy intake (Dreon et al. 1988; Miller et al. 1990; Tucker and Kano 1992; Parekh et al. 1998). 
As a reference, in humans 20-35% of daily total calories should come from fat, and 45-65% from 
carbohydrates (focusing on complex carbs that have a higher fiber content and take longer for the 
body to break down into glucose, while avoiding refined carbs and foods with added sugar and 
low nutritional value) (CDC 2011b; CDC 2011a). Having taken all these factors into 
consideration, an animal model of choice to study the development of obesity and its resulting 
T2D is that of diet-induced obesity (DIO) in C57BL/6 mice. It relies on high-calorie diet and 
inactivity, without any genetic involvement. Increased dietary fat content has been shown to 
produce obesity in mice and rats (Schemmel et al. 1970; West et al. 1992; Parekh et al. 1998). 
The high-fat diet used in the studies composing this thesis is made up of 60% of the kcal coming 
from fat, as opposed to 5% in the standard laboratory chow diet (see Appendix A Figures 1 and 
2). Mice fed a high-fat diet exhibit significant weight gain, hyperglycemia, hyperinsulinemia, and 
hyperlipidemia, reflecting the establishment of the metabolic syndrome and a pre-diabetic state 
(Jiang et al. 2005).  
 
1.12 Aim and scope 
Based on the in vitro data obtained thus far, P. balsamifera and its active principle salicortin 
possess strong antiobesity potential, by potently inhibiting adipogenesis and triglyceride 
accumulation. Concerning L. laricina, it can be beneficial in treating both obesity and diabetes by 
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acting as a mitochondrial uncoupler and exhibiting similar mechanisms of action to both the 
commonly used antidiabetic medications metformin and rosiglitazone. Therefore, the aim of this 
thesis is to investigate and validate the antiobesity and antidiabetic potential of P. balsamifera 
and its active principle salicortin, as well as that of L. laricina, in mitigating (preventing) or 
reducing (treating) the development of obesity and insulin resistance in C57BL/6 mice subjected 
to a high-fat diet for a period of 8 or 16 weeks, respectively (Figure 48; see Appendix A, figure 1 
for standard laboratory chow diet composition, and figure 2, for high-fat diet composition). The 
plants extracts, as well as the active principle were each added (in powder form) into the high-fat 
diet, and mixed to ensure proper distribution throughout the food. An example of the calculation 
used for plant extracts or active principle dosing can be seen in Appendix A Figure 3. The 
calculation is based on assessment of average food consumption and body weight. Incorporation 
of the plant extracts or the active principle into the diet did not in any case alter its texture. Both 
balsam poplar and tamarack were administered at doses of 125 and 250 mg/kg of body weight. 
The choice of these doses is based on previous dose-searching experiments (doses ranging from 
125 to 500 mg/kg) conducted by our team in various animal models using different plant species. 
In natural health product research, it is common to use a starting dose of 100 mg/kg of body 
weight for crude plant extracts (Haddad et al. 2012). It is to note that these doses do not bear a 
direct relationship with human therapeutic doses, and as is the case with conventional 
medications, they cannot be easily translated into human equivalents (Haddad et al. 2012). 
Salicortin was administered at 12.5 mg/kg of body weight, since it composes 10% of the whole 
plant extract, and the effective starting dose of balsam poplar is 125 mg/kg of body weight. 
Measurements were taken over time for parameters such as body weight, food intake and 
glycemia. The area under the curve (AUC) was calculated for these continuous measurements. 
The AUC simplifies statistical analysis, especially when the number of repeated measures is too 
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high, or if the interval between repeated measures is not identical (ANOVA for repeated 
measures is not able to adjust for this difference)(Bryant 1983; Matthews et al. 1990; Fekedulegn 
et al. 2007). The AUC also integrates the concept of trend/tendency, something that an ANOVA 
test on repeated measures does not do. This will allows us to determine the time-course of balsam 
poplar, salicortin and tamarack; whether treatments are effective at onset, later in time, 
throughout or even if they lose their efficacy with time. Finally, in order to determine the 
signaling pathways that are involved in regulating glucose and lipid metabolism, tissues such as 
the liver, muscle and adipose tissue, all implicated in obesity and the development of insulin 
resistance, were closely examined.  
a)      b) 
 
 
Figure 48: a) C57BL/6 mice: mouse on left fed a high-fat diet (DIO model) and mouse on right 
fed a standard laboratory chow diet (Chow control); b) Schematic representation of the DIO 
model submitted to a HFD for 8 weeks (prevention study) or 16 weeks (treatment study), where 
plant indicates administration of either P. balsamifera, or L. laricina or Salicortin (Haddad et al. 
2012). 
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Abstract 
Ethnobotanical relevance: In previous in vitro bioassay studies, Populus balsamifera L. 
(Salicaceae), a medicinal plant ethnobotanically identified from the traditional pharmacopoeia of 
the Cree of Eeyou Istchee (Eastern James Bay area of Canada), exhibited a strong anti-obesity 
potential by potently inhibiting adipogenesis in 3T3-L1 adipocytes. Aim of the study: To evaluate 
the effectiveness of this plant extract in mitigating the development of obesity and the metabolic 
syndrome in diet-induced obese (DIO) C57BL/6 mice. Materials and methods: Mice were 
subjected for eight weeks to a standard diet (CHOW), a high fat diet (HFD; DIO group), or HFD 
to which P. balsamifera was incorporated at 125 and 250 mg/kg. Results: The results showed that 
P. balsamifera decreased in a dose-dependent manner the weight gain of whole body, 
retroperitoneal fat pad and liver as compared to DIO controls and reduced the severity of hepatic 
macrovesicular steatosis and triglyceride accumulation. This plant extract also decreased 
glycemia in the second half of the feeding period and improved insulin sensitivity by diminishing 
insulin levels and the leptin/adiponectin ratio, as well as augmenting adiponectin levels. These 
effects were associated with slightly but significantly reduced food intake with 250 mg/kg P. 
balsamifera as well as with an increase in energy expenditure (increase in skin temperature and 
increased expression of uncoupling protein-1; UCP-1). Data also suggest other mechanisms, such 
as inhibition of adipocyte differentiation, decrease of hepatic inflammatory state and potential 
increase in hepatic fatty acid oxidation. Conclusion: Taken together, these results confirm the 
potential of P. balsamifera as a culturally adapted therapeutic approach for the care and treatment 
of obesity and diabetes among the Cree.  
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List of abbreviations 
ACC: acetyl-CoA carboxylase 
AMPk: adenosine monophosphate-activated protein kinase 
BAT: brown adipose tissue 
C/EBP: CCAAT-enhancer binding proteins 
CPT-1: carnitine palmitoyltransferase-I 
DIO: diet-induce obese 
ERK: extracellular signal-regulated kinase 
FAS: fatty acid synthase 
Glut4: glucose transporter 4 
HFD: high-fat diet 
IKK: IkB kinase 
MAPk: mitogen-activated protein kinase 
NAFLD: non-alcoholic fatty liver disease 
NASH: non-alcoholic steatohepatitis 
NF-#B: nuclear factor kappa light chain enhancer of activated B cells 
P. balsamifera: Populus balsamifera L. (Salicaceae) or balsam poplar 
PPAR: peroxisome proliferator-activated receptor 
SOX: Sry-related HMG box 
T2D: type 2 diabetes 
UCP-1: uncoupling protein-1 
WAT: white adipose tissue 
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2.1. Introduction 
 According to the World Health Organization (WHO), obesity is defined as excess fat 
accumulation that represents a risk to health (WHO, 2011). Sedentary lifestyle and a high-calorie 
diet are the most prominent factors involved in the development of obesity. Over time, this excess 
in body weight increases the risk of developing chronic health problems, such as type 2 diabetes 
(T2D), cardiovascular disease and cancer (WHO, 2011). Therefore, obesity constitutes a major 
public health problem worldwide with astounding human and economic consequences (Withrow 
and Alter, 2010). 
Obesity contributes to around 55% of all cases of T2D by altering the body’s response to 
insulin and creating a pro-inflammatory state (Eberhardt, 2004). Hence, taking into account the 
pathways that are involved in lipid and glucose homeostasis as well as inflammation in the main 
insulin-sensitive tissues, namely liver, muscle, and fat, is of great importance. Indeed, the liver 
plays a central role in systemic glucose and lipid homeostasis. The muscle is the principal tissue 
involved in postprandial glucose disposal, accounting for about 80% of glucose uptake through 
insulin- or exercise-sensitive glucose transporters, Glut4. Finally, adipose tissue is a key player in 
the development of insulin resistance and T2D. Abdominal fat (white adipose tissue; WAT) 
releases adipokines, such as adiponectin and leptin, which affect insulin resistance, satiety and 
energy expenditure. Brown adipose tissue (BAT) is implicated in thermal regulation (uncoupling 
protein-1; UCP-1) and fatty acid oxidation (CPT-1, PPAR"). These represent potential targets of 
effective anti-obesity and ensuing anti-diabetic therapies.  
The prevalence of obesity is increasing at an alarming rate worldwide, and has tripled in 
the past 25 years among diverse Canadian populations, reaching 25 % in recent statistics (PHAC, 
2009; PHAC, 2011a; PHAC, 2011b; Statistics and Canada, 2005). In particular, Canadian 
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Aboriginal populations are highly affected by this disease, where the prevalence of obesity and 
overweight is 2-3 times higher than the rest of the Canadian population (Garriguet, 2008). Since 
this disease is linked to T2D, the prevalence of the latter is also especially high among these 
populations, where it reached 29% in 2009 among adults (>20 yrs) of the Cree of Eeyou Istchee 
(CEI) in the Eastern James Bay area of Quebec (Dannenbaum et al., 2008; Dannenbaum et al., 
2010). 
Due to the cultural disconnect of modern T2D therapies and in order to respond to the 
CEI primary health care needs, our team (CIHR-TAAM) conducted an extensive ethnobotanical 
study among the CEI Elders and Healers to identify culturally relevant anti-diabetic treatments 
(Leduc et al., 2006). Seventeen plant extracts were identified and further studied in a variety of in 
vitro bioassays for their anti-diabetic potential. One of these CEI plant extracts, 
Populus balsamifera L. (Salicaceae), also known as balsam poplar, contains a number of active 
components, such as salicylates and other phenolics, namely salicin, salicortin, salireposide, 
populoside. It displayed a potent anti-obesity potential in vitro. It effectively prevented 3T3-L1 
adipogenesis by maintaining pre-adipocyte fibroblastic morphology and acting as a PPAR! 
antagonist during early processes of adipocyte differentiation (Harbilas et al., 2009; Martineau et 
al., 2010a; Martineau et al., 2010b).   
These findings warrant further investigation of the anti-obesity potential of P. balsamifera 
and its ensuing preventive effect on the development of diabetes in vivo. Our hypothesis is that 
Populus balsamifera L. (Salicaceae) can mitigate weight gain and prevent or attenuate the 
development of insulin resistance in the diet-induced obese C57BL/6 mouse (DIO) model. This is 
an animal model of choice to study the development of obesity, which relies on high-calorie diet 
and inactivity to trigger obesity without any genetic involvement (Buettner et al., 2007; Collins et 
al., 2004). After 8 weeks on a high fat diet, DIO animals display raised body and abdominal fat 
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pad weights, generally exhibit mild hyperglycemia and hyperinsulinemia, alongside an increase 
in the leptin/adiponectin ratio and ectopic fat storage in insulin-sensitive tissues such as the liver 
and muscle. These parameters reflect the establishment of the metabolic syndrome and a pre-
diabetic state. Indeed, the metabolic syndrome is characterized by the presence of three out of the 
five following symptoms: central obesity (increased waist circumference or waist-to-hip ratio), 
elevated triglycerides, lowered HDL, raised blood pressure, as well as high fasting glycemia 
levels or the use of medications in order to control hyperglycemia (Alberti, 2006). Other 
parameters that appear to be related to the metabolic syndrome, and that should be included in a 
research-related context, include body fat distribution with a particular focus on central fat 
distribution, leptin, adiponectin and insulin levels, as well as liver fat content (Alberti, 2006).  
In this study, we concomitantly administered extracts of balsam poplar to mice fed the 
high fat diet and report that it significantly mitigates the development of obesity and attenuates 
the associated insulin resistance. 
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2.2 Materials and Methods 
2.2.1 Plant extracts 
Specimens of Populus balsamifera L., belonging to the Salicaceae family, were collected on the 
territories of the CEI of Northern Quebec, Canada. Dr. Alain Cuerrier, taxonomist at the 
Montreal Botanical Garden, confirmed the botanical identity of the plant species. Voucher 
specimens were deposited in the Marie-Victorin herbarium of the Montreal Botanical Garden in 
Montreal, Quebec, Canada (Mis03-49). The crude 80% ethanolic extract of Populus balsamifera 
L. (Salicaceae), which will be referred to as P. balsamifera or by its common name balsam 
poplar, was prepared as previously described (Harbilas et al., 2009).  
2.2.2 Animals and Diets 
Four-week old male non-diabetic C57BL/6 mice were purchased from Charles River 
Laboratories (Saint-Constant, QC, Canada). All mice had ad libitum access to food and water. 
They were housed in individual cages and maintained on a 12 h light-dark cycle in a temperature-
controlled animal room. Following acclimatization, the mice were divided into groups of 
approximately 12 mice each before being treated for 8 weeks. The control groups consisted in a 
negative control group (Chow) receiving a standard diet (SD) purchased from Charles River 
(18% protein content, 4.5% crude fat, Charles River Animal rodent diet) and a positive control 
group (DIO) receiving a high fat diet (HFD) acquired from Bio-Serv  (Bio-Ser Diet #F3282, 
Frenchtown, NJ, 60% fat by energy). The remaining groups received the HFD to which was 
incorporated the dried 80% crude ethanolic plant extract of P. balsamifera at levels adjusted to 
deliver 125 or 250 mg/kg body weight. Body weight, food and water intake, as well as glycemia 
were measured 3 times/week during the course of the study. These measurements were always 
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performed at the same time, day, in the same order and by the same person, every week for the 
entire duration of the protocol. Glycemia was measured by collecting blood from pricked tail vein 
and using a commercial glucometer (Accu-Check Roche, Montreal, QC, Canada). In order to 
determine the overall effect of treatment regimens on parameters measured continuously, we 
calculated the total area under the curve (AUCT). We also fractionated such measurements into 
the first and second half of the feeding period corresponding to weeks 0-4 (F1) and weeks 4-8 
(F2), respectively, in order to gain insight on the temporal (early/late) effects of the plants. All 
experimental protocols were approved by the animal experimentation ethics committee of the 
Université de Montréal and were carried out in full respect of the guidelines from the Canadian 
Council for the Care and Protection of Animals.  
2.2.3 Surgical Procedure 
At the end of the experimental protocol, the mice were anesthetized using 50 mg/kg pentobarbital 
intraperitoneally and then sacrificed by exsanguination via the inferior vena cava. Livers were 
flushed with a physiological saline solution and the median lobes were then dissected; one of the 
sections being placed immediately in a 10% formalin solution for subsequent histopathological 
analysis. The remaining dissected liver sections were immediately placed in liquid nitrogen, and 
then stored at -80°C until further use. During the sacrifice, various organs were removed, 
collected and weighed; notably, liver, muscle, white adipose tissue (WAT; epididymal and 
retroperitoneal fat pads), and subscapular brown fat (BAT). All were placed in liquid nitrogen 
and then stored at -80°C until further use.  
2.2.4 Blood parameters 
Plasma insulin, adiponectin and leptin were assessed by radioimmunoassay (RIA: Linco 
Research, St-Charles, MO) according to manufacturer’s instructions. In order to avoid 
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interrupting the dietary plant treatment, mice were not fasting when their glycemia and insulin 
levels were measured. Plasma levels of circulating lipids (Triglycerides (TG), total cholesterol, 
HDL, LDL) were measured by the Department of Biochemistry of Sainte-Justine’s Children 
Hospital (Montreal, QC, Canada).  
2.2.5 Histological evaluation and tissue triglyceride measurement 
The dissected liver sections embedded in paraffin were cut, mounted on glass slides and stained 
with hematoxylin phloxine saffron (HPS) by the Institut de recherche en immunovirologie et 
cancer (IRIC), Department of Histology (Université de Montréal, Montreal, QC, Canada). Each 
stained liver section was analyzed for the severity of lipid accumulation in the hepatocytes. The 
extent of hepatocyte lipid accumulation was then scored based on the percentage of hepatocytes 
that contained macrovesicular fat: namely, grade 0 (0-5%), grade 1(5-33%), grade 2 (33-66%), 
and grade 3 (66-100%) (Brunt et al., 1999; Kleiner et al., 2005). Part of the frozen liver and 
muscle sections were used to determine the extent of triglyceride content. Liver and muscle 
samples, 100 mg of each sample, were ground into powder under liquid nitrogen and then 
extracted using Folch’s chloroform/methanol (2:1) method. Triglyceride content was then 
quantified using a commercial kit (Randox Laboratories Ltd., UK). Our research team has 
observed a strong correlation between quantified hepatic triglyceride content and stratification of 
liver lipid accumulation by histological analysis (Haddad et al., 2009; Haddad et al., 2011).  
2.2.6 Skin temperature 
In order to evaluate the temperature of the animals, a non-invasive and least stressful procedure 
was used by applying a probe on the external intercostal region of the animal for 2 minutes 
(Dallmann et al., 2006). The skin temperature was read and recorded with a digital thermometer 
(Cole-Parmer Instrument Company, USA) at weeks 4 and 8 of the feeding period. 
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2.2.7 Western Blot analysis  
Frozen liver, WAT, and BAT were homogenized in RIPA lysis buffer (50mM Hepes, 150mM 
NaCl, 5mM EGTA, 2mM MgCl2, 5% glycerol, 1% Triton X-100, 0.1% SDS, 1% Na-
deoxycholate, pH 7.4) containing protease inhibitors (complete mini EDTA-free; Roche 
Diagnostics, Laval, QC) and phosphatase inhibitors (2mM PMSF, 10mM NaF, 100µ& Na-
orthovanadate, 1mM Na-pyrophosphate). In order to measure Glut4 expression in the muscle, 
samples were homogenized in sucrose buffer (Tris buffer pH 7.4, 20mM Tris-HCl, 255mM 
sucrose, 1mM EDTA), centrifuged (12000g for 12 min) and supernatant removed to carry out 
western blot analysis. Western blot analysis was performed on total liver, muscle, WAT and BAT 
homogenates by loading equal amounts of protein (50µg) on 10% SDS-polyacrylamide gels that 
were subjected to electrophoresis and then transferred to nitrocellulose membranes (BioRad 
Laboratories, ON, Canada). Membranes were probed with the following antibodies: p-Akt (Ser 
473), Akt, phospho p44/42 MAPK, 44/42 MAPK, p-IKK"#, #-actin (each at 1:1000 in blocking 
buffer incubated overnight at 4°C; Cell Signaling Tech Inc., Danvers, MA, USA). PPAR", 
PPAR!, UCP-1 were also measured using a 1:200 dilution in blocking buffer and incubated either 
at 1h room temperature (RT) or overnight at 4°C  (Santa Cruz Biotechnology inc., Santa Cruz, 
CA, USA). The membranes were then washed and probed for 1h at RT in blocking buffer with 
HRP-conjugated secondary antibodies: anti-rabbit (1:10000; Jackson Immunoresearch 
Laboratories Inc., West Grove, PA), or anti-mouse (1:4000; Cell Signaling Tech Inc., Danvers, 
MA, USA), or anti-goat (1:5000; Santa Cruz Biotechnology inc., Santa Cruz, CA, USA). The 
immunoreactive proteins were detected by enhanced chemiluminescence method (GE Healthcare, 
Baie d’Urfé, QC, Canada). Densitometric analysis was performed using NIH Image J software 
(version 1.42q, NIH, USA).  
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2.2.8 Statistical analysis 
Data were analyzed by one-way analysis of variance (ANOVA), followed by Bonferonni post-
hoc test, as appropriate using Sigma Stat software (Jandel Scientific, San Rafael, CA). Areas 
under the curve (AUC) were calculated by using PRISM software (GraphPad, San Diego, CA, 
USA). Data are expressed as mean ± SEM of the indicated number of determinations. Statistical 
significance was set at p < 0.05.   
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2.3 Results 
2.3.1 DIO model: an obese and prediabetic state 
As expected, C57BL/6 mice fed with HFD for 8 weeks displayed a typical DIO profile: 
1) increased whole body, liver and fat pad (WAT and BAT) weights (Figure 1 & Table 1); 
2) elevated blood lipid profile (total cholesterol, LDL, and HDL; Table 2); 3) higher levels of 
grade 2 and 3 hepatic steatosis (Table 3); 4) increased hepatic and muscle TG levels (Figure 2, 
panels A and B); and 5) increased circulating Leptin/Adiponectin ratio, an indicator of insulin 
resistant state (Table 2) (Finucane et al., 2009). Taken together, these findings thus confirm the 
prediabetic and insulin resistant state of the DIO group. Of note, all these changes occurred 
without any significant change in energy intake (data not shown).  
2.3.2 P. balsamifera significantly diminishes body weight gain and hepatic 
steatosis while improving insulin resistance of DIO mice 
While control DIO mice gained about 70% of their weight during the second half of their 
feeding period (between weeks 4 to 8; F2; Table 1), P. balsamifera’s reduction of weight gain 
was immediate (weeks 0-4; F1) and was maintained throughout the entire feeding period (F1 and 
F2) with the same intensity. This was associated with smaller size WATs (retroperitoneal fat pad; 
by 12% - 17%; p < 0.05 Table 1) as compared to DIO congeners. However, the circulating lipid 
profile (LDL, HDL, and total cholesterol) was not significantly affected by administration of the 
plant extract (Table 2). Finally, P. balsamifera exhibited no toxicity as demonstrated by unaltered 
blood biochemical parameters and tissue histological examination (data not shown).  
P. balsamifera also displayed a mild effect on glycemia. The highest dose significantly 
reduced the AUC of glycemia-vs-time by 10% as compared to DIO controls during the F2 period 
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(p<0.05; Table 2). This is also the period when the DIO group glycemia increased most as 
compared to respective values in non-obese CHOW controls (increase of 24 and 13% for AUCF2 
and AUCF1 of DIO versus CHOW; p<0.05; Table 2). Similarly, blood glycemia of plant fed 
animals was 17% lower than that of DIO control animals on the day of sacrifice, albeit this 
difference failed to reach statistical significance (Table 2). In parallel, insulin sensitivity was 
improved with the plant extract administration as evidenced by the tendency for insulin levels to 
be reduced (by 42-45%; NS; Table 2), the significant increase of adiponectin levels (by 40-62%; 
p<0.05; Table 2) and decrease of Leptin/Adiponectin ratio (by 43-49%; p<0.05; Table 2). 
Furthermore, liver weights were smaller by 14% - 22% (p<0.05; Table 1) and the prevalence of 
grade 2 and 3 steatotic livers was prevented by 40% when P. balsamifera was added to HFD 
(30% versus 50% for Plant and DIO groups respectively; Chi square p<0.05; Table 3). Hepatic 
(NS; Figure 2A) and muscle (p<0.05; Figure 2B) TG levels were lowered by approximately 40% 
in animals treated with P. balsamifera at 250 mg/kg, although the change was only statistically 
significant in muscle. 
 
2.3.3 P. balsamifera has only a mild effect on energy intake, but significantly 
increases skin temperature and UCP-1 levels in BAT  
Parameters of energy intake and energy expenditure were also assessed. Although overall 
energy intake was not significantly altered by experimental protocols (AUCT for food intake 
expressed in kcal), a slight but significant decline was observed in the group fed with 250 mg/kg 
of the plant extract during the F2 period only as compared to DIO control group (8% reduction; 
p<0.05; data not illustrated).  
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We also used skin temperature as an indirect measure of energy expenditure, which was 
recorded at the midpoint (4 weeks) and at the end (8 weeks) of the feeding protocol. As figure 3 
demonstrates, CHOW and DIO control animals exhibited similar superficial body temperatures 
after 4 and 8 weeks of treatment. Interestingly, animals fed with P. balsamifera experienced a 
significant increase in their skin temperature at 4 weeks as compared to that of the control DIO 
group and this was maintained at 8 weeks (p < 0.05). Notably, skin temperature of animals 
ingesting P. balsamifera for 8 weeks was increased by 1.3°C and 1.8°C at 125 mg/kg and 250 
mg/kg doses respectively (p<0.05; Figure 3). These results correlated with a strong tendency for 
the protein levels of uncoupling protein-1 (UCP-1) to increase in BAT of P. balsamifera treated 
animals (22%-49%, NS; Figure 4A).  
   
2.3.4 P. balsamifera activates the MAPK pathway in retroperitoneal adipose 
tissue  
In order to establish the mechanisms of action of P. balsamifera, we then investigated key 
molecular events involved in the development of obesity and diabetes in the major insulin-
responsive tissues, beginning with adipose tissue. Since P. balsamifera was previously shown to 
inhibit 3T3-L1 preadipocytes proliferation and differentiation in vitro (Martineau et al., 2010a; 
Martineau et al., 2010b), we investigated the ERK pathway, which has been shown to inactivate 
PPAR! transcriptional activity (Camp and Tafuri, 1997; Hu et al., 1996) during adipogenesis. As 
shown in Figure 4B 44/42 MAPK phosphorylation levels significantly increased with the 125 
mg/kg dose of P. balsamifera (63% vs DIO; p < 0.05) in WAT. This was associated with a slight, 
albeit not statistically significant decrease in PPAR! expression levels (11% decrease, NS; Figure 
4C). 
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2.3.5 P. balsamifera significantly decreases hepatic inflammation while 
improving hepatic lipid and glucose metabolism 
When we probed liver tissue for levels of Akt phosphorylation, and therefore activation, no 
significant differences were observed (Figure 4D). However, DIO animals tended to display 
elevated values of the phosphorylated protein, consistent with the associated hyperinsulinemic 
state described above. Interestingly Akt phosphorylation in animals treated with P. balsamifera at 
250 mg/kg returned to levels recorded in non-obese Chow controls (Figure 4D; N.S.). More 
dramatically, P. balsamifera significantly and dose-dependently decreased liver p44/42 MAPK 
phosphorylation levels (by 48% and 79% for 125 mg/kg and 250 mg/kg groups versus DIO; 
p=0.086 and p < 0.05, respectively; Figure 4E). Furthermore, hepatic IKK-"# phosphorylation, a 
marker of inflammatory state (Arkan et al., 2005; Kim et al., 2001; Yuan et al., 2001), was 
doubled in the HFD as compared to Chow (p= 0.093; Figure 4F). Addition of P. balsamifera to 
HFD decreased IKK-!# phosphorylation as compared to DIO controls, especially at the 250 
mg/kg dose (by 45%, p < 0.05; Figure 4F). In contrast, PPAR" expression did not display 
statistically significant differences between treatment groups; albeit values appeared to be 
increased in animals treated with the plant extract (by 20% and 31% for 125 mg/kg and 250 
mg/kg groups, respectively Figure 4G). Finally, we probed skeletal muscle tissue for Glut4 
protein and found no variation in levels of expression between the plant extract-treated and 
control DIO animals (data not shown).   
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2.4 Discussion 
Our research team has developed a comprehensive and structured approach to identify 
Boreal forest plants stemming from the traditional pharmacopoeia of the CEI that exhibit 
promising potential for the treatment and care of diabetes and its complications. Seventeen plants 
were selected for study on the basis of their traditional use against a set of symptoms related to 
diabetes (Fraser et al., 2007; Harbilas et al., 2009; Leduc et al., 2006). Balsam poplar or P. 
balsamifera attracted our team’s attention because it unexpectedly and potently prevented 3T3-
L1 adipocyte differentiation in an in vitro bioassay designed to assess glitazone-like adipogenesis 
and insulin sensitizing biological activity (Harbilas et al., 2009). This inhibitory effect suggested 
that balsam poplar might have therapeutic potential against obesity. However, if inhibition of 
adipogenesis was the sole action of the plant, it could lead to redistribution of fat stores to other 
tissues such as the liver and muscle, thus contributing to insulin resistance. Therefore, the careful 
assessment of the plant’s effect in the DIO mouse model of obesity and insulin resistance was 
warranted.  
In the present study, concomitant administration of P. balsamifera with a HFD was 
employed to assess the potential of this plant extract to attenuate the development of obesity and 
the associated metabolic disturbances. Our results clearly indicate that P. balsamifera 
significantly mitigates whole body weight gain of mice subjected to a continuous hypercaloric 
fat-laden diet. They even suggest a dose-dependent effect on many of the measured parameters.  
This was also associated with a significant reduction in WAT (retroperitoneal fat pads) weight 
gain. It is worthy to note that retroperitoneal fat pads, as part of the visceral adipose tissue, have 
been involved in the negative effects of obesity in humans (Freedland, 2004; Oben et al., 2006), 
while epididymal fat does not exhibit such involvement (Morton et al., 2005) Therefore, P. 
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balsamifera’s targeted effect on retroperitoneal fat pads heightens its therapeutic potential for the 
metabolic syndrome. This effect on WAT size could be the result of the observed increase in 
44/42 MAPK activation. Indeed, such activation has been associated with an inhibition of 
adipocyte differentiation in vitro and in vivo (Donzelli et al., 2010) (Finucane et al., 2009) and 
has been shown to inhibit the transcription activity of PPAR! as well as to activate SOX9, which 
in turn decrease the expression of C/EBP# and C/EBP $ (Sul, 2009). Although PPAR! levels did 
not vary significantly with ingestion of P. balsamifera, other effectors of adipogenesis could be 
involved and require further study.  
Most significantly, changes in weight gain occurred without drastic effect on cumulative 
energy (hence caloric) intake, since only a slight decline was recorded with the higher dose of P. 
balsamifera during the second half of treatment (F2 period). However, the intensity of this 
reduction in caloric intake (8%) amounted to about one third of the observed decrease in weight 
gain during that same period (24%). Nevertheless, this apparent slight anorexic effect will require 
further investigation.  
Another interesting observation is the increase in superficial body temperature induced by 
P. balsamifera treatment. This elevation occurred in an apparent dose-dependent manner after 8 
weeks of treatment, therefore suggesting that increased energy expenditure in the form of heat 
could represent part of P. balsamifera’s mode of action to afford beneficial actions on obesity 
and the metabolic syndrome. These findings are corroborated by the tendency for P. balsamifera 
to increase brown adipose tissue expression of UCP-1, the mitochondrial protein used to generate 
heat by non-shivering thermogenesis in BAT.  However, detailed analysis of energy expenditure 
in animals fed with this plant extract is required to confirm this interpretation. 
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 Balsam poplar exhibited a mild effect on glycemia, decreased blood levels in the second 
half of feeding period (4 to 8 weeks) occurring only with the 250 mg/kg dose. This suggests that 
the plant’s effect on glycemia is not immediate and might be the consequence of improved 
obesity and/or of the insulin resistant state. This is consistent with the lack of significant change 
in muscle Glut4 protein expression, which would have been expected to have a direct impact on 
glycemia.  
Nevertheless, several lines of evidence highlight the capacity of P. balsamifera to 
mitigate the development of an insulin resistant state in DIO animals. Firstly, insulin levels in 
balsam poplar fed group were almost half of those of DIO group, although data variability 
precluded statistical significance. This variability could be partially explained by the fact that 
insulin measurements were conducted in non-fasting animals in order to respect the treatment 
protocols. Indeed, we needed to ensure an uninterrupted delivery of the plant preparations to the 
animals, extracts being incorporated into the diet. In addition, the primary goal of this study was 
to evaluate the anti-obesity effect of the plant in a diet-induced obesity model. Hence, fasting the 
animals would likely have resulted in a drop of food intake and potentially in body weight, which 
could have biased data interpretation. On the other hand, elevated circulating levels of 
adiponectin and low leptin/adiponectin ratio represented a second line of evidence to support 
plant-induced improvements in insulin resistance and this is consistent with the literature (Abbasi 
et al., 2004; Finucane et al., 2009; Tschritter et al., 2003; Weyer et al., 2001; Yamamoto et al., 
2002). Thirdly, the increase of muscle TG levels observed with the DIO model was significantly 
attenuated with ingestion of P. balsamifera, thus contributing to the improvement of insulin 
sensitivity.  
Furthermore, balsam poplar treatment diminished the development of liver steatosis by 
40%, which shifted the severity of liver fat accumulation towards grades of weak and absent 
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steatosis as opposed to moderate and high steatosis in DIO controls. This correlated with a strong, 
albeit not significant, tendency to decrease hepatic triglyceride levels as compared to DIO group. 
In fact, DIO associated hepatic steatosis, as seen in human non-alcoholic fatty liver disease 
(NAFLD) and its more severe manifestation of non-alcoholic steatohepatitis (NASH), is 
recognized as being an important component of the metabolic syndrome and is involved in the 
development of insulin resistance in the liver (den Boer et al., 2004; Girard and Lafontan, 2008).  
Therefore, improvement of hepatic steatosis represents an important feature of any therapy 
directed against the metabolic syndrome, potentially such as P. balsamifera.  
At the molecular level, the 250 mg/kg dose of P. balsamifera shows a tendency to 
normalize hepatic Akt levels. This is consistent with the concurrent decrease in insulin levels, 
itself indicative of an improvement in insulin sensitivity. At the same time, balsam poplar 
essentially prevented the DIO-related increase in hepatic p44/42 MAPK activity. This pathway 
has been associated with more intense pre-replicative phases of hepatocyte proliferation and 
hyperplasia leading to the development of NAFLD (Chavez-Tapia et al., 2009). It is therefore 
possible that reduced MAPK phosphorylation contributed, at least in part, to the observed 
decrease in hepatic steatosis and TG content.  On the other hand, P. balsamifera had only a 
marginal impact on PPAR" pathway, normally responsible for enhancing lipid #-oxidation. 
However, other components controlling TG synthesis (FAS) or #-oxidation (AMPK, ACC) could 
be involved and future studies will need to assess their implication. 
Finally, the presence of a low-grade inflammatory state is another important component 
of obesity and the metabolic syndrome leading to diabetes. IKK-"", a protein kinase that is 
implicated in the stimulatory pathway of the pivotal pro-inflammatory transcription factor NF-#B 
(Arkan et al., 2005; Kim et al., 2001; Yuan et al., 2001), has been associated with insulin 
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resistance in several models of the metabolic syndrome. Our results show that the highest dose of 
P. balsamifera significantly prevented phosphorylation of hepatic IKK-"". This clearly indicates 
a reduced inflammatory state and completes several lines of evidence that converge in support of 
a significant positive impact of balsam poplar extracts on insulin sensitivity in an in vivo context 
of obesity and metabolic syndrome. 
It is worthy to note that no changes in the behavior of mice treated with the plant extracts 
were observed. Moreover, P. balsamifera treatment yielded no significant liver toxicity. It must 
be stressed that balsam poplar has been used safely for generations by several Aboriginal peoples 
of the Northern hemisphere (Arnason et al., 1981; Leighton, 1985; Marles et al., 2000; Marles 
and Farnsworth, 1995; Moerman, 1998), including CEI populations. In addition, the inner bark of 
balsam poplar (the plant part used by the CEI and hence evaluated in the current studies) is 
considered as an emergency food (Leighton, 1985; Marles et al., 2000). 
In summary, this study confirms that P. balsamifera, a Boreal forest medicinal plant 
identified through ethnobotanical surveys in CEI (Fraser et al., 2007; Harbilas et al., 2009; Leduc 
et al., 2006), exerts a significant anti-obesity and anti-diabetic potential in the DIO mouse model 
of metabolic syndrome. Results notably and clearly show that balsam poplar can attenuate the 
development of obesity by decreasing weight gain and significantly improving insulin sensitivity 
in normal mice continuously consuming a hypercaloric fat-laden diet. It is important to point out 
that P. balsamifera’s effect on final body weight gain (7% decrease compared to DIO controls at 
the end of our protocol) is in the same efficacy range as the anti-obesity treatments currently 
available on the market, which yield 5-10% decrease in body weight (Grundy, 2006). 
Furthermore, P. balsamifera’s ability to inhibit adipogenesis in vitro was corroborated by 
decreased WAT weight in vivo and, importantly, without fat redistribution to ectopic sites such as 
the liver and muscle, as evidenced by decreased steatosis and TG accumulation in those tissues.  
  
131 
In conclusion, these findings thereby bring solid evidence that P. balsamifera can mitigate 
the development of obesity and its ensuing negative metabolic impacts, thus validating its 
traditional use in the context of these diseases. Indeed, in view of the soaring rise in obesity and 
diabetes among Aboriginal Canadian populations, P. balsamifera offers an interesting option for 
the care and treatment of these diseases stemming from CEI Traditional Medicine. Therefore, our 
results provide strong impetus for the integration of P. balsamifera in culturally adapted clinical 
studies as well as care and treatment regimens for obesity and diabetes among the Cree, alongside 
lifestyle changes such as a healthy diet and exercise.  
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2.7 Figure Legends 
Figure 1 : Cumulative change in body weight (CCBW) in C57BL/6 mice treated with either 
standard diet (CHOW), HFD (DIO), or HFD in combination with P.balsamifera at 125 or 250 
mg/kg for a period of 8 weeks. All values are mean ± SEM (n=10 to 13). *denotes significantly 
different as compared to DIO group (one way ANOVA, Bonferonni post-hoc test; p < 0.05).  
 
Figure 2: A) Hepatic triglyceride levels, and B) Muscle triglyceride levels of C57BL/6 mice 
treated with either standard diet (CHOW), HFD (DIO), or HFD in combination with P. 
balsamifera at 125 or 250 mg/kg for a period of 8 weeks. All values are mean ± SEM (n=10 to 
13). *denotes significantly different as compared to DIO group (one way ANOVA, Bonferonni 
post-hoc test; p < 0.05).  
 
Figure 3: Skin temperature after 4 weeks and 8 weeks of treatment, from mice fed standard diet 
(CHOW), HFD (DIO) and HFD with P. balsamifera at 125 and 250 mg/kg. All values are mean 
± SEM from 10-13 animals in each group. *denotes significantly different as compared to DIO 
group (one way ANOVA, Bonferonni post-hoc test; p < 0.05). 
 
Figure 4 : Samples of BAT, WAT and liver from mice fed a standard diet (CHOW), HFD (DIO) 
and HFD with P. balsamifera at 125 and 250 mg/kg were homogenized and analyzed by 
immunoblotting. Blots were quantified by densitometry and data are expressed as mean ± SEM 
from 10-13 animals in each group. Representative immunoblots and their quantification are 
shown for samples probed with A) UCP-1 in BAT, B) phospho p-44/42 MAPK in adipose tissue, 
C) PPAR! in adipose tissue, D) phospho Akt in liver, E) phospho p-44/42 MAPK in liver, F) 
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phospho IKK!" in liver, G) PPAR" in liver. *denotes significantly different as compared to DIO 
group (one way ANOVA, Bonferonni post-hoc test; p < 0.05).  
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Table 1: Effects of obesity and P. balsamifera treatments on body and organ weights  
 
  
CHOW DIO 
P. balsamifera          
125 mg/kg 
P. balsamifera          
250 mg/kg 
Parameters at  Body Weight (g) 29.5± 0.6
*
 43.4 ± 0.8 41.6 ± 0.7 40.2 ± 1.0
*
 
sacrifice Retroperitoneal Fat Pad (g) 0.41 ± 0.04
*
 1.39 ± 0.06 1.23 ± 0.04
*
 1.16 ± 0.05
*
 
 Epididymal Fat Pad (g) 0.85 ± 0.05
*
 2.39 ± 0.09 2.57 ± 0.06 2.58 ± 0.09 
 Brown Fat Pad (g) 0.15 ± 0.01
*
 0.31 ± 0.03 0.28 ± 0.02 0.26 ± 0.03 
 Liver Weight (g) 1.60 ±0.04
*
 1.83 ± 0.10 1.57 ± 0.05
*
 1.43 ± 0.08
*
 
Continuous  CCBW - AUCT 347.1 ± 16.1
*
 702.8 ± 30.3 603.0 ± 28.5
*
 529.8 ± 26.6
*
 
measurements CCBW - AUCF1 111.9 ± 6.0
*
 174.4 ± 8.5 147.1 ± 7.8
*
 130.2 ± 6.5
*
 
 CCBW - AUCF2 224.5 ± 10.5
*
 506.4 ± 21.3 435.6 ± 20.4
*
 382.0 ± 19.9
*
 
 
Measurements were obtained after 8 weeks of treatment with either standard diet (Chow), HFD (DIO), and HFD in combination with 
P. balsamifera at 125 or 250 mg/ kg. All values represent the mean ± SEM (n=10 to 13). Total area under the curve (AUCT) for 
CCBW-vs-time was calculated based on CCBW curve shown in Figure 1, and then fractionated into the first and second half of the 
feeding period corresponding to weeks 0-4 (F1) and weeks 4-8 (F2), respectively. * denotes that groups are significantly different as 
compared to DIO (one-way ANOVA, Bonferonni post-hoc test; p < 0.05). 
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Table 2: Effects of obesity and P. balsamifera treatments on systemic parameters  
 
  
CHOW DIO 
P. balsamifera          
125 mg/kg 
P. balsamifera          
250 mg/kg 
Parameters at  Glucose (mmol/L) 7.1 ± 0.2
*
 10.3 ± 0.5 8.5 ± 0.2 8.5 ± 0.3 
sacrifice Insulin (ng/mL) 1.27 ± 0.10
*
 10.11 ± 1.84 5.85 ± 0.61 5.53 ± 1.72 
 TG (mmol/L) 0.75 ± 0.07
*
 0.53 ± 0.05 0.43 ± 0.03 0.43 ± 0.04 
 LDL (mmol/L) 0.20 ± 0.05
*
 0.82 ± 0.06 0.89 ± 0.07 0.78 ± 0.06 
 HDL (mmol/L) 0.83 ± 0.04
*
 1.22 ± 0.07 1.34 ± 0.04 1.34 ± 0.04 
 Total cholesterol (mmol/L) 1.39 ± 0.07
*
 2.27 ± 0.10 2.43 ± 0.10 2.32 ± 0.07 
 Leptin (ng/mL) 13.12 ± 2.08
*
 42.13 ± 4.30 35.42 ± 3.00 36.98 ± 2.47 
 Adiponectin (µg/mL) 8.81 ± 0.63 8.62± 0.69 12.10± 0.55* 14.00 ± 0.58* 
 Leptin/adiponectin ratio 1.46± 0.17
*
 5.39 ± 0.75 3.07 ± 0.37
*
 2.74 ± 0.25
*
 
Continuous  Glycemia - AUCT 468.9 ± 6.7
*
 556.8 ± 9.0 553.2 ± 7.5 546.6 ± 12.6 
measurements Glycemia - AUCF1 220.4 ± 4.3
*
 249.5 ± 5.2 263.0 ± 6.4 268.2  ± 5.1 
 Glycemia - AUCF2 184.2 ± 2.8
*
 228.8 ± 6.3 213.5 ± 4.3 204.9 ± 6.9
*
 
Measurements were obtained after 8 weeks of treatment with either standard diet (Chow), HFD (DIO), and HFD in combination with 
P. balsamifera at 125 or 250 mg/ kg. All values represent the mean ± SEM (n=10 to 13), and were taken at the end of the protocol on 
sacrifice day. Total area under the curve (AUCT) for glycemia levels-vs-time was calculated, and then fractionated into the first and 
second half of the feeding period corresponding to weeks 0-4 (F1) and weeks 4-8 (F2), respectively. * denotes that groups are 
significantly different as compared to DIO (one-way ANOVA, Bonferonni post-hoc test; p < 0.05). 
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Table 3: Effect of P. balsamifera on histological analysis (scoring) of liver lipid accumulation (steatosis)  
Histology CHOW DIO 
P. balsamifera          
125 mg/kg 
P. balsamifera          
250 mg/kg 
Grade 0 10 1 3 5 
Grade 1 0 5 6 4 
Grade 2 0 5 3 2 
Grade 3 0 1 1 2 
n 10 12 13 13 
Chi square P < 0.05 
 
Histological scoring of HPS-stained livers from C57BL/6 mice treated for a period of 8 weeks with either standard diet (Chow), HFD 
(DIO), or HFD in combination with P. balsamifera at 125 or 250 mg/kg. Percentage of hepatocytes containing macrovesicular 
steatosis, grade 0 : 0-5 %, grade 1 : 5-33 %, grade 2 : 33-66 %, grade 3 : more than 66 %.  
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Abstract 
Background: The prevalence of the metabolic syndrome is on the rise among the Cree of Eeyou 
Istchee (CEI - Northern Quebec) as a result of increases in obesity and insulin resistance. Non-
traditional diet and sedentary lifestyle along with cultural disconnect of modern type 2 diabetes 
(T2D) therapies are involved. Exploring treatments from within CEI traditional pharmacopeia 
represents a valuable alternative. Populus balsamifera, or Balsam poplar (BP), a CEI plant from 
the Canadian Boreal Forest, demonstrated anti-obesity properties in vitro. Its active component 
salicortin was identified through a bioassay-guided fractionation approach. Aim: The present 
study aimed to assess the potential effects of BP extract and salicortin at reducing obesity and 
attenuating insulin resistance in a mouse model of diet-induced obesity and T2D. Materials and 
Methods: C57Bl/6 mice were subjected to high fat diet (HFD) for eight weeks resulting in 
obesity, hyperinsulinemia and mild steady-state hyperglycemia. BP or salicortin was introduced 
in the HFD for an additional eight weeks. Results: BP and salicortin effectively reduced body 
weight, retroperitoneal fat pad weight, and lipid content of the liver, as compared to HFD 
controls. This was accompanied by a small yet statistically significant reduction in food intake 
only in animals treated with BP. Glycemia, insulinemia, leptin and adiponectin levels were also 
improved as compared to HFD controls. Key components of signaling pathways were assessed 
by Western blot analysis in the three main insulin-sensitive tissues, namely liver, muscle and 
adipose tissue. The pathways activated most potently by BP and slightly by salicortin are 
involved in glucose regulation and lipid oxidation. Conclusion: BP and salicortin thus reduce 
obesity while increasing insulin sensitivity and modulating key components of glucose and lipid 
metabolism. These results confirm the validity of the CEI traditional pharmacopeia as alternative 
and complementary antiobesity and antidiabetic therapies.   
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Keywords: Anti-obesity, antidiabetic, adipokines, C57BL/6 mice, Balsam poplar, Aboriginal 
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3.1 Introduction 
Obesity results from a variety of risk factors, including unhealthy dietary habits and a 
sedentary lifestyle, resulting in higher energy input than output [1]. It also increases the risk for 
other chronic illnesses such as type 2 diabetes (T2D) and insulin resistance (IR)[1]. Insulin 
resistance is characterized by a decreased ability of insulin sensitive tissues to respond to insulin 
action. Skeletal muscle is the principal tissue involved in glucose metabolism through insulin-
dependent or exercise-sensitive glucose transport (Glut4)[2] implicating the Akt [3] and AMPK 
[4] pathways, respectively. These pathways are also implicated in glucose metabolism in the liver 
[5-7] and adipose tissue [3, 8-12]. The liver is considered to be the principal tissue involved in 
glucose storage and production [13]. Adipose tissue synthesizes and stores fatty acids and is 
recognized as an endocrine organ; releasing adipokines (leptin, adiponectin) that are implicated in 
glucose and lipid metabolism [14-20]. Obesity not only leads to excessive fat storage in adipose 
tissue, but also to ectopic fat storage in other insulin sensitive tissues such as the muscle and liver 
(non-alcoholic fatty liver disease; NAFLD). This, in part, contributes to the development of 
insulin resistance [21, 22].  
Several metabolic and signaling pathways are involved in perpetrating the disturbances of 
obesity and insulin resistance in the three main insulin-sensitive tissues. PPAR! is involved in the 
differentiation of adipose tissue; inducing lipid accumulation [23]. Other pathways are involved 
in lipid entry (FAT/CD36, FABP4)[24-27], lipid metabolism (SREBP-1c and FAS)[28, 29], and 
oxidation (ACC, CPT-1, PPAR", UCP pathways) [30]. The ERK pathway, involved in cell 
proliferation and differentiation, also seems to play an important role in both the liver (leads to 
NAFLD)[31] and adipose tissue [32, 33]. The IKK"# pathway is involved in the inflammatory 
response characteristic of obesity and indirectly mediates insulin resistance [27].  
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In Canada, the Cree of Eeyou Istchee (CEI) of Eastern James Bay have a prevalence of 
obesity and T2D that is respectively at least 1.5 [34, 35] and 4 times higher [36] than the general 
Canadian population. This may be the consequence of major lifestyle changes (decreased 
physical activity and gradual adoption of non-traditional diets), as well as cultural difficulty to 
comply with modern T2D treatments. Our team has been working with the CEI to identify plants 
stemming from their traditional pharmacopeia that could offer culturally adapted complementary 
and alternative treatments for obesity and T2D. As part of an ethnobotanical survey, Populus 
balsamifera L. (Salicaceae) (balsam poplar) was identified as a plant used by the CEI to treat a 
variety of symptoms associated with T2D. As part of an in vitro bioassay platform used to screen 
for the antidiabetic potential of CEI plants, the 3T3-L1 cell line was selected to assess glitazone-
like activity and stimulation of adipogenesis. Populus balsamifera L., also known as balsam 
poplar, unexpectedly and potently inhibited the accumulation of intracellular triglycerides [37-
39], suggesting potential anti-obesity activity. In subsequent studies conducted in the same cell 
line, a bioassay-guided fractionation approach identified salicortin, a salicylate glycoside, as the 
principal active component of P. balsamifera responsible for the observed inhibition of 
adipogenesis [38]. Salicortin is abundant in poplar, willow bark, and throughout the salicaceae 
family [38]. Although salicylates are well known for having anti-inflammatory properties, 
improving insulin sensitivity [40-42], and even having anti-proliferative effects [43], anti-
adipogenic activity had never been ascribed prior to the studies conducted by our team . We thus 
introduced P. balsamifera extract, alongside a high-fat diet (HFD), to study the plant’s ability to 
mitigate the development of obesity using the in vivo diet-induced obese (DIO) C57BL/6 mouse 
model. The results clearly demonstrated that the plant extract substantially attenuated weight gain 
and the development of insulin resistance [44].  
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In the present studies, we sought to evaluate the effectiveness of P. balsamifera as well as 
its active principle salicortin at treating obesity and insulin resistance once they have been 
established in the same model [45, 46]. As previously described by other researchers [47] and 
discussed further below, DIO mice respond in a stratified manner to the HFD; some animals 
being resistant to the HFD (low responders – LR) while others show the clearcut profile of 
metabolic disease (high responders – HR). P. balsamifera and salicortin were thus administered 
to the latter DIO mice in order to determine their potential effectiveness in countering obesity and 
insulin resistance.  
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3.2 Materials and Methods 
3.2.1 Plant extracts 
Specimens of Populus balsamifera L. (Salicaceae), were collected on CEI territory (Eastern 
James Bay, Quebec, Canada). Dr. Alain Cuerrier, taxonomist at the Montreal Botanical Garden, 
confirmed the botanical identity and voucher specimens were deposited in the Marie-Victorin 
herbarium of the Montreal Botanical Garden in Montreal, Canada (Mis03-49). A crude 80% 
ethanolic extract of P. balsamifera was prepared as previously described [37]. Salicortin, the 
active principle of P. balsamifera, was produced through fractionation, isolation and purification 
of the crude plant extract as previously described [38]. The structure of the purified compound 
was identified and confirmed by 
1
H and 
13
C NMR and by comparison with previously reported 
data. 1D- and 2D!NMR spectra were generated using an Avance 400 spectrometer (Bruker 
Biospin Corporation) [38].  
3.2.2 Animals and Diets 
Four-week old male non-diabetic C57BL/6 mice (Charles River Laboratories, Saint-Constant, 
QC, Canada) were housed in individual cages, maintained on a 12 h light-dark cycle in a 
temperature and humidity-controlled animal room and given free access to food and water. 
Following acclimatization, the mice were divided into groups of approximately 12 mice each. 
Chow controls received a standard diet (SD; 18% protein content, 4.5% crude fat; Charles River 
Animal rodent diet) for 16 weeks. Other groups were fed a high fat diet (HFD; Bio-Serv Diet 
#F3282; 60% energy from fat) for eight weeks. P. balsamifera at 125 or 250 mg/kg, and 
salicortin at 12.5 mg/kg were incorporated in the HFD and treatments continued for an additional 
8 weeks (DIO controls receiving only HFD). Balsam poplar extract studies were initiated first 
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while the active compound was being identified, isolated or purified. Since, salicortin composes 
10% of the whole plant extract, and that the most efficient dose of balsam poplar was 125 mg/kg, 
salicortin was administered at 12.5 mg/kg. Hence, experimental groups of plant extract and 
salicortin are compared to distinct CHOW non-obese and DIO controls. However, both 
experimental protocols were conducted in an identical manner, and DIO controls reacted in a 
fully comparable fashion relative to non-obese Chow congeners in both studies. Body weight, 
food and water intake, as well as glycemia were measured 3 times/week during the entire study. 
Glycemia was measured by pricking the tail vein and by using a commercial glucometer (Accu-
Check Roche, Montreal, QC, Canada). Measurements were always performed at the same 
time/day, in the same order and by the same person. All experimental protocols were approved by 
the animal experimentation ethics committee of the Université de Montréal and were carried out 
in full respect of the guidelines from the Canadian Council for the Care and Protection of 
Animals.  
3.2.3 Data and animal segregation 
The area under the curve (AUC) was calculated for parameters measured in a continuous 
manner throughout the study. The total AUC was then separated into two parts: fraction 1 (F1), 
representing AUC between week 0 and 4 (first month of treatment), and fraction 2 (F2) 
corresponding to the AUC between week 4 and 8 of plant extract administration (second month 
of treatment). This segregation served to determine the plant extract’s temporal course of action, 
i.e. whether early in onset (first 4 weeks), later (last 4 weeks) or present throughout the study. 
Once the experimental feeding protocol had been carried out, we became aware of the studies of 
Peyot and collaborators [47] discriminating low responders (LR) and high responders (HR) in the 
DIO mouse model. As discussed by these authors and observed in our own studies, pooling 
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animals with different characteristics, such as low weight gain, weak IR and near-normal 
glycemia, with animals with high weight gain, frank IR, and hyperglycemia, can yield misleading 
results [47]. Therefore, we segregated the DIO animals based on these published criteria and 
analyzed our data accordingly. As expected, low responder animals exhibited a near normal 
metabolic profile and treatment with the plant extract or its active component essentially had little 
if any effect. This is positive in the sense that P. balsamifera extract and salicortin may have a 
desirable safety margin by being active only in metabolically compromised animals. This also 
confirms the validity of the segregation. Hence, data are presented for the effects of plant extract 
and active principle in HR animals only. This segregation did however reduce our sample size, 
hence contributing to data variability. 
 
3.2.4 Surgical Procedure 
At the end of the experimental protocol, mice were anesthetized with an intraperitoneal injection 
of 50 mg/kg pentobarbital and sacrificed by exsanguination. Livers were flushed with 
physiological saline, dissected, immediately placed in liquid nitrogen and stored until further use 
at -80°C. Soleus skeletal muscle, white adipose tissue (WAT; epididymal and retroperitoneal fat 
pads), subscapular brown adipose tissue (BAT), and kidneys were also collected, placed in liquid 
nitrogen and stored at -80°C until further use.  
  
162
3.2.5 Blood parameters 
Plasma insulin, adiponectin and leptin were assessed by radioimmunoassay (RIA: Linco 
Research, St-Charles, MO). To avoid interrupting dietary plant treatment and disturbing the HFD 
feeding pattern (hence affecting the DIO model), mice were not fasting when blood parameters 
were measured. Plasma levels of AST, ALT, LDH, creatinine, alkaline phosphatase and 
circulating lipids were measured by the Department of Biochemistry of Sainte-Justine’s Children 
Hospital (Montreal, QC, Canada).  
 
3.2.6 Tissue triglyceride measurement 
Part of the frozen liver and muscle sections (around 100 mg of each sample) were ground into 
powder under liquid nitrogen and extracted using Folch’s chloroform/methanol (2:1) method 
[48]. Triglyceride content was quantified using a commercial kit (Randox Laboratories Ltd., 
UK).  
 
3.2.7 Western Blot analysis  
Western blot analysis was performed on frozen liver, muscle, and WAT using the following 
antibodies: p-Akt (Ser 473), Akt, p-AMPK (Thr 172), AMPK, Glut4, p-ACC, ACC, FAS, 
FABP4, phospho p44/42 MAPK, p44/42 MAPK, p-IKK!", "-actin (each at 1:1000 in blocking 
buffer incubated overnight at 4°C; Cell Signaling Tech Inc., Danvers, MA, USA). PPAR!, 
PPAR#, CPT-1, CD36, UCP-2, SREBP1-c were measured using a 1:200 dilution in blocking 
buffer and incubated either at 1h room temperature (RT) or overnight (Santa Cruz Biotechnology 
inc., Santa Cruz, CA, USA). The following HRP-conjugated secondary antibodies were used: 
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anti-rabbit (1:10000; Jackson Immunoresearch Laboratories Inc., West Grove, PA), anti-mouse 
(1:4000; Cell Signaling Tech Inc., Danvers, MA, USA), or anti-goat (1:5000; Santa Cruz 
Biotechnology inc., Santa Cruz, CA, USA). Immunoreactive proteins were detected by enhanced 
chemiluminescence method (GE Healthcare, Baie d’Urfé, QC, Canada). Densitometric analysis 
was performed using NIH Image J software (version 1.42q, NIH, USA).  
 
3.2.8 Statistical analysis 
Data were analyzed by one-way analysis of variance (ANOVA) with Bonferroni post-hoc 
analysis, or by unpaired Student’s t test (Sigma Stat software, Jandel Scientific, San Rafael, CA), 
as appropriate. Areas under the curve (AUC) were calculated with PRISM software (GraphPad, 
San Diego, CA, USA). Data are expressed as the mean ± SEM of the indicated number of 
determinations. Statistical significance was set at p<0.05.   
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3.3 Results 
3.3.1 Metabolic profile of responders to the High Fat Diet  (DIO controls) 
As anticipated in relation to recent data by Peyot et al. [47], roughly half of the mice consuming 
the HFD became obese and insulin resistant. Compared to Chow controls, such DIO control 
animals gained body weight, increased liver, BAT and WAT weights (Table 1, p<0.05) and 
displayed hyperlipidemia (total cholesterol, LDL, HDL). These mice also exhibited increased 
plasma glucose and insulin levels, an enhanced leptin/adiponectin ratio (Table 2, p<0.05) as well 
as elevated hepatic and muscle triglyceride (TG) levels (Table 3; p<0.05 compared to Chow), 
thus confirming the presence of an insulin resistant state. Only mice displaying an altered 
metabolic profile at 8 weeks of HFD feeding were selected for the present study and randomized 
to receive P. balsamifera or its active component, salicortin, for an additional 8 weeks. 
 
3.3.2 P. balsamifera and salicortin decrease body weight, liver weight and 
steatosis in DIO mice  
Treatment with P. balsamifera (at 125 mg/kg) significantly decreased body weight. This decrease 
reached 13% at sacrifice when compared to DIO controls (p<0.05; Table 1). When taking into 
account continuous measurements, the area under the curve (AUC) of cumulative changes in 
body weight (CCBW) was lowered by 8% (p<0.05; Figure 1A) with 125 mg/kg of P. 
balsamifera. This effect was gradual, beginning within the first month (F1=6% reduction; N.S.; 
Figure 1B), but becoming more pronounced in the second month of the treatment (F2=10% 
decrease; p<0.05; Figure 1C). Animals receiving 250 mg/kg of P. balsamifera exhibited a similar 
pattern of effects, albeit without reaching statistical significance. Mice fed the active compound, 
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salicortin, also displayed a significant decrease in body weight amounting to an 8% drop at 
sacrifice (p<0.05; Table1) and a 15% decrease in total AUC of CCBW (p<0.05; Figure 1A). 
Interestingly, its effect was immediate with 18% decrease in the F1 AUC (p<0.05; Figure 1B) 
that continued into the second month, albeit slightly less prominently (F2=13%; p<0.05; Figure 
1C).  
Concomitantly, retroperitoneal fat pad weight was smaller when animals were treated with either 
dose of balsam poplar (9%-17% reduction) or with salicortin (10% decrease) than in those 
receiving HFD alone, although these changes failed to reach statistical significance (Table 1; 
N.S). In contrast, the drop in liver weight was significant in the three aforementioned treated 
groups (decrease by 27%-35%; p<0.05 vs DIO controls; Table 1). Consistent with these results, 
hepatic triglyceride (TG) content was also reduced by 44% to 53% in the treated animals in 
comparison to DIO controls (p<0.05; Table 3). Muscle triglycerides, however, were not 
significantly altered by any of treatments (N.S.; Table 3).  
It must be noted that a weak anorexic effect was observed in animals receiving P. balsamifera at 
125 mg/Kg dose. Indeed, the AUC of cumulative food intake of this group was significantly 
reduced by 6% as compared to DIO congers (p<0.05, data not shown). No such effect was 
observed with the higher dose of P. balsamifera or with salicortin.  
 
3.3.3 P. balsamifera and salicortin improve insulin sensitivity, while only the 
active principle modulates lipidemia in DIO mice 
Along with body weight changes, P. balsamifera (at 125 and 250 mg/kg) and salicortin improved 
insulin sensitivity, albeit with slightly different profiles. Firstly, continuous measurement of 
glycemia showed that both doses of whole plant extract as well as the active significantly reduced 
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total AUC by 17-%-18% and by 11% respectively. Although P. balsamifera and salicortin effects 
were rather rapid in onset, the effect of the whole plant was constant throughout the treatment 
period (F1=F2), whereas that of the active decreased with time (F1=14%, p<0.05 vs DIO 
controls; F2=9%, N.S.; Figure 1 panels B & C). At sacrifice, glycemia of the three treatment 
groups was reduced as compared to their respective controls, albeit not in a statistically 
significant manner (Table 2). Secondly, insulinemia diminished by 73% with balsam poplar at 
125 mg/Kg (p<0.05) and by 85% with 250 mg/Kg (p=0.052) as well as with salicortin (p<0.05) 
in comparison to DIO controls (Table 2). Thirdly, the two doses of P. balsamifera decreased 
leptin/adiponectin ratio by 41%-54% as compared to congeners receiving HFD alone (p<0.05; 
Table 2). Salicortin also significantly decreased this ratio, although to a lesser extent (by 21%; 
p<0.05; Table 2). In terms of the circulating lipid profile, only the salicortin treated group 
exhibited significantly lowered total plasma cholesterol and LDL levels, which were reduced by 
25% and 40% respectively (Table 2; p < 0.05) as compared to the DIO controls. Altogether, these 
findings illustrate an improvement in insulin sensitivity when balsam poplar or its active 
principle are added to the HFD. 
Finally, P. balsamifera and salicortin tended to normalize several systemic parameters of 
toxicity, although this did not reach statistical significance, except in the case of AST levels for 
salicortin (p<0.05; Table 2) and LDH levels for P. balsamifera at 125 mg/Kg (p<0.05; Table 2).  
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3.3.4 P. balsamifera and salicortin do not affect skeletal muscle Glut4 or the 
Akt and AMPK pathways, yet the plant extract improves components related 
to muscle lipid oxidation  
Despite the significant reduction of overall glycemia exerted by the plant extract and its active, 
analysis of protein components involved in muscle glucose homeostasis did not exhibit any 
statistically significant changes. There was a tendency for Glut4 expression to increase in animals 
treated with P. balsamifera at 125 mg/kg, (Table 4; N.S. balsam poplar vs corresponding DIO 
controls). Similarly, insulin-dependent Akt phosphorylation tended to increase in animals fed 
with salicortin, although data variability precluded any definitive interpretation of these results. 
The insulin-independent AMPK pathway remained more clearly unchanged.  
In contrast, components involved in muscle lipid homeostasis showed evidence of improvement 
with balsam poplar treatment. Indeed, P. balsamifera at 125 mg/kg more than doubled muscle 
PPAR! expression levels (Table 4; 137% increase compared to DIO p<0.05). When looking at 
components involved in muscle fatty acid oxidation and synthesis, again only the plant extract 
seemed to act on such pathways, by tending to increase phosphorylated ACC levels and to 
normalize FAS levels back down to Chow levels (Table 4; N.S. compared to DIO controls). The 
p44/42 MAPK pathway linked to exercise and insulin stimulation was significantly activated 
with salicortin (Table 4, p < 0.05), and showed a tendency to do so with the plant extract at 250 
mg/kg (Table 4, N.S.). 
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3.3.5 The effects of P. balsamifera and salicortin on liver components of 
glucose and lipid homeostasis  
Both doses of P. balsamifera significantly increased hepatic phosphorylated Akt in HFD-fed 
animals (Table 4; increases by 111% and 87% for 125 and 250 mg/kg groups, respectively; 
p<0.05 compared to DIO controls), while the active showed only a slight tendency to do so (22% 
increase). A number of parameters related to hepatic lipid homeostasis or inflammation showed 
interesting tendencies, but none of these effects reached statistical significance. In all cases, 
tendencies were more pronounced with the 125 than the 250 mg/kg dose of P. balsamifera. 
Notably, PPAR! appeared to be increased by both balsam poplar and the active, while CPT-1 
seemed to be increased only by the plant extract (Table 4, N.S.). As for IKK!" it appeared to be 
affected only by the plant extract, exhibiting a decrease of 43% and 30% with 125 and 250 mg/kg 
doses, respectively (Table 4; N.S.).  
 
3.3.6 The effect of P. balsamifera and salicortin on adipose tissue components 
of glucose and lipid homeostasis 
P. balsamifera at 125 mg/kg showed a strong tendency to increase phosphorylated Akt levels in 
adipose tissue (Table 4; increase by 65%, p=0.068 compared to DIO controls). Likewise, CPT-1 
expression in animals treated with the plant extract at 250 mg/kg exhibited a strong tendency to 
be enhanced (Table 4; increase by 47%, p=0.079 compared to DIO), whereas the active had a 
similar albeit much weaker effect on this parameter (Table 4; 11% increase; N.S.). In contrast, 
FABP4 was clearly and significantly increased by P. balsamifera at both doses (54% and 60% at 
125 and 250 mg/kg respectively, Table 4, p<0.05 compared to DIO controls), while salicortin 
showed only a slight tendency to do so (16%, N.S., Table 4;). Salicortin and balsam poplar 
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showed a tendency to normalize PPAR! and phosphorylated p44/42 MAPK to levels similar to 
those observed in Chow animals (Table 4). Other components failed to show any significant 
changes in plant or active treated animals compared to their respective DIO controls.  
  
170
3.4 Discussion 
According to the World Health Organization (WHO), 75% of the world population still 
relies on traditional medicine for primary health care needs and this often involves crude 
preparations of medicinal plants [49]. In the Canadian province of Quebec, regional health 
authorities assigned to the CEI are currently considering the usefulness of Cree traditional 
medicine, notably its associated pharmacopoeia, to deal with several health concerns such as 
Type 2 diabetes; a condition that has reached epidemic proportions in the region [36]. Our group 
has been working since 2003 with communities and health authorities in CEI to build the 
scientific evidence base in support of this initiative. An ethnobotanical study was conducted in 
collaboration with CEI Elders and healers that identified several plants used to treat diabetes 
symptoms [37, 50, 51]. One of these was Populus balsamifera L. (Salicaceae) or balsam poplar. 
The plant did not demonstrate much anti-diabetic potential in in vitro bioassays; for instance, it 
had little effect on muscle glucose uptake [37]. However, the plant caught our attention by its 
complete inhibition of triglyceride accumulation and adipogenesis in the 3T3-L1 adipocyte cell 
line [37], suggesting potential therapeutic usefulness against obesity. Salicortin, a salicylate 
glycoside, abundant in poplar, willow bark, as well as throughout the Salicaceae family, was 
identified through bioassay-guided fractionation as the constituent of P. balsamifera having the 
most potential to inhibit adipogenesis in the 3T3-L1 cell line [38]. Prior to our studies, anti-
adipogenic activity had never been ascribed to balsam poplar, to members of its botanical family, 
or to its known phytochemical constituents, such as salicortin [38]. The goal of the present study 
was to evaluate the effectiveness of balsam poplar and salicortin as anti-obesity, anti-adipogenic, 
and consequently anti-diabetic agents in an in vivo mouse model. 
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 The DIO mouse model was used in this study. It closely mimics human metabolic 
syndrome (notably obesity and insulin resistance) and requires lesser quantities of plant extracts 
(also, more importantly, of active principles) than larger animals for long-term studies. Indeed, in 
this model, a period of 8 weeks is necessary to establish obesity and insulin resistance, as 
confirmed in the present studies. The plant was then incorporated into the high fat diet for a 
further 8 weeks to fully assess its potential to treat obesity and the associated metabolic 
disturbances. After 16 weeks on a high fat diet, control DIO animals develop obesity, mild 
hyperglycemia, hyperinsulinemia, hyperleptinemia, and increased ectopic fat storage (notably 
hepatic steatosis), all reflecting the establishment of the metabolic syndrome and an insulin 
resistant state. In previous studies, a less severe model was used whereby animals were subjected 
to a HFD for only 8 weeks; P. balsamifera being administered from the onset of the HFD feeding 
in order to evaluate its potential to prevent obesity and its associated insulin resistant state [44]. 
The plant extract effectively reduced body weight gain, retroperitoneal fat pad weight, liver lipid 
content, as well as circulating glucose, insulin and leptin levels. It also activated pathways that 
were involved with glucose and lipid oxidation, as well as thermoregulation. The onset of action 
of the plant extract was immediate and sustained throughout its course of administration.  
The results of the current study clearly demonstrate that P. balsamifera as well as its 
active salicortin were able to significantly reduce the body weight of mice despite their being 
subjected to a continuous hypercaloric fat-laden diet; the plant’s effect being more potent and 
statistically significant at 125 mg/kg than 250 mg/kg. Several anthropomorphic, systemic and 
tissue parameters were thus examined to circumscribe the possible mechanisms of action of the 
plant extract and its active principle, salicortin.  
A first potentially important lead came from data on cumulative food intake. Indeed, the 
plant extract at 125 mg/kg slightly but significantly reduced energy intake, and this was mainly 
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visible in the second month of treatment (F2; data not shown). This correlated well with the 
plant’s temporal action on body weight. This suggests that the plant may exhibit slight appetite-
modifying effects that warrant further investigation. However, the reduction in caloric intake was 
weaker than the weight loss measured, roughly half to two-thirds as important when considering 
total or F2 AUC measurements of cumulative weight changes, respectively. On the other hand, 
the active salicortin decreased the overall AUC of CCBW more effectively than the plant extract, 
and did so without affecting cumulative energy intake, suggesting different profiles of biological 
activity.  
On the other hand, although obesity was only partly countered by P. balsamifera and 
salicortin, systemic glucose homeostasis was more significantly improved. Indeed, continuous 
glycemia measurements showed that the plant and its active had an overall effect to reduce blood 
glucose variations toward normal values observed in Chow-fed controls. Even more telling was 
the dramatic decrease of insulinemia seen with P. balsamifera at 125 mg/kg and with salicortin. 
Likewise, the leptin-to-adiponectin ratio, also reflective of insulin resistance, was essentially 
halved with the plant extract, and decreased by 1.5 fold with the active. Interestingly, salicortin 
also significantly improved the blood lipid profile by decreasing LDL and total cholesterol levels, 
whereas the plant extract had no significant impact on systemic parameters of lipid homeostasis. 
This again points to variations in biological activity between the crude extract and the purified 
active principle. 
Further analysis of the major insulin responsive tissues, notably skeletal muscle, liver and 
adipose tissue, yielded data that highlights potential mechanisms at several levels of metabolic 
control. Firstly, excessive skeletal muscle TG accumulation was not corrected by P. balsamifera 
or salicortin treatment. However, the crude plant extract did more than double the expression of 
PPAR!, which could lead to increased fatty acid oxidation [30] and improved muscle insulin 
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sensitivity [52]. The latter was supported by the tendency for increased Glut4 expression and 
p44/42 MAPK phosphorylation observed in animals receiving 125 mg/kg of the plant. In 
contrast, salicortin treatment only significantly affected muscle p44/42 MAPK activation, again 
hinting at different actions of the plant extract and its active.  
In contrast, in the liver, P. balsamifera and salicortin treatment more than halved the 
elevated levels of accumulated TGs. Since hepatic steatosis is increasingly recognized as a major 
contributor to systemic insulin resistance [53, 54], this action may have played a significant role 
in improving systemic glucose homeostasis and insulin sensitivity. Indeed, analysis of key tissue 
proteins indicated that P. balsamifera treatment induced a doubling of liver Akt phosphorylation. 
Since Akt is a major component of the insulin-signaling cascade, part of the effect of balsam 
poplar could involve improved hepatic insulin sensitivity. Indeed, Akt inhibits glucose 
production and promotes glycogen deposition in the liver [5, 6, 13]. In hepatic cell lines, our 
group recently found that P. balsamifera inhibits glucose-6-phosphatase [55]. Other components 
also tended to be modulated by P. balsamifera in the liver and suggest that the plant may favor 
salvaging lipid metabolism. Indeed, PPAR! were increased by treatment with the plant and its 
active principle, this transcription factor being known to enhance fatty acid oxidation [30]. The 
tendency for a reduction of IKK!" by the plant treatment, on the other hand, points to a potential 
improvement of inflammatory components known to be involved in non-alcoholic fatty liver 
disease and ensuing metabolic disturbances [27, 56]. Such effects of P. balsamifera and salicortin 
on liver lipid homeostasis and inflammation will require confirmation in future studies. 
Despite large reductions in WAT weight at sacrifice consistent with the significant 
reduction in body weight, such changes induced by P. balsamifera and salicortin failed to reach 
statistical significance due to data variability. Nonetheless, analysis of adipose tissue components 
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yielded a number of insightful results. Firstly, the tendency for P. balsamifera and salicortin to 
reduce the p44/42 ERK MAP kinase is consistent with the parallel tendency for WAT weight 
reductions. Indeed, the ERK pathway is involved in adipogenesis and insulin resistance [32, 57] 
and our group observed that P. balsamifera inhibits clonal expansion in 3T3-L1 adipocytes [39]. 
On the other hand, FABP-4, a lipid chaperone carrying fatty acids to cellular pathways of 
oxidation, was significantly increased by plant treatment. As in liver, adipose tissue Akt and 
CPT-1 expression also showed a strong tendency to be increased, supporting the notion that P. 
balsamifera can enhance insulin-dependent lipid oxidative pathways. The active showed much 
weaker actions on adipose tissue components, notably mild tendencies to increase FABP-4 and 
CPT-1 expression.  
The effects of both the crude plant extract and of the active principle salicortin occurred 
without any overt sign of toxicity Indeed, unaltered liver and renal functional parameters confirm 
that the plant and its active salicortin are innocuous. Indeed, products of this tree have been used 
safely for generations by several Aboriginal peoples of the Northern hemisphere [58, 59]. The 
inner bark of P. balsamifera (from which the plant extract used in the current studies was 
derived) is even documented as a survival food [59, 60].  
Interestingly, the majority of metabolically and statistically significant changes were 
obtained with the lower dose of 125 mg/kg of P. balsamifera, whereas the larger 250 mg/kg dose 
exerted lesser or no effects. Such a counterintuitive dose-response relationship is not uncommon 
with polymolecular drug mixtures that crude plant extracts represent. Indeed, synergistic and 
antagonistic interactions between phytochemical components can yield such response profiles 
[61]. This is also supported by the aforementioned differences in the biological activity profile 
between the crude plant extract and salicortin. It is conceivable that other components in the 
crude extract may complement salicortin’s activity. 
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Indeed, the action of the active principle alone on continuously measured parameters 
(body weight and blood glucose) appeared to wane with time, since effects were more 
pronounced in the first month of administration (F1) than in the second (F2). This may limit the 
use of the active at this dose and may have contributed to mask effects on protein components in 
insulin-sensitive tissues. Further studies need to be conducted in order to determine if this 
apparent time-dependent decline in activity develops at any dosage, and if so, with what time 
course. Nevertheless, salicortin has a sufficiently promising biological profile in DIO mice to 
warrant further studies potentially leading to clinical assessments. 
In summary, P. balsamifera and salicortin exerted significant weight-reducing properties 
in obese, insulin resistant mice in the face of continued HFD feeding. Part of the plant extract’s 
effect appears to emanate from a putative weak anorexic effect that will need to be defined. The 
plant and the active had even more profound beneficial effects on systemic glucose homeostasis 
and indirect indices of insulin sensitivity. Analysis of tissue components involved in glucose and 
lipid homeostasis uncovered several potential lead mechanisms in key insulin responsive organs 
such as skeletal muscle, liver and adipose tissue. Generally, components involved in insulin-
dependent lipid oxidative pathways were most prominently and coordinately modulated in 
animals treated with the plant extract. Such actions would favor the “wastage” of energy derived 
from excess lipids consumed through the HFD, thereby reducing the negative metabolic impact 
of obesity. This is highly relevant for Aboriginal populations like the CEI whose rapid changes in 
dietary habits over the last decades also involves a higher intake of lipid-enriched calorie-dense 
foods. It is noteworthy that salicortin did not always activate the same pathways and to the same 
degree as the plant extract, suggesting that other plant constituents in the crude extract may also 
participate in beneficial biological activity toward metabolic disease.  
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In conclusion, the present studies confirm the high potential of P. balsamifera as a 
complementary treatment derived from CEI traditional medicine, which can help combat the 
devastating effects of obesity, often leading to Type 2 diabetes. Having identified salicortin as an 
important active principle in vitro – its anti-obesity and mild anti-diabetic effects having also 
being validated by the present in vivo treatment study – it can now be considered as a valuable 
tool to ensure the quality and efficacy of P. balsamifera preparations. Salicortin can also serve as 
a template to develop novel therapeutic agents for the treatment of obesity and type 2 diabetes. 
Additional studies should further clarify the mode of action of the plant and its active. This will 
pave the way toward clinical studies designed to determine if P. balsamifera and salicortin can be 
used in a safe and efficacious manner, alongside conventional medical treatments, for the 
treatment of metabolic diseases.  
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3.7 Figure Legends 
 
Figure 1: Area under the curve (AUC) of cumulative changes in body weight (CCBW) for A) 
Total 8-week treatment period, B) First 4 weeks of treatment (F1), C) Second 4 weeks of 
treatment (F2). C57BL/6 mice were administered either standard diet (Chow), HFD (DIO), and 
for the last 8 of the 16 weeks a HFD in combination with P. balsamifera at 125 or 250 mg/ kg, or 
with Salicortin 12.5 mg/kg. All values are mean ± SEM. Fraction 1 (F1) consists in the AUC 
between week 0 and 4, and fraction 2 (F2) corresponds to the AUC between week 4 and 8 of 
administration of the plant extract. The number of animals for the crude plant extract protocol 
was: CHOW (n=12), DIO (n=8), P. balsamifera 125 (n=5) and P. balsamifera 250 (n=7); and for 
the Salicortin protocol: CHOW (n=12), DIO (n=7), Salicortin (n=9). 
†
denotes DIO significantly 
different as compared to Chow (unpaired Student’s t test; p < 0.05). 
*
denotes significantly 
different as compared to respective DIO (one way ANOVA; p < 0.05). 
§
denotes significantly 
different as compared to respective DIO (unpaired Student’s t test; p < 0.05). 
 
Figure 2: Area under the curve (AUC) of cumulative changes in blood glucose levels for A) 
Total 8-week treatment period, B) First 4 weeks of treatment (F1), C) Second 4 weeks of 
treatment (F2). C57BL/6 mice were administered either standard diet (Chow), HFD (DIO), and 
for the last 8 of the 16 weeks a HFD in combination with P. balsamifera at 125 or 250 mg/ kg, or 
with Salicortin 12.5 mg/kg. All values are mean ± SEM. Fraction 1 (F1) consists in the AUC 
between week 0 and 4, and fraction 2 (F2) corresponds to the AUC between week 4 and 8 of 
administration of the plant extract. The number of animals for the crude plant extract protocol 
was: CHOW (n=12), DIO (n=8), P. balsamifera 125 (n=5) and P. balsamifera 250 (n=7); and for 
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the Salicortin protocol: CHOW (n=12), DIO (n=7), Salicortin (n=9).  
†
denotes DIO significantly 
different as compared to Chow (unpaired Student’s t test; p < 0.05). 
*
denotes significantly 
different as compared to respective DIO (one way ANOVA; p < 0.05). 
§
denotes significantly 
different as compared to respective DIO (unpaired Student’s t test; p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
191 
Table 1: Effects of obesity, P. balsamifera, and salicortin treatments on body and organ 
weights at sacrifice 
 
Measurements were obtained after 16 weeks of treatment with either standard diet (Chow), HFD 
(DIO), and for the last 8 of the 16 weeks with HFD in combination with P. balsamifera at 125 or 
250 mg/ kg, or with the active Salicortin at 12.5 mg/kg. All values are expressed as a percentage 
of respective Chow controls (reference set at 100%) and represent the mean ± SEM. The number 
of animals for each group for the P. balsamifera protocol were: CHOW (n=12); DIO (n=8); P. 
balsamifera 125 (n=5); P. balsamifera 250 (n=7); and for the salicortin protocol: CHOW (n=12); 
DIO (n=7); Salicortin (n=9). 
†
 denotes DIO significantly different as compared to Chow 
(unpaired Student’s t test; p < 0.05). 
*
 denotes significantly different as compared to respective 
DIO (one way ANOVA, Bonferonni post hoc test; p < 0.05). 
§
 denotes significantly different as 
compared to respective DIO (unpaired Student’s t test; p < 0.05). 
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Table 2: Effects of obesity, P. balsamifera, and salicortin treatments on systemic parameters 
at sacrifice  
 
Measurements were obtained after 16 weeks of treatment with either standard diet (Chow), HFD 
(DIO), and for the last 8 of the 16 weeks with HFD in combination with P. balsamifera at 125 or 
250 mg/ kg, or with the active Salicortin at 12.5 mg/kg. All values are expressed as a percentage 
of their respective Chow controls (reference set at 100%) and represent the mean ± SEM. The 
number of animals for each group for the P. balsamifera protocol were: CHOW (n=12); DIO 
(n=8); P. balsamifera 125 (n=5); P. balsamifera 250 (n=7); and for the salicortin protocol: 
CHOW (n=12); DIO (n=7); Salicortin (n=9). 
†
denotes DIO significantly different as compared to 
Chow (unpaired Student’s t test; p < 0.05). 
*
denotes significantly different as compared to 
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respective DIO (one way ANOVA, Bonferonni post hoc test; p < 0.05). 
§
denotes significantly 
different as compared to respective DIO (unpaired Student’s t test; p < 0.05). 
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Table 3: Effects of obesity as well as P. balsamifera and salicortin treatments on hepatic and 
muscular triglyceride accumulation  
 
The colorimetric dosage of TG levels in both the liver and muscle was determined using a 
commercial kit (Randox Laboratories ltd). Measurements were obtained after 16 weeks of 
treatment with either standard diet (Chow), HFD (DIO), and for the last 8 of the 16 weeks with 
HFD in combination with P. balsamifera at 125 or 250 mg/ kg, or with the active Salicortin at 
12.5 mg/kg. All values are expressed as percentage of respective Chow (reference set at 100%) 
and represent the mean ± SEM. The number of animals for each group for the P. balsamifera 
protocol were: CHOW (n=12); DIO (n=8); P. balsamifera 125 (n=5); P. balsamifera 250 (n=7); 
and for the salicortin protocol: CHOW (n=12); DIO (n=7); Salicortin (n=9). 
†
 denotes DIO 
significantly different as compared to Chow (unpaired Student’s t test; p < 0.05). 
*
denotes 
significantly different as compared to respective DIO (one way ANOVA, Bonferonni post hoc 
test; p < 0.05). 
§
denotes significantly different as compared to respective DIO (unpaired Student’s 
t test; p < 0.05). 
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Table 4: Effects of obesity as well as P. balsamifera and salicortin treatments on tissue 
components involved in glucose and lipid homeostasis 
 
 
Samples of muscle, liver, and WAT were obtained after 16 weeks of treatment with either 
standard diet (Chow), HFD (DIO), and for the last 8 of the 16 weeks with HFD in combination 
with P. balsamifera at 125 or 250 mg/ kg, or with the active Salicortin at 12.5 mg/kg. The 
samples were homogenized and analyzed by immunoblotting. Blots were quantified by 
densitometry. All values are expressed as percentage of respective Chow (reference set at 100%) 
and represent the mean ± SEM. The number of animals for each group for the P. balsamifera 
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protocol were: CHOW (n=12); DIO (n=8); P. balsamifera 125 (n=5); P. balsamifera 250 (n=7); 
and for the salicortin protocol: CHOW (n=12); DIO (n=7); Salicortin (n=9). 
†
 denotes DIO 
significantly different as compared to Chow (unpaired Student’s t test; p < 0.05). 
*
denotes 
significantly different as compared to respective DIO (one way ANOVA, Bonferonni post hoc 
test; p < 0.05). 
§
denotes significantly different as compared to respective DIO (unpaired Student’s 
t test; p < 0.05). 
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Abstract 
Larix laricina K.Koch is a medicinal plant belonging to traditional pharmacopoeia of the Cree of 
Eeyou Istchee (Eastern James Bay area of Canada). In vitro screening studies revealed that, like 
metformin and rosiglitazone, it increases glucose uptake, adipogenesis, activates AMPK, and 
uncouples mitochondrial function. The objective of this study was to evaluate the anti-diabetic 
and anti-obesity potential of L. laricina in diet-induced obese (DIO) C57BL/6 mice. Mice were 
subjected for eight or sixteen weeks to a high fat diet (HFD), or HFD to which L. laricina was 
incorporated at 125 and 250 mg/kg either at onset (prevention study), or in the last 8 of the 16 
weeks of administration of the HFD (treatment study). L. laricina effectively decreased glycemia 
levels, improved insulin resistance and slightly decreased abdominal fat pad and body weights. 
This occurred in conjuction with increased energy expenditure as demonstrated by elevated skin 
temperature in the prevention study, and suggested improvement in mitochondrial function and 
ATP synthesis in the treatment protocol. L. laricina is thus a promising alternative and 
complementary therapeutic approach for the treatment and care of obesity and diabetes among 
the Cree.  
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4.1 Introduction 
The prevalence of obesity and type 2 diabetes (T2D) has reached epidemic proportions 
worldwide. In Canada alone, obesity and T2D affect 25%  [1-3] and roughly 6% [4] of the 
population respectively. The incidence of these diseases is worsened among the aboriginal 
population of Canada. The Cree of Eeyou Istchee (CEI) of the Northern James Bay Area of 
Quebec are particularly affected where 21% of adults over the age of 20 are diagnosed as diabetic 
and 38% as obese [5-10]. This increased prevalence might be caused by their adoption of more 
westernized way of living : sedentary lifestyle, non-traditional diet (with increased consumption 
of carbohydrates and saturated fats) in addition to a low-compliance to modern T2D therapies 
[11-13]. The implementation of educational programs on lifestyle intervention (diet and exercise) 
has come to no avail, wherefrom the importance to identify alternative and culturally-adapted 
treatments or solutions for obesity and T2D [6, 9-11, 13, 14].  
Currently, around 70-95% of the population in the world relies on alternative and complementary 
medicine in order to respond to their primary health care needs. Since the CEI possess a rich 
traditional pharmacopoeia, we conducted an ethnobotanical survey to identify plant species with 
potential to treat symptoms related to T2D [15]. These plant species were screened for their anti-
diabetic potential in extensive in vitro studies [16-24]. Of the 17 plants identified, Larix laricina 
K.Koch, belonging to the Pinaceae family, demonstrated anti-diabetic potential by increasing 
glucose uptake and phosphorylation levels of AMPK and ACC in C2C12 myotubes to levels 
almost comparable to those of metformin [20, 24]. It also potentiated adipogenesis in 3T3-L1 
adipocytes, thus acting like the commonly used thiazolidinedione (TZD), rosiglitazone [24]. In 
addition, we showed that L. laricina was one of the strongest uncouplers by severely disrupting 
mitochondrial function and decreasing ATP production [20]. Uncouplers increase metabolic rate 
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and therefore fuel consumption in order to compensate for decreased ATP, which makes them 
potential anti-obesity agents [20]. Obesity contributes to 55% of all cases of T2D, therefore 
affecting one or the other might have therapeutic potential for both diseases [25]. 
There are a variety of medications available on the market that help in the management of T2D. 
Some of them, such as the antidiabetic medications metformin (biguanide) and exenatide (GLP-1 
analogue), have been reported to produce a minimal amount of weight loss, albeit not strong 
enough to be considered as an anti-obesity agent [26, 27]. The diet-induced obese (DIO) mice is 
an excellent model to study the well-documented relation of losing weight and improving insulin 
resistance. It relies on high-calorie diet and inactivity (no genetic involvement) to induce 
significant weight gain, hyperglycemia and hyperinsulinemia, thus reflecting the establishment of 
the metabolic syndrome and a pre-diabetic state. Therefore, we wanted to study the anti-diabetic 
and anti-obesity potential of L. laricina using DIO mouse model using two different 
administration regiments. Animals either received the plant concomitantly with high fat diet 
(prevention study), or received the plant after becoming obese and pre-diabetic (treatment study). 
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4.2 Materials and Methods 
4.2.1 Plant extracts 
Specimens of the plant species used in this study, L. laricina K. Koch, of the Pinaceae family, 
were collected in 2004 on the territories of the CEI of Northern Quebec, Canada. Dr. Alain 
Cuerrier, taxonomist at the Montreal Botanical Garden, confirmed the botanical identity of the 
plant species. Voucher specimens of the plant species were deposited in the Marie-Victorin 
herbarium of the Montreal Botanical Garden in Montreal, Quebec, Canada (Whap04-11, Mis03-
12, Mis03-47). Crude 80% ethanolic extract of L. laricina was prepared as previously described 
[24].  
4.2.2 Animals  
Four-week old male non-diabetic C57BL/6 mice were purchased from Charles River 
Laboratories (Saint-Constant, QC, Canada). All mice had ad libitum access to food and water. 
They were housed in individual cages and maintained on a 12 h light-dark cycle in a temperature-
controlled animal room. All experimental protocols were approved by the animal 
experimentation ethics committee of the Université de Montréal and were carried out in full 
respect of the guidelines from the Canadian Council for the Care and Protection of Animals.  
 
4.2.3 Prevention Protocol 
Following acclimatization, the four-week old male non-diabetic C57BL/6 mice were divided into 
four groups of approximately 12 mice each, where they were monitored for 8 weeks. The control 
groups consisted in administering to one group (Chow) a standard diet purchased from Charles 
River (18% protein content, 4.5% crude fat, Charles River Animal rodent diet) and to another 
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group (DIO) a high fat diet (HFD) acquired from Bio-Serv  (Bio-Ser Diet #F3282, Frenchtown, 
NJ, 60% fat by energy). The remaining groups received the HFD to which was incorporated the 
dried 80% crude ethanolic plant extract of L. laricina at levels adjusted to deliver 125 or 250 
mg/kg body weight.  
 
4.2.4 Treatment protocol 
Following acclimatization, the four-week old male non-diabetic C57BL/6 mice were divided into 
four groups of approximately 12 mice each. Chow controls received a standard diet (18% protein 
content, 4.5% crude fat; Charles River Animal rodent diet) for 16 weeks. Other groups were fed a 
HFD (Bio-Serv Diet #F3282; 60% energy from fat) for 8 weeks. L. laricina at 125 or 250 mg/kg 
was incorporated in the HFD and treatments continued for an additional 8 weeks, with DIO 
controls receiving only HFD. Based on published observations and criteria, the animals fed a 
HFD were segregated into low responders (LR) and high responders (HR) (roughly 50/50) 
according to the data just prior to plant administration (at 8 weeks). Indeed, it has been reported 
that pooling animals with a more normal metabolic profile even when fed with HFD (such as low 
weight gain, weak IR and near-normal glycemia; LR) with animals displaying overt obesity and 
insulin resistant state when fed HFD (such as high weight gain, frank IR, and hyperglycemia; 
HR) can yield misleading results [28]. For simplicity reasons, LR fed with the HFD in the 
presence or absence of the plant extract will not be depicted since they portrayed an almost 
normal metabolic profile.  
The data representing the effect of a HFD on C57BL/6 mice as compared to their CHOW fed 
congeners will not be discussed since the DIO mouse model is well established. However, our 
model (in both the prevention and treatment studies) follows the expected and published data. In 
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addition, the CHOW group was used as a non-obese control to insure that the model is functional 
and therefore the results of this group are not presented. Therefore, the effects of the plant extract, 
L. laricina, will be compared to their respective HFD controls for all the stated parameters, for 
both the prevention and treatment protocols. 
 
4.2.5 Continuous physiological and morphological parameters   
In both protocols body weight, food and water intake, as well as glycemia were measured 3 
times/week during the course of the study, consistently at the same time, day, in the same order 
by the same person, throughout the entire duration of the protocols. In order to assess blood 
glucose levels, blood was collected from puncturing the tail vein and measured using a 
commercial glucometer (Accu-Check Roche, Montreal, QC, Canada). The area under the curve 
(AUC) was calculated for these parameters, and the total AUC was then separated into two parts: 
fraction 1 (F1), representing AUC between weeks 0 and 4, and fraction 2 (F2) corresponding to 
the AUC between weeks 4 and 8 of plant extract administration. This segregation served to 
determine the temporal course of action of L. laricina in both the prevention and treatment 
protocols, i.e. whether it was effective early in onset (first 4 weeks), later (last 4 weeks) or 
throughout the study.  
4.2.6 Surgical Procedure 
At the end of each experimental protocol, the mice were anesthetized using 50 mg/kg 
pentobarbital intraperitoneally, and then sacrificed by exsanguination via the inferior vena cava. 
During the sacrifice, various organs were removed, collected and weighed; notably, liver, muscle, 
white adipose tissue (WAT; epididymal and retroperitoneal fat pads), and subscapular brown fat 
(BAT). All were placed in liquid nitrogen and then stored at -80°C until further use. As for the 
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livers, they were flushed with a physiological saline solution, weighed and the median lobes were 
then dissected, immediately placed in liquid nitrogen, and then stored at -80°C until further use.  
4.2.7 Blood parameters 
In order to ensure uninterrupted delivery of plant extract, and to avoid the complications of 
interrupting the dietary plant treatment (ex. drop in food intake and body weight caused by 
fasting the animals), glycemia, insulin, adipokines, correspond to non-fasting measurements. 
Plasma insulin, adiponectin and leptin were assessed by radioimmunoassay (RIA: Linco 
Research, St-Charles, MO) according to manufacturer’s instructions.  
 
4.2.8 Tissue triglyceride measurement 
Tissue triglyceride content was measured by grinding up into powder, under liquid nitrogen, 
around 100 mg of each of the collected liver and muscle samples, and then using Folch’s 
chloroform/methanol (2:1) extraction method [29]. Triglyceride content was then quantified 
using a commercial kit (Randox Laboratories Ltd., UK).  
4.2.9 Skin temperature 
In the prevention protocol, after 4 and 8 weeks of treatment, the temperature of the animals was 
read and recorded with a digital thermometer (Cole-Parmer Instrument Company, USA) by 
placing a probe on the external intercostal region of the animal for 2 minutes. This procedure is 
non-invasive and the least stressful for the animals [30].  
 
4.2.10 Isolation of Mitochondria and Measurement of Respiration 
Following anesthetization, the liver of mice from the treatment protocol were flushed with Krebs-
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Henseleit buffer (pH 7.4, 22°C). Mitochondria were then isolated following the method of 
Johnson and Lardy, as previously described [31-33].  
 
4.2.11 Statistical analysis 
Data were analyzed by one-way analysis of variance (ANOVA), followed by post-hoc analysis 
(Bonferroni-Dunn test or Holm-Sidak) as appropriate using Sigma Stat software (Jandel 
Scientific, San Rafael, CA). Areas under the curve (AUC) were calculated by using PRISM 
software (GraphPad, San Diego, CA, USA). Data are expressed as mean ± SEM of the indicated 
number of determinations. Statistical significance was set at p < 0.05.   
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4.3 Results 
4.3.1 L. laricina significantly improved glycemia in the treatment protocol  
Glycemia levels, which increased with HFD as compared to CHOW (by 19%; data not shown), 
were not significantly altered when L. laricina was added concomitantly with the HFD 
(prevention study; NS; Figures 1A-C). However, HFD-induced hyperglycemia (32% as 
compared to CHOW congeners; data not shown) significantly decreased in the group receiving 
the plant as treatment (following 8 weeks on HFD; Figures 1A-C). Indeed, blood glucose levels, 
as measured by the area under the curve (AUC) of glycemia versus time, decreased in a dose 
dependent manner by 10% and 12% with 125 mg/kg and 250 mg/kg doses respectively (AUCT; 
p<0.05; Figure 1A). In order to determine the temporal aspect of this anti-hyperglycemic effect, 
we fractionated the AUC between the first month of treatment (weeks 0-4 : AUCF1; Figure 1B) 
and second month (weeks 4-8: AUCF2; Figure 1C).  Our findings show that L. laricina lowered 
glycemia levels from the onset of the treatment (by 11-13%; p<0.05; Figure 1B) and this was 
maintained throughout the treatment, albeit remained significant with highest dose only (13% at 
250 mg/kg; p<0.05; Figure 1C).  
 
4.3.2 L. laricina significantly decreased insulin levels in the treatment protocol 
only, while decreasing leptin/adiponectin ratio in both protocols  
Administration of either dose of L. laricina tended to lower insulin levels by 25% to 35% in the 
prevention study, but failed to reach statistical significance (NS; Table 1). In the treatment 
protocol however, L. laricina induced-decrease of insulinemia levels reached 72% with the 
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250 mg/kg dose (p<0.05; Table 1), suggesting improvement of insulin resistance state and 
coinciding with the plant’s highest effect on glycemia as mentioned above. 
Other indicators were measured to confirm the re-establishment of insulin sensitivity. Adipose 
tissue is considered an endocrine organ, releasing into circulation adipokines, such as leptin and 
adiponectin, involved in the development of insulin resistance. A decrease of leptin/adiponectin 
ratio is thus considered as a marker of improved insulin sensitivity. In both prevention and 
treatment protocols, L. laricina tended to increase adiponectin levels by 16-26%, however 
reaching statistical significance with the 125 mg/kg dose in the prevention protocol only  
(p<0.05; Table 1). In parallel, Leptin levels were reduced with L. laricina administration by 4-
16% in the prevention study and by 21-30% in the treatment study, without however being 
statistically significant (NS; Table 1). Overall, these changes in adipokines levels resulted in 
significant decrease of the leptin/adiponectin ratio. Indeed, administration of L. laricina 
significantly lowered this ratio by 37% at 250 mg/kg in the prevention study (p<0.05; Table 1) 
and by 29-31% with both doses in the treatment study (p<0.05; Table 1). Therefore, L. laricina 
seems to decrease systemic insulin resistance.  
Furthermore, since accumulation of lipids in the liver and skeletal muscle have been implicated in 
insulin resistance, we measured hepatic and muscular triglyceride levels (TG). Despite L. laricina 
decreasing systemic insulin resistance, as suggested by improvement in the aforementioned 
parameters, hepatic or muscular triglyceride levels were not significantly altered (NS, Table 2).  
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4.3.3 L. laricina diminished body weight gain in both the prevention and 
treatment protocols, while decreasing fat pad weight in the prevention 
protocol only 
Continuous measurements of cumulative change in body weight (CCBW), represented as the area 
under the curve (AUC), revealed that while the effect of L. laricina on body weight gain was 
immediate in the prevention protocol for both doses (10% for AUCF1; NS; Figure 2B), it only 
reached significant proportions in the second half of the protocol (AUCF2) with the highest dose, 
decreasing it by 14% as compared to DIO controls (AUCF2; p<0.05; Figure 2C). In contrast, in 
the treatment protocol, L. laricina produced its strongest and most significant effect in the first 
half of administration lowering AUCF1-CCBW by 10% at 250 mg/kg as compared to DIO 
congeners (AUCF1; p<0.05; Figure 2B). However, its anti-obesity effect was not maintained; L. 
laricina reduced AUCF2 by only 4% at 250 mg/kg (NS; Figure 2C).  
Consistent with the observed decrease in body weight gain, L. laricina significantly lowered 
retroperitoneal/abdominal fat pad weight in the prevention study by 15% at 250 mg/kg (p<0.05; 
Table 3) as compared to DIO controls. As for the treatment, it corresponded to a slight decrease 
with both doses (5%-11%; NS; Table 3).  
It is interesting to note that, in both protocols, mice administered L. laricina maintained similar 
food intake to their DIO controls (NS; Figure 2D-F), while being less prone to gaining weight. 
Finally, L. laricina exhibited no toxicity as demonstrated by unaltered blood biochemical 
parameters and tissue histological examination (data not shown).  
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4.3.4 L. laricina improved mitochondrial function  
Regulation of body temperature requires regulating both heat production and heat loss. 
Mitochondria metabolism is an important source of heat production. For the most part, variations 
in the rate of electron transport are directly related to the demand by the cells for ATP. However, 
exogenous substances, which uncouple mitochondria, can lead to the disruption of oxidative 
phosphorylation, decreasing ATP synthesis and increasing heat production. Previous screening 
studies have shown that L. laricina uncoupled mitochondrial function in isolated Wistar rat 
hepatocytes [20]. Therefore, we used skin temperature as an indirect measure of energy 
expenditure and possible mitochondrial uncoupling in the prevention study. After 4 and 8 weeks 
of treatment, we observed a gradual and dose dependent increase in skin temperature with L. 
laricina administration (p<0.05; Figure 3A & B). 
 Having perfected the isolation of mitochondria in mice, we opted to directly evaluate 
mitochondrial function in the treatment study in plant-treated mice compared to DIO controls. As 
expected DIO mice, which have increased fatty acid deposition in the liver, exhibited a lower 
respiratory control ratio (RCR) accompanied by decreased ATP production, in comparison to 
CHOW animals, although data variability precluded statistical significance (Table 4; N.S.). 
Despite a small sample, animals treated with 250 mg/Kg of L. laricina seemed to restore 
mitochondrial function and capacity to the level of chow values, as observed by an increase in 
RCR and ATP  synthesis (Table 4; N.S.).  
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4.4 Discussion 
According to International Diabetes Federation latest figures, the number of people living 
with diabetes will rise from 366 millions in 2011 to 552 millions by 2030 [34]. The magnitude 
and impact of this disease dictate the urgent need for action. Although several drugs exist on the 
market to treat diabetes, the need to discover novel therapeutic options is warranted, especially in 
aboriginal context, such as the CEI [6, 9-11, 13, 14]. Indeed, recent lifestyle changes and non-
compliance with western medicines could account for the staggering diabetes prevalence of 29% 
in adults over 20 years old in this community [5, 6, 11-13].  
In our quest to discover a culturally adapted diabetes treatment, we identified L. laricina 
from the CEI pharmacopoeia as potential anti-diabetic medicinal plant. Initial in vitro screening 
showed that this plant stimulated glucose uptake, potentiated adipogenesis [24], activated AMPK 
and acted as mitochondrial uncoupler/inhibitor (on normal isolated mitochondria) [20]. These 
effects are reminiscent of the action of Metformin, which partially mediates its action through 
inhibition of mitochondrial respiration, activation of AMPK and upregulation of glucose uptake 
as well [20, 35-39]. It was therefore interesting to test the antidiabetic effect of L. laricina in a 
mouse model mimicking type 2 diabetes as a consequence of obesity by subjecting C57BL/6 
mice to HFD (Diet-induced-Obesity model; DIO). We tested the plant in two different regiments: 
1) L. laricina was administered concomitantly with HFD for 8 weeks in order to confirm its 
capacity to attenuate the development of obesity, diabetes and the associated insulin resistance 
(prevention study); 2) L. laricina was administered to obese and insulin resistant C57BL mice 
(already on HFD for 8 weeks) for 8 weeks to test its ability to reverse the establishment of both 
of these states (treatment study).  
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Typically, the DIO model is characterized by increased body weight gain, hyperglycemia 
and establishment of insulin resistant state (hyperinsulinemia, increase of the leptin/adiponectin 
ratio, ectopic fat storage in the liver and muscle)[40, 41]. We therefore examined these 
parameters to determine the effect of L. laricina in vivo. 
 The results of the present studies confirm that L. laricina holds great promise as an anti-
diabetic medicinal plant. Although this plant had no effect of glycemia when administered 
concomitantly with HFD (prevention study), on the contrary, it significantly decreased glycemia 
in the treatment study, in a suggestive dose-dependent manner. These findings correlate well with 
our in vitro data where this plant extract increased glucose uptake in skeletal muscle cells and 
adipocytes [24], which accounts for 85% of postprandial glucose disposal, [42] and increased 
AMPK activity in C2C12 muscle cells [20]. It is worthy to note that glycemia levels of animals 
receiving HFD in the treatment study are higher than those in the prevention study (32% vs 19% 
respectively, compared to CHOW). One could suggest that L. laricina exert its anti-
hyperglycemic effect better when disease processes are more pronounced, thus explaining the 
observed difference in the plant’s effect between the prevention and the treatment study.  
Insulin resistance parameters were also modulated with administration of L. laricina in 
both treatment regiments. While strong tendencies are apparent in the prevention study, 
insulinemia and leptin/adiponectin ratio were significantly decreased in the treatment study 
(especially with the highest dose of L. laricina), suggesting improvement of systemic insulin 
resistance. Intriguingly, L. laricina failed to decrease hepatic and muscle triglycerides in both 
studies. Several lines of evidence suggest that hepatic triglyceride accumulation lead to insulin 
defective signaling in the liver with increased hepatic glucose output.  However, Buettner et al 
have shown that TG accumulation in the liver is not always sufficient to impair insulin signaling 
[43, 44]. In fact, they argue that systemic factors (such as adipokines, free fatty acids, pro-
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inflammatory cytokines) may play an important role in the regulation of hepatic glucose output 
and insulin sensitivity in vivo [43, 44]. Hence, our data on the lack of depletion in intrahepatic 
and intramuscular triglyceride levels needs to be evaluated in further detail. Indeed, continued 
administration of HFD along side L. laricina could make elimination of steatosis difficult. 
Another possibility could be that since oxidation pathways are saturated with fatty acids being 
mobilized from the adipose tissue (decrease in adipose tissue weight due to probable hormone-
sensitive lipase activity), this could consequently hinder any decrease in tissue triglyceride stores 
[45]. In all cases, since adiponectin levels tended to increase and leptin/adiponectin ratio (an 
indicator of insulin resistance) [46-50] significantly decreased with ingestion of L. laricina, pro-
insulin resistant systemic factors seem to be decreased and insulin sensitivity improved. 
Interestingly, we have shown that treatment of hepatic cells in vitro L. laricina inhibits the 
activity of enzymes implicated in hepatic gluconeogenesis, such as glucose-6-phosphatase and 
activates those promoting glycogen formation, such as glycogen synthase (GS), thus directly 
modulating hepatic glucose output [51].  
This plant showed slight decrease of body weight with both studies, which was significant 
if continuous measurements were taking into account for the first and second month of 
administration. These changes occurred while the animals were on a continuous hypercaloric/fat-
laden diet, and without any observed change in energy intake. This could represent an indirect 
modulation of body weight as a consequence of L. laricina anti-diabetic activity, which in some 
cases is similar to Metformin. 
L. laricina administration also decreased retroperitoneal fat pad weight significantly in the 
prevention study, and showed a tendency to do so in the treatment study. This represents an 
important action in the fight against insulin resistance since visceral adipose tissue has been 
implicated in the detrimental effects of obesity and insulin resistance [52]. Hence, modulation of 
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this tissue would influence adipokine secretion and contribute to the improvement of insulin 
sensitivity, as can be seen in our plant-treated mice.  
On the molecular level, we have shown that L. laricina activates AMPK in C2C12 
myotubes [20] and H4IIE hepatic cell line [51]. This activation may be secondary to a variety of 
factors, including adiponectin or metabolic stress induced by the disruption of mitochondrial 
energy transduction [53-56]. In the literature, it has been reported that animals (mice or rat) fed a 
high-fat diet exhibit a decreased mitochondrial respiratory capacity (state 3/state 4), as was 
observed in this treatment protocol in mice administered a HFD [57]. Increased consumption of 
dietary fat may lead to alterations in mitochondrial membrane composition, increased ROS 
production and peroxidation of fatty acids, which could damage mitochondrial structures, all 
affecting mitochondrial function [57]. Uncoupling agents are beneficial in alleviating the 
mitochondrial stress induced by a HFD, by increasing fatty acid oxidation, and decreasing ROS 
production [58]. In the treatment study, L. laricina at 250 mg/kg showed a tendency to improve 
mitochondrial capacity and ATP production to levels comparable to those observed in animals 
fed a standard Chow diet. As demonstrated in previous in vitro screening studies, the uncoupling 
effect of L. laricina is short-lived, and is followed by a prolonged activation of AMPK and an 
overshoot phenomenon occurring to restore energy homeostasis, where ATP production is greatly 
increased, through raised carbohydrate and lipid oxidation [20]. Other benefits of increased 
AMPK activity include protecting cells from further damage by potentiating mitochondrial 
biogenesis [20, 59, 60]. Therefore, it seems that in the current animal treatment protocol, the 
long-term effect of L. laricina improved mitochondrial capacity, and most probably through 
AMPK activation regulated glucose homeostasis. Of note, uncoupling agents usually lead to 
increased heat production due to increased energy expenditure. L. laricina treated animals in the 
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prevention study exhibited elevated skin temperature, thus confirming its uncoupling activity in 
vivo.  
In conclusion, this study confirms the anti-diabetic activity of L. laricina in the context of 
diet-induced obesity in a mouse model. The results clearly show that L. laricina decreased 
hyperglycemia, insulin resistance and improved mitochondrial function in the treatment study, 
while partially modulating parameters involved in insulin sensitivity in the prevention one. It also 
had a slight effect on body weight gain in both studies. The exact mechanisms of action of L. 
laricina remain to be identified, but results point toward possible activation of AMPK and its 
downstream effectors.  In view of the soaring increase in both obesity and diabetes among 
aboriginal populations and in particular the CEI, L. laricina represents a valuable alternative, and 
culturally-adapted treatment for both these diseases.  
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4.7 Figure Legends 
Figure 1 : Area under the curve (AUC)  of non-fasting glycemia levels, in C57BL/6 mice treated 
with either HFD (DIO), or L. laricina at 125 or 250 mg/ kg, which was incorporated in the HFD 
for 8 weeks in the prevention protocol and for the last 8 of 16 weeks in the treatment protocol. 
Total AUC for blood glucose levels-vs-time (A) was calculated and then fractionated into the 
first and second half of the feeding period corresponding to weeks 0-4 (AUCF1; B) and weeks 4-8 
(AUCF2; C), respectively.  All values are mean ± SEM. Number of animals/group for prevention 
protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13, and for the treatment protocol DIO 
= 7; L. laricina 125 = 5; L. laricina 250 = 8). *denotes significantly different as compared to DIO 
group (one way ANOVA; post-hoc analysis Holm-Sidak or Bonferroni-Dunn test; p < 0.05).  
 
Figure 2: Area under the curve (AUC) of cumulative change in body weight (CCBW; panels A-
C) and cumulative change in energy intake (CCEI; panels D-F) in C57BL/6 mice treated with 
either HFD (DIO), or L. laricina at 125 or 250 mg/ kg, which was incorporated in the HFD for 8 
weeks in the prevention protocol and for the last 8 of 16 weeks in the treatment protocol. Total 
AUC for CCBW-vs-time (A) or CCEI-vs-time (D) was calculated and then fractionated into the 
first and second half of the feeding period corresponding to weeks 0-4 (AUCF1; B or E) and 
weeks 4-8 (AUCF2; C or F), respectively. All values are mean ± SEM. Number of animals/group 
for prevention protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13, and for the 
treatment protocol DIO = 7; L. laricina 125 = 5; L. laricina 250 = 8). *denotes significantly 
different as compared to DIO group (one way ANOVA; post-hoc analysis Holm-Sidak or 
Bonferroni-Dunn test; p < 0.05).  
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Figure 3:  Skin temperature was measured in the prevention study after 4 weeks (A) and after 8 
weeks (B) of treatment, from mice treated with either HFD (DIO), or L. laricina at 125 or 250 
mg/ kg, which was incorporated in the HFD for 8 weeks. All values are mean ± SEM. Number of 
animals/group for prevention protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13. 
*denotes significantly different as compared to DIO group (one way ANOVA; post-hoc analysis 
Holm-Sidak or Bonferroni-Dunn test;  p < 0.05).  
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Table 1: Effects of HFD and L. laricina administration on systemic parameters at sacrifice 
Prevention Protocol Treatment Protocol 
  
DIO 
L. laricina          
125 mg/kg 
L. laricina          
250 mg/kg 
DIO 
L. laricina          
125 mg/kg 
L. laricina          
250 mg/kg 
Insulin  
(ng/mL) 
9.2 ± 1.8 6.9 ± 1.1 6.0 ± 0.9 39.9 ± 5.8 29.4 ± 9.1 11.0 ± 1.9
*
 
Leptin  
(ng/mL) 
39.3 ± 3.5 37.7 ± 3.2 33.1 ± 2.0 39.0 ± 3.0 27.1 ± 5.4 30.9 ± 2.1 
Adiponectin 
(µg/mL) 
8.8 ± 0.7 11.1 ± 0.8
*
 10.8 ± 0.4 11.1 ± 0.6 10.9 ± 0.7 12.8 ± 0.6 
Leptin/adiponectin 
ratio 
4.9 ± 0.6 3.7 ± 0.5 3.1 ± 0.2
*
 3.5 ± 0.2 2.5 ± 0.5
*
 2.4 ± 0.2
*
 
 
Measurements were obtained after 8 weeks (prevention) or 16 weeks (treatment) of 
administration with either HFD (DIO), or L. laricina at 125 or 250 mg/ kg, which was 
incorporated in the HFD for 8 weeks in the prevention protocol and for the last 8 of 16 weeks in 
the treatment protocol. All values represent the mean ± SEM (prevention protocol DIO = 11; L. 
laricina 125 = 13; L. laricina 250 = 13, and for the treatment protocol DIO = 7; L. laricina 125 = 
5; L. laricina 250 = 8). * denotes that treated groups are significantly different as compared to 
DIO (one-way ANOVA; post-hoc analysis Holm-Sidak or Bonferroni-Dunn test; p < 0.05).  
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Table 2: Effects of HFD and L. laricina administration on hepatic and muscular triglyceride 
accumulation  
Prevention Protocol Treatment Protocol 
  
DIO 
L. laricina          
125 mg/kg 
L. laricina          
250 mg/kg 
DIO 
L. laricina          
125 mg/kg 
L. laricina          
250 mg/kg 
Liver TG levels 
(mg/g total liver) 
331 ± 54 407 ± 47 374 ± 52 1041 ± 173 919 ± 240 1138 ± 118 
Muscle TG levels  
(µg/mg) 
84 ± 12 60 ± 6 65 ± 8 212 ± 29 224 ± 80 255 ± 33 
 
The colorimetric dosage of TG levels in both the liver and muscle was determined using a 
commercial kit (as described in detail in Material and Methods). Measurements were obtained 
after 8 (prevention) or 16  (treatment) weeks of administration with either HFD (DIO), or L. 
laricina at 125 or 250 mg/ kg, which was incorporated in the HFD for 8 weeks in the prevention 
protocol and for the last 8 of 16 weeks in the treatment protocol. All values represent the mean ± 
SEM (prevention protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13, and for the 
treatment protocol DIO = 7; L. laricina 125 = 5; L. laricina 250 = 8). * denotes that treated 
groups are significantly different as compared to DIO (one-way ANOVA; post-hoc analysis 
Holm-Sidak or Bonferroni-Dunn test;  p < 0.05). 
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Table 3: Effects of HFD and L. laricina administration on body and organ weights at 
sacrifice  
Prevention Protocol Treatment Protocol 
  
DIO 
L. laricina          
125 mg/kg 
L. laricina          
250 mg/kg 
DIO 
L. laricina          
125 mg/kg 
L. laricina          
250 mg/kg 
Retroperitoneal  
Fat Pad (g)                       
1.34 ± 0.05 1.26 ± 0.04 1.14 ± 0.05
*
 1.51 ± 0.08 1.35 ± 0.24 1.44 ± 0.04 
Epididymal  
Fat Pad (g) 
2.40 ± 1.00 2.56 ± 0.08 2.56 ± 0.07 1.21 ± 0.03
†
 1.32 ± 0.18 1.85 ± 0.12
*
 
Brown  
Fat Pad (g) 
0.30 ± 0.03 0.33 ± 0.01 0.28 ± 0.02 0.44 ± 0.01 0.37 ± 0.06 0.42 ± 0.02 
Liver Weight (g) 1.77 ± 0.09 1.85 ± 0.05 1.80 ± 0.07 2.62 ± 0.15 2.44 ± 0.38 2.57 ± 0.12 
Liver index 410 ± 2 429 ± 1 437 ± 1 551 ± 3 539 ± 5 555 ± 2 
Measurements were obtained after 8 weeks (prevention) or 16 weeks (treatment) of 
administration with either HFD (DIO), or L. laricina at 125 or 250 mg/ kg, which was 
incorporated in the HFD for 8 weeks in the prevention protocol and for the last 8 of 16 weeks in 
the treatment protocol.  The liver index corresponds to: liver weight (mg) / body weight (mg). All 
values represent the mean ± SEM (prevention protocol DIO = 11; L. laricina 125 = 13; L. 
laricina 250 = 13, and for the treatment protocol DIO = 7; L. laricina 125 = 5; L. laricina 250 = 
8). * denotes that treated groups are significantly different as compared to DIO (one-way 
ANOVA; post-hoc analysis Holm-Sidak or Bonferroni-Dunn test;  p < 0.05).  
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Table 4: Effects of obesity as well as L. laricina administration on hepatic mitochondrial 
function  
Treatment Protocol 
  
CHOW DIO 
L. laricina          
125 mg/kg 
L. laricina          
250 mg/kg 
State 3 62.90 ± 4.50 59.81 ± 8.34 51.41 ± 6.91 62.91 ± 3.34 
State 4 18.23 ± 1.05 17.43 ± 0.89 16.20 ± 1.04 16.29 ± 0.85 
RCR 3.45 ± 0.08 3.37 ± 0.32 3.18 ± 0.35 3.87 ± 0.14 
ATP synthesis 3.53 ± 0.53 3.20 ± 0.52 2.73 ± 0.40 3.52 ± 0.25 
 
Mitochondrial function was measured as described in detail in Materials and Methods, after 16 
weeks  of administration with either standard diet (CHOW), HFD (DIO), or L. laricina at 125 or 
250 mg/ kg, which was incorporated in the last 8 of 16 weeks in the treatment protocol. State 3 
represents the rate of oxygen consumed during oxidative phosphorylation; state 4 represents the 
rate of oxygen consumption obtained after oxidative phosphorylation; RCR (respiratory control 
ratio) represents the ratio between state 3 and state 4.  All values represent the mean ± SEM (for 
the treatment protocol CHOW = 4; DIO = 5; L. laricina 125 = 4; L. laricina 250 = 4).  
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Figure 1 
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239 
Figure 3 
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5.1 General Summary 
Obesity and type 2 diabetes (T2D) have reached epidemic proportions worldwide, 
affecting both genders, as well as all age groups and ethnicities, with a predominance in the past 
decade especially among children and young adults. These morbid diseases not only result in 
devastating complications, whether they be physical or even psychological, but they also lead to a 
tremendous economical burden in countries around the world (Figure 49).  
 
Figure 49: Complications arising from childhood obesity (adapted from:(Ebbeling et al. 
2002; Batch and Baur 2005)).  
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In Canada, the aboriginal population is particularly affected, with the rate of obesity and 
T2D, being around 1.5 fold and 4-5 times higher, respectively than the rest of the population. The 
aboriginal population that our team focused on are the Cree of Eeyou Istchee (CEI) of the 
Northern James Bay Area of Quebec, which fall within the aforementioned prevalence of both 
these diseases. The high incidence of obesity and T2D among the CEI may be due to a change in 
their dietary habits. They had a long-standing tradition of being hunter-gatherers, which included 
fishing, eating green and root vegetables, fruits and berries. That lifestyle provided them with 
protective properties against diabetes (PHAC 2011a). They have now switched to a more western 
diet high in calories, saturated fats and simple sugars (Young 2000; Shah 2003; Kuhnlein et al. 
2004). Other factors that may be involved, include a sedentary lifestyle (decreased physical 
activity), and genetic predisposition, with reference to the thrifty gene, which predisposes to 
conserve calories. This can be useful in times of famine, but detrimental with current food 
availability, lifestyle, and quality of diet (Neel 1962; Hegele et al. 1999; Neel 1999; Young 2000; 
Hegele 2001; Shah 2003). There are many other environmental factors that can have a negative 
impact on the health of the aboriginal population and therefore in the development of T2D. These 
social determinants of health include poor housing conditions, low level of education, 
unemployment, limited access to health care due to geographical location but also language 
barriers, and lack of culturally appropriate services, which also lead to low compliance to modern 
medications (Hales and Barker 2001; FNIGC 2007; Reading 2009; Southam et al. 2009; Carriere 
2010).  
Despite educational and dietary intervention programs that have been instituted with the 
objective of minimizing the incidence of obesity and T2D, both these disease continue to be on 
the rise among all aboriginal populations including the CEI. It has been noticed that in order for 
the CEI to have more compliance to any form of therapy, there needs to be an increase in 
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sensitivity to their culture and traditional medicines (Rideout and Menzies 1994). Wherefrom 
stems the necessity in reinforcing their traditional way of living, i.e. promoting healthy living and 
eating by going back to their hunter-gatherer lifestyle, as well as identifying and validating 
alternative treatments that are culturally relevant, and stemming from the CEI’s own traditional 
pharmacopoeia (Boston 1997; Berman 1999; Gray-Donald 2000; Young 2000; Légaré 2004a; 
Légaré 2004b).  
Our team conducted an ethnobotanical study among the Elders and healers of six 
communities, Mistissini, Whapmagoostui, Nemaska, Waskaganish, Wemindji, and Oujé-
Bougoumou based on 15 symptoms associated with T2D (Leduc et al. 2006; Fraser et al. 2007). 
There were over 30 plants that were identified, with 17 of the most promising ones having been 
screened in vitro for their antidiabetic potential, by using cell-based screening assays that look at 
primary defects and secondary complications (Spoor et al. 2006; Harbilas et al. 2009; Martineau 
et al. 2010). These assays determined the ability of the plants to increase glucose uptake in 
C2C12 myotubes and 3T3-L1 pre-adipocytes, adipogenesis in 3T3-L1 pre-adipocytes, insulin 
secretion and !-cell proliferation, as well as their impact on protecting PC12-AC (neuronal 
precursor) cells against glucose toxicity and deprivation, and their anti-oxidant potential. The 
mechanisms of action of some of these plants were also examined in vitro, such as inhibition of 
Glut-2 or SGLT-1, activation of AMPK, ACC, ATP production, and their potential to uncouple 
mitochondrial respiration (Eid et al. 2010a; Eid et al. 2010b; Martineau et al. 2010; Nistor Baldea 
et al. 2010). Based on these studies, roughly half of the plant species revealed antidiabetic 
potential. Some plants also demonstrated a strong antiobesity potential. The two plant species 
that were of particular interest were Populus balsamifera L. (Salicaceae) and Larix  laricina K. 
Koch (Pinaceae).  
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P. balsamifera was the only plant among the 17 to completely inhibit triglyceride 
accumulation (no visible lipid droplets) during adipogenesis in 3T3-L1 pre-adipocytes. Cells 
retained pre-adipocytic fibroblastic morphology (Harbilas et al. 2009; Martineau 2010a). This 
may be due to the fact that the crude plant extract exhibits PPAR antagonist action, as determined 
by gene-reporter assay (Martineau 2010a). The phytochemical compound, salicortin (salicylate 
glycoside) was identified through bioassay-guided fractionation in the adipogenesis assay, and 
revealed itself as the principal active component (10% of crude extract) of P. balsamifera 
responsible for the observed inhibition of adipogenesis (Martineau 2010b). It is of great 
importance that, prior to the in vitro studies conducted by our team and the in vivo studies that 
compose this thesis, the antiobesity potential had not been ascribed to P. balsamifera, or any of 
its known phytochemical constituents such as salicortin (Harbilas et al. 2009; Martineau 2010a; 
Martineau 2010b). Salicortin was however known for its anti-inflammatory and anti-proliferative 
effects (Subramanian et al. 2006).  
Concerning L. laricina, it demonstrated antidiabetic potential by increasing glucose 
uptake and phosphorylation of AMPK and ACC (no activation of the Akt pathway) in C2C12 
myotubes. Its action was comparable to levels comparable to the commonly prescribed 
antidiabetic medication Metformin (Spoor et al. 2006; Martineau et al. 2010). It also potentiated 
adipogenesis in 3T3-L1 adipocytes acting like the thiazolidinedione drug rosiglitazone, which is 
another class of antidiabetic medication (Spoor et al. 2006). In addition, hepatocytes isolated 
from Wistar rats, L. laricina was identified as one of the strongest uncouplers, severely disrupting 
mitochondrial function and ATP production (Martineau et al. 2010). Uncouplers are known to 
increase metabolic rate and fuel consumption, as a compensatory mechanism for decreased ATP 
production, suggesting that they may also serve as potential antiobesity treatments. 
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These results prompted further research in terms of validating the antiobesity and 
antidiabetic potential of P. balsamifera and its active salicortin, as well as that of L. laricina in an 
in vivo mouse model. The choice of the animal model, C57BL/6 diet-induced obese mice, was 
based on the fact that more than half of the cases of T2D are due to obesity, a combination of a 
hypercaloric high-fat diet and physical inactivity, and by reason of the incredibly high incidence 
of both these diseases among the CEI.  The C57BL/6 mice are a widely used model that rely on a 
high-calorie diet and inactivity, without genetic involvement, to induce significant body and 
adipose tissue weight gain. This results in alterations in adipokine secretion, hyperglycemia, 
hyperinsulinemia, and hyperlipidemia, all reflecting the establishment of the metabolic syndrome 
and a pre-diabetic state (Jiang et al. 2005; Cefalu 2006a). Two distinct experimental protocols 
were used in the in vivo studies that make up this thesis and they were termed prevention and 
treatment protocols. The objective of the prevention protocol was to evaluate the potential of the 
plants to attenuate the development of obesity and its associated metabolic disturbances by 
administering either P. balsamifera or L. laricina concomitantly with the high-fat diet (HFD) for 
a period of 8 weeks. Conversely, the treatment protocol consisted in administering the HFD for a 
period of 8 weeks, allowing obesity and a state of metabolic syndrome to become established. 
Thereafter, over another 8 week period, P. balsamifera or its active principle salicortin, or L. 
laricina were incorporated to the HFD. This enabled to determine their respective potential at 
inhibiting further weight gain and even partially reversing the established state of obesity and 
metabolic syndrome.  
In order to better highlight the results of the plant species and the active principle, it is 
important to briefly summarize the effects of the HFD on the model. The positive control group 
was termed DIO (diet-induced obesity), whereby a HFD was administered for either 8 weeks 
(prevention) or 16 weeks (treatment). DIO animals develop (to various degrees depending on the 
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protocol) significant body weight gain, increased retroperitoneal (abdominal) fat pad weight, 
dysregulation of adipokines secretion (adiponectin and leptin), upregulation of leptin/adiponectin 
ratio, increased blood glucose levels (hyperglycemia), hyperinsulinemia, and increased ectopic 
fat storage in the liver and muscle. 
 
5.2 Summary of article 1 (chapter 2) 
In the prevention study, P. balsamifera significantly attenuated body weight gain in mice 
continuously fed a hypercaloric fat laden diet, with results suggesting a dose-dependent effect. P. 
balsamifera’s expected capacity to inhibit adipogenesis in vivo was corroborated by a decrease in 
retroperitoneal fat pad weight. P. balsamifera appeared to modulate the 44/42 MAPk pathway, 
increasing activation in the adipose tissue. The ERK pathway is associated with inhibition of 
adipogenesis in vitro and in vivo. It is known to inhibit transcriptional activity of PPAR! 
(activating SOX9 which in turn decreases expression of C/EBP" and C/EBP#)(Rosen et al. 2002; 
Sul 2009). Balsam poplar treatments produced a slight variation in PPAR! levels, however there 
may have been other adipogenesis effectors that may have been more strongly impacted and 
require further study.  
As mentioned, the abdominal adipose tissue is associated with the negative effects of 
obesity, releasing adipokines and inflammatory cytokines that contribute to the onset of insulin 
resistance and secondary complications. P. balsamifera, not only altered abdominal weight but 
adipokine secretion as well. It increased adiponectin levels, and decreased the leptin/adiponectin 
ratio. Balsam poplar therefore contributed to the overall improvement of insulin sensitivity, 
which was further confirmed with its strong tendency to decrease glycemia and insulinemia 
levels.  
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Non-alcoholic fatty liver disease (NAFLD) and its more severe form of non-alcoholic 
steatohepatitis (NASH) is also recognized as being an important component of the metabolic 
syndrome and is involved in the development of insulin resistance in the liver (den Boer et al. 
2004; Girard and Lafontan 2008).  Therefore, improvement of hepatic steatosis represents an 
important feature of any therapy directed against the metabolic syndrome. There have been 
studies that have shown that increased ERK has been linked to more intense pre-replicative phase 
hepatocyte proliferation, hyperplasia and NAFLD (Chavez-Tapia et al. 2009). However, P. 
balsamifera decreased ERK (44/42 MAPk) in the liver. This may in part explain the decrease in 
hepatic steatosis observed in these animals. Balsam poplar shifted the severity of liver fat 
accumulation towards grades of weak and absent steatosis, as opposed to moderate and high 
steatosis in DIO controls. This finding correlated well with the strong tendency to reduce hepatic 
TG levels and increase PPAR! levels (promotes fatty acid oxidation). Balsam poplar at its 
highest dose  showed a tendency to normalize Akt levels, which is consistent with decreased 
insulinemia levels, while concomitantly being indicative  of  improvement in insulin sensitivity. 
IKK-!!, a marker of inflammatory state and associated with insulin resistance in several models 
of the metabolic syndrome (Kim et al. 2001; Yuan et al. 2001; Arkan et al. 2005), was decreased 
in the liver of animals treated with P. balsamifera indicating a reduced inflammatory state. This 
completed several lines of evidence that support that balsam poplar improved insulin sensitivity 
by decreasing inflammation and ectopic fat storage (reduction in hepatic and skeletal muscle 
triglycerides). 
Modifying either energy intake or energy expenditure, or even both can also regulate 
obesity. P. balsamifera decreased caloric intake at its highest dose, and may in part explain 
decrease in body weight (decrease in food intake amounts to 1/3 of observed decrease in body 
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weight). This slight anorexic effect requires further investigation. Balsam poplar also increased 
superficial body temperature, with results suggesting a dose-dependent effect. Superficial body 
temperature is an indication of energy expenditure in the form of heat. This finding correlated 
with balsam poplars’ strong tendency to increase UCP-1 expression in BAT (associated with 
non-shivering thermogenesis).  
 
 
Figure 50: Schematic representation of the effects of P. balsamifera in the prevention protocol 
(article 1/chapter 2). In this figure the symbols used represent: 
a 
the dose of 125 mg/kg is 
significantly different as compared to DIO controls (see appropriate section for details on 
statistical analysis); 
b
 the dose of 250 mg/kg is significantly different as compared to DIO 
controls (see appropriate section for details on statistical analysis); 
ab
 both the 125 and 250 mg/kg 
doses are significantly different as opposed to DIO controls (see appropriate section for details on 
statistical analysis). No symbol next to the stated parameters indicates that the plant extract did 
produce an effect, however without reaching statistical significance.  
 
5.3 Summary of article 2 (chapter 3)  
In the treatment protocol, both P. balsamifera, more potent at 125 mg/kg than 250 mg/kg, 
and its active principle salicortin effectively modulated obesity and diabetes parameters. The 
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plant species reduced energy intake at 125 mg/kg, which may have contributed to its action on 
body weight. It is noteworthy, that the reduction in caloric intake was weaker than the weight loss 
measured. Nevertheless, this slight appetite-modifying effect does warrant further investigation. 
On the other hand, salicortin decreased body without affecting energy intake, suggesting different 
profiles of biological activity. It is to note that salicortin was identified as being the active 
principle in balsam poplar, based only on its ability to inhibit adipogenesis in vitro. It was not 
evaluated in vitro for any other beneficial effects that it may possess. Therefore, the current in 
vivo data suggests that there are certainly other phytochemical components (excluding salicortin) 
present within balsam poplar that may contribute to its appetite-modifying effect.  
Glucose homeostasis was almost completely restored with P. balsamifera and salicortin. 
Glycemia levels returned to almost normal levels, and insulinemia was decreased by around 7 
and 4 fold respectively. Likewise, the leptin-to-adiponectin ratio, also reflective of insulin 
resistance, was decreased with the plant extract and the active principle. Only salicortin 
significantly improved blood lipid profile (LDL and total cholesterol levels). Once again this 
points to variations in biological activity between the crude extract and the purified active 
principle. 
The liver, adipose tissue, and skeletal muscle are all important players in the development 
of obesity, insulin resistance, and the metabolic syndrome. Therefore, a variety of effectors 
involved in glucose metabolism and fatty acid oxidation were evaluated in these tissues. As 
mentioned, hepatic steatosis is an important contributor to the development of insulin resistance 
and the metabolic syndrome, wherefrom the importance in decreasing hepatic TG, as was 
observed with both balsam poplar and salicortin. Both the plant extract and the active principle 
modulated pathways associated to hepatic lipid metabolism. They both showed tendencies at 
increasing levels of PPAR! or CPT-1, favoring fatty acid oxidation, and decreasing ERK 
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phosphorylation. Hepatic IKK!", inflammatory component involved with NAFLD, also tended 
to be decreased by P. balsamifera (Arkan et al. 2005; Tilg and Moschen 2010). P. balsamifera 
also increased Akt phosphorylation in the liver (active principle demonstrated mild tendency) 
converging in the several lines of evidence that hepatic insulin sensitivity is improved.  
Consistent with the observed reduction in body weight, both balsam poplar and salicortin 
greatly reduced retroperitoneal fat pad weight. However due to data variability, it failed to reach 
significant proportions. Nonetheless, analysis of a variety of adipose tissue components involved 
in glucose and lipid metabolism yielded a number of insightful results. Once more, the variations 
observed in the ERK pathway suggest that this may be the target pathway of both P. balsamifera 
and salicortin. A variety of factors are implicated in the regulation of the ERK pathway rendering 
interpretation of the data complex. In the treatment protocol, balsam poplar and the active 
principle showed tendencies in decreasing phosphorylated ERK levels, correlating with slight 
tendencies to increase PPAR# levels (see section 5.5.2 for possible explanations on ERK 
regulation). The plant species, and to lesser extent the active principle, seemed to upregulate 
factors associated with lipid metabolism, such as FABP4, a lipid chaperone that carries FA to 
cellular pathways of oxidation, and CPT-1 (strong tendency). Balsam poplar demonstrated a 
strong tendency at increasing Akt phosphorylation/activation, once again converging in the lines 
of evidence that insulin sensitivity was improved with plant species administration. Akt 
activation leads to Glut4 translocation and increased glucose uptake, as well as inhibition of 
lipolysis consequently decreasing TG being circulated to tissues such as the liver.  In general, the 
active principle exhibited a weaker effect on the adipose tissue parameters measured herein.  
Finally, in the muscle excessive muscle TG levels were not altered with P. balsamifera or 
salicortin treatment. However, the crude plant extract did seem to increase PPAR!, which can 
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lead to increased fatty acid oxidation, potentially favoring increased muscle sensitivity to insulin. 
This was supported by P. balsamifera at 125 mg/kg increasing Glut4 expression and 
MAPK44/42 phosphorylation, and salicortin activating only the latter of the two pathways, 
highlighting once more their different biological activities.  
In summary, analysis of key insulin responsive organs, such as liver, adipose tissue and 
skeletal muscle, uncovered potential lead mechanisms that are involved in glucose and lipid 
metabolism, and which were activated by balsam poplar and salicortin. In general, P. balsamifera 
at 125 mg/kg was more efficient overall in improving parameters associated to obesity and 
insulin resistance. In addition it was the only treatment condition that decreased food intake. Such 
counterintuitive dose-response relationships are not uncommon with polymolecular drug mixture, 
as is the case with the crude extract. Synergistic and antagonistic interactions occur between the 
phytochemical components, yielding conflicting response profiles, which is supported by 
aforementioned differences in biological activities between the plant extract and the active 
principle. It is therefore conceivable that there are other components in the crude extract that 
complement salicortin’s activity. It is to note, that despite the active principle improving 
physiological (body and organ weights) or systemic parameters associated with obesity or insulin 
resistance, its effectiveness waned with time. This limits the use of the active principle at this 
dosage, and may have even contributed to masking effects on protein components responsible for 
glucose or lipid metabolism in insulin-responsive tissues.  
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Figure 51: Schematic representation of the effects of P. balsamifera and salicortin in the 
treatment protocol (article 2/chapter 3). In this figure the symbols used represent: 
a 
the dose of 
125 mg/kg is significantly different as compared to DIO controls (see appropriate section for 
details on statistical analysis); 
b
 the dose of 250 mg/kg is significantly different as compared to 
DIO controls (see appropriate section for details on statistical analysis); 
ab
 both the 125 and 250 
mg/kg doses are significantly different as opposed to DIO controls (see appropriate section for 
details on statistical analysis). 
abc
 balsam poplar at 125 and 250 mg/kg, as well as salicortin are 
significantly different when compared to their respective DIO controls. 
c
 salicortin is 
significantly different as compared to DIO controls (see appropriate section for details on 
statistical analysis). The numbers indicated in the parentheses represent the doses at which 
balsam poplar showed a strong tendency to alter the parameter in question. No symbol next to the 
stated parameters indicates that the effect produced by the plant extract or the active principle did 
not reach statistical significance.  
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5.4 Summary of article 3 (chapter 4) 
L. laricina was not only of interest by reason of its strong antidiabetic and antiobesity 
potential, but also because it is widely used and preferred by the CEI Elders and healers. In vitro 
data revealed that L. laricina increased glucose uptake in skeletal C2C12 myotubes, and 3T3-L1 
adipocytes, potentiated adipogenesis, activated AMPK, and acted as a mitochondrial uncoupler 
(Spoor et al. 2006; Martineau et al. 2010). Both these tissues account for 85% of postprandial 
glucose disposal (DeFronzo 2004). In vivo data confirmed that L. laricina effectively modulated 
insulin resistance parameters, such as glycemia, insulinemia, and leptin/adiponectin ratio, 
showing strong tendencies in the prevention study and reaching significant proportions in the 
treatment protocol, especially at its highest dose of 250 mg/kg. This could suggest that L. laricina 
exerts its anti-hyperglycemic effect better when disease processes are more pronounced, 
explaining in part the difference in effect between the prevention and treatment study.  
L. laricina did not alter muscle or hepatic TG levels neither in the prevention or treatment 
protocols. Ectopic fat storage is an important factor in insulin resistance leading to impaired 
insulin receptor function or signaling in the liver and muscle, as well increased hepatic glucose 
output. However, other systemic factors are involved such as those released from visceral adipose 
tissue, for example adipokines, free fatty acids, pro-inflammatory cytokines  (TNF-, IL-1, IL-6, 
resistin, etc.)(Buettner et al. 2004). The lack of effect on hepatic or muscle TG needs to be 
evaluated in more detail, but can be explained by continuous administration of HFD in plant-
treated animals, which could make elimination of steatosis more difficult.  Another possibility is 
that oxidative pathways are being saturated with FA mobilized from adipose tissue (decrease in 
adipose tissue weight and probable hormone-sensitive lipase (HSL) activity), hindering in the 
process any decrease in tissue TG stores.  
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It is believed by reason of the data obtained at a molecular level in C2C12 myotubes 
(Martineau et al. 2010), and H4IIE hepatic cell lines (Nachar 2011), that L. laricina exerts its 
beneficial effects on glucose and lipid metabolism regulation through AMPK activation, and 
inhibition of enzymes involved in hepatic gluconeogenesis, for example glucose-6-phosphatase, 
GSK-3!, promoting regulation of glycogen formation such as glycogen synthase (Nachar 2011). 
Activators of AMPK include adiponectin and metabolic stress induced by disruption of the 
mitochondrial energy transduction. Mice on a HFD have a decreased mitochondrial respiratory 
control ratio state 3/4 (as was observed in the treatment protocol), and this may be due to the fact 
that an increase in dietary fat creates alterations in mitochondrial function. State 3 represents the 
rate of oxygen consumption during oxidative phosphorylation. It is controlled mainly by activity 
of ATP turnover (adenine nucleotide translocate, ATP synthase, etc.), and substrate oxidation 
(substrate uptake, processing enzymes, electron transport chain, etc.). State 4 represents the basal 
rate of oxygen consumption, and is influenced by proton leak and any ATPases (recycle ATP into 
ADP). A change in any aspect implicated in controlling state 3 or 4 leads to a change in 
respiratory control ratio (RCR). This implies that RCR is a useful measure of mitochondrial 
function: a high RCR indicates good function, while a decrease/low RCR is indicative of 
dysfunction (Brand and Nicholls 2011). Therefore, a combination of an increase in high fatty acid 
supply, as seen with HFD administration, an increase in the proton gradient (which slows-down 
electron transport chain), and a decrease in oxidative capacity, all lead to increased ROS 
production and peroxidation of FA, which amount to mitochondrial damage (Hesselink 2007; 
Crescenzo et al. 2011). Uncoupling agents alleviate mitochondrial stress induced by a HFD by 
decreasing proton gradient (through the flip/flop mechanism described in section 1.6.3), FA 
peroxidation, ROS production (the flip/flop mechanism allows for export of formed peroxides or 
fatty acid anions before they become peroxidized), and increasing fatty acid oxidation (Hamilton 
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and Kamp 1999; Schrauwen and Hesselink 2004; Hesselink 2007; Crescenzo et al. 2011). L. 
laricina in the treatment protocol showed tendencies of improvement in mitochondrial capacity 
and ATP production, reaching levels comparable to those observed in animals fed a standard 
Chow diet. In previous in vitro screening studies, the uncoupling effect of L. laricina was 
reported to be short lived, followed by a prolonged activation of AMPK and an overshoot 
phenomenon, which restores energy homeostasis and increases ATP production through 
increased carbohydrate and lipid metabolism. AMPK activation has additional benefits, such as 
protecting mitochondria from further damage by potentiating mitochondrial biogenesis. 
Uncoupling usually leads to increased heat production, due to increased energy expenditure. This 
was observed among animals in the prevention protocol as an indirect measure of uncoupling. 
L. laricina also had an impact on body weight in both studies, producing significant 
effects when looking at continuous measures, and this occurred while animals were on an 
uninterrupted hypercaloric-fat-laden diet, without altering energy intake. 
Retroperitoneal/abdominal fat pad weight was decreased as well with plant extract 
administration, altering adipokine secretion (adiponectin and leptin), therefore improving insulin 
sensitivity. The impact of L. laricina on body weight parameters can be an indirect consequence 
of its antidiabetic activity, such as occurs with use of the commonly prescribed antidiabetic 
medication Metformin. 
 
  
  
256
 
Figure 52: Schematic representation of the effects of L. laricina in the prevention and treatment 
protocol (article 3/chapter 4). In this figure the symbols used represent: 
a 
the dose of 125 mg/kg is 
significantly different as compared to DIO controls (see appropriate section for details on 
statistical analysis); 
b
 the dose of 250 mg/kg is significantly different as compared to DIO 
controls (see appropriate section for details on statistical analysis); 
ab
 both the 125 and 250 mg/kg 
doses are significantly different as opposed to DIO controls (see appropriate section for details on 
statistical analysis). The numbers indicated in the parentheses represent the doses at which 
tamarack showed a strong tendency to alter the parameter in question. No symbol next to the 
stated parameters indicates that the effect produced by the plant extract did not reach statistical 
significance.  
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5.5 Pespectives 
5.5.1 Perspectives article 1 
Many effectors, in addition to the ones evaluated in this article, may be involved in 
regulating adipogenesis, adiponectin expression, as well as fatty acid synthesis and oxidation in 
both the liver and muscle.  
In this article, balsam poplar showed a tendency to decrease PPAR! levels, explaining in 
part downregulation of adipogenesis and a decrease in retroperitoneal fat pad weight. Other 
effectors involved in regulating adipogenesis include cyclooxygenase-2 (COX2), which plays an 
important role in early adipocyte differentiation (i.e. inhibition of COX2 attenuates adipocyte 
differentiation) (Fajas et al. 2003; Yan et al. 2003). Matrix metalloproteinase 2 and 9 (MMP-2 
and MMP-9), two key enzymes involved in modulation of extracellular matrix (ECM), regulate 
adipose tissue remodeling which occurs with obesity (hypertrophy, hyperplasia, 
angiogenesis)(Bouloumie et al. 2001). The timely regulated expression p38 MAPk is also crucial, 
since its activity is high during initial stage of differentiation but decreases as fibroblasts undergo 
terminal differentiation into adipocytes (Engelman et al. 1999). AMPK stimulation is also 
implicated in adipocyte maturation by inhibiting cell proliferation (Hwang et al. 2005). SREBP-
1c enhances adipose tissue conversion by inducing PPAR! expression (Feve 2005). Further 
studies are required to determine the implication of each one of the aforementioned effectors. 
Although it is counterintuitive that decreased PPAR!  expression is associated with 
increased adiponectin levels, it is to note that, once again, it is not the only transcription factor 
that regulates expression of adiponectin, these include C/EBP", C/EBP#, FOXO1, SIRT1, etc 
(Swarbrick and Havel 2008). We can hypothesize that since balsam poplar produced slight yet 
significant decrease in food intake, this effect might mimic a certain level of caloric restriction 
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with an effect on SIRT1 that could have increased adiponectin expression. Indeed SIRT1 
decreases PPAR! expression, and deacetylates FOXO1, which enhances the interaction between 
FOXO1 and CEBP", as well as that of these two transcription factors with the adiponectin 
promoter. This results in increased transcription of adiponectin gene in adipocytes (Liang et al. 
2009). !his hypothesis is purely speculative and requires further study. 
Balsam poplar decreased hepatic and muscle TGs, reaching significance only in the latter. 
This therefore warrants further investigation into the pathways involved in fatty acid synthesis 
and oxidation in both these organs, such as FAS, SREBP-1c, AMPK and ACC, CPT-1, and 
PPAR" in the muscle, just to name a few.  
 
5.5.2 Perspectives article 2 
Based on the data presented within this article, P. balsamifera and its active salicortin 
modulate the ERK pathway, which is involved in cellular proliferation and differentiation as well 
as insulin sensitivity. This pathway has also been reported to play an important role in 
adipogenesis and the development of NAFLD. Depending on the stimuli, the ERK pathway in the 
adipose tissue can either have proliferative or differentiating effect. It has been reported that 
activators such as insulin favor adipogenesis through increased MAPk activation (Aubert et al. 
1999); this was observed with the control animals fed a HFD that were also considered 
hyperinsulinemic. The early versus late phases of differentiation can also impact ERK 
phosphorylation: increased during early stage of adipocyte maturation allowing for proliferation 
and inhibiting adipogenesis (decreased PPAR! levels); decreased in late phase allowing for 
adipocyte differentiation and adipogenesis (increased PPAR! levels)(Aubert et al. 1999). In the 
treatment protocol, balsam poplar and the active principle decreased phosphorylated ERK levels, 
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hinting towards stimulation of adipogenesis, correlating with slight tendency to increase PPAR! 
levels. These findings coincide with previous in vitro data. P. balsamifera added during early 
phase (comparable to prevention protocol) of 3T3-L1 adipocyte differentiation inhibits 
adipogenesis (corresponding in vivo to increased ERK levels and decreased PPAR!). However, 
when balsam poplar was added in the late phase (comparable to treatment protocol) it partially 
inhibits adipogenesis in the 3T3-L1 cell line, giving rise to adipocytes with normal morphology 
and to a small extent visible lipid droplets (corresponding in vivo to decreased ERK and increased 
PPAR!). This reasoning can possibly explain the lack of significance in retroperitoneal fat pad 
weight observed in the treatment protocol. Nevertheless, lipid metabolism in the adipose tissue 
may be regulated by other pathways that may be of interest for future studies: TG esterification 
(ex. glycerol-3-phosphate acyltransferase/GPAT), lipolysis (hormone-sensitive lipase or 
lipoprotein lipase), TG secretion from the adipose tissue, other effectors involved in adipogenesis 
such as COX-2, C/EBP" or # or $. 
P. balsamifera and salicortin alter body weight, adipose tissue weight, adipokine 
secretion, glycemia and insulinemia levels, decrease hepatic TG, and improve glucose and lipid 
metabolism by modulating intracellular pathways in key insulin-sensitive tissues such as muscle, 
liver and adipose tissue (mostly insulin/Akt dependent pathways and their downstream effectors). 
It is to note that there was more difficulty in identifying a specific mechanism of action 
with salicortin as opposed to balsam poplar. This may be attributed to the apparent time-course 
dependent tolerance present at the dosage used. Further dose searching experiments are required. 
They will aid in determining if this apparent time-dependent change in activity develops with any 
dosage of salicortin, and if so with what time course. This approach will aid in unmasking the 
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outcome of the active principle on protein components responsible for the observed beneficial 
effects. 
P. balsamifera improved insulin sensitivity by activating the Akt pathway in the liver and 
in the adipose tissue (regulating glucose uptake, lipogenesis, and inhibiting lipolysis). Hepatic 
Akt activation leads to inhibition of glucose production and favors glycogen formation. In vitro 
screening studies on hepatic H4IIE cell lines indicate that P. balsamifera activated the Akt 
pathway and inhibited glucose-6-phosphatase (Nachar 2011). Future studies on in vivo livers are 
required to evaluate the effect of P. balsamifera and salicortin on effectors involved in hepatic 
glucose production (such as G-6-Pase, PEPCK, fructose-1,6-biphosphatase) and glycogen 
formation (such as GSK-3). Lipid oxidation pathways, such as PPAR! and CPT-1, seemed to be 
activated by either the plant extract or the active principle. However other pathways may be 
involved in regulating lipid metabolism and would be of interest in future studies. Such examples 
include hepatic lipid export (incorporation in lipoproteins such as VLDL)(Begriche et al. 2006), 
lipid mobilization in the adipose tissue (lipogenesis, lipolysis, lipoprotein lipase, lipid oxidation), 
and fat absorption in the intestine (transported by chylomicrons to liver), as well as measuring 
lipid fecal content.  
Finally, animal segregation into high and low responders reduced sample size, limiting 
interpretation of the results. In the future, increasing initial sample size prior to segregation may 
resolve this issue.  
 
5.5.3 Perspectives Article 3 
The exact mechanism of action for L. laricina remains to be identified, but results point 
towards possible activation of AMPK and downstream effectors (need to be investigated in future 
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in vivo studies). The beneficial effects of L. laricina can also be attributed to its ability at 
increasing mitochondria uncoupling, which is associated with heat production (need to evaluate 
UCPs expression in liver, muscle, BAT) and stimulation of the AMPK pathway.  
L. laricina improved diabetes and obesity parameters in both the prevention and treatment 
protocols, while decreasing abdominal adipose tissue weight. In vitro data suggesting that L. 
laricina is a PPAR! agonist requires confirmation with a specific gene-reporter assay. PPAR! 
agonists such as rosiglitazone increase adipogenesis and intracellular triglyceride accumulation.  
They are also associated with an improvement in insulin sensitivity, increasing adiponectin levels 
(as observed in these studies) and activating AMPK pathways that influence downstream 
effectors involved in glucose (inhibiting hepatic glucose production) or lipid metabolism 
(increasing fatty acid oxidation). PPAR! agonists are usually associated with increased body 
weight and adiposity, while improving insulin sensitivity by shifting triglyceride accumulation 
from insulin-sensitive tissues, such as the liver and muscle, to fat tissue depots, mostly 
subcutaneous fat tissue (Larsen et al. 2003).  In our studies, there was no observed increase in 
abdominal adipose tissue weight, or body weight (subcutaneous tissue not measured). This may 
suggest that instead of L. laricina acting as a pure PPAR! agonist, it may have dual 
PPAR!/PPAR" properties. In other words, it increases lipid uptake while concomitantly 
increasing fatty acid oxidation (reports of PPAR" expression in white adipose tissue). However 
this hypothesis remains to be investigated (Ferreira et al. 2006; Walker et al. 2007; Laurent et al. 
2009).  
In addition to these, other pathways involved in the regulation of glucose (insulin 
pathway, glucose transporters, glucose production and glycogen storage, etc.) and lipid 
metabolism (FAS, SREBP1-c, CPT-1, PPAR", PPAR!, lipolysis, lipogenesis, lipid absorption, 
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lipoproteins, etc.) need to be evaluated in all insulin-sensitive tissues (liver, muscle, adipose 
tissue). For instance, in vitro studies on hepatic H4IIE cell lines have indicated that L. laricina 
inhibits hepatic glucose production while promoting glycogen storage. The effectors involved in 
hepatic glucose production (such as G-6-Pase, PEPCK, fructose-1,6-biphosphatase) and glycogen 
formation (such as GSK-3) require further investigation in an in vivo context. One of these 
pathways may be responsible for the improvement in glucose metabolism observed in animals 
treated with L. laricina. 
 
5.5.4 General perspectives  
It is of the outmost importance to control both weight gain and glycemia levels, since both 
lead to devastating complications that contribute to the morbidity and mortality associated with 
obesity and T2D. Obesity, especially visceral, leads to low-grade inflammation, releasing into 
circulation pro-inflammatory cytokines that contribute to the development of insulin resistance 
and diabetes. Therefore it would be of interest to evaluate the effect of the plant extracts and the 
active principle on these parameters (TNF-!, IL-1", IL-6, resistin, C-reactive protein, and so on). 
Obesity also leads to hepatic steatosis (NAFLD and NASH), dyslipidemia, insulin resistance and 
diabetes. It increases the risk of cerebrovascular (stroke), cardiovascular (hypertension, atrial 
fibrillation, etc.), respiratory (obstructive sleep apnea, asthma, etc.) diseases, as well as 
gastrointestinal disorders (reflux, hepatobiliary disease, etc.). In addition, there are higher rates of 
kidney disease and osteoarthritis, as well as anesthetic and surgical complications (Malnick and 
Knobler 2006). Uncontrolled glycemia levels, whether hyperglycemic or hypoglycemic, can lead 
to sometimes severe adverse effects. Hypoglycemia may cause lethargy, impaired mental 
functioning, irritability, shaking, weakness, loss of consciousness, and may even lead to brain 
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damage (de Courten-Myers et al. 2000; NIDDK 2008a; NIDDK 2008b). Conversely,  
hyperglycemia can lead to microvascular complications such as neuropathy, nephropathy, 
retinopathy and macrovascular complications, such as myocardial infarction and stroke.  
Previous in vitro screening studies conducted by our team, evaluated the potential of 
plants to protect against glucose toxicity and deprivation in PC12-AC pre-neuronal cells 
(neuropathy), as well as their anti-oxidant potential (since ROS leads to cellular damage and 
contributes to complications associated to T2D). P. balsamifera was among the plants that 
protected pre-neuronal cells (PC12-AC) against glucose toxicity. Therefore, it is of interest to 
evaluate in the same animal model used in this thesis, the potential of P. balsamifera and its 
active salicortin, as well as L. laricina at minimizing complications associated to obesity and 
diabetes. This could be achieved by looking more closely at their anti-oxidant potential and their 
ability to protect against the development of nephropathy and neuropathy. Their anti-oxidant 
potential can be evaluated by looking at malondialdehyde (MDA) levels (marker of oxidative 
stress), or anti-oxidant enzymes such as catalase, superoxide dismutase (SOD), glutathione 
reductase or glutathione peroxidase, or anti-oxidant molecules such as glutathione levels (GSH), 
uric acid, bilirubine (Yeum et al. 2004; Valko et al. 2007; Weydert and Cullen 2009). Evaluating 
glomerular histopathology, as well as the albumine/creatinine ratio in urine (Soler 2012), will 
give insight on the potential of the plant extracts or the active principle to decrease nephropathy. 
Measuring sorbitol pathway intermediates, conducting physiological and behavioral tests, such as 
tactile or thermal algesia response, as well as sensory and motor nerve conduction velocity, lipid 
peroxidation products and lipidomics will help determine the efficacy of the plant extracts or the 
active principle at improving neuropathy. It is to note, that lipidomics is the study of all lipids 
present in a specific cell type, for example dorsal root ganglions, and their implication in disease 
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development and prediction, such as peripheral neuropathy (Obrosova et al. 2004; Watson 2006; 
Obrosova et al. 2007). One of our collaborators has been looking at the lipidomics profile, more 
specifically glycerophospholipids such as platelet activating factors (PAF) and 
lysophosphatidylcholines (LPC), of dorsal root ganglions collected from the mice used in this 
thesis. PAFs and LPCs are potent inflammatory lipids associated with diabetic retinopathy and 
neurodegeneration (Smith et al. 2008; Cheng et al. 2009; Kennedy et al. 2011). They have been 
looking at the potential of balsam poplar, salicortin, and tamarack in decreasing these 
inflammatory mediators as compared to their HFD controls, and therefore at their likelihood in 
preventing or reducing peripheral neuropathy.  
 
5.6 Limitations 
Although both plant species and the active principle yielded very promising results in 
both the prevention and treatment protocols in terms of antiobesity and antidiabetic agents, there 
are certain limitations that exist in terms of data interpretation. For instance, assays usually 
utilized to further confirm the antidiabetic potential of any agent, such as oral-glucose tolerance 
test (OGTT) or intra-peritoneal insulin tolerance test (ITT) were not performed in the studies that 
compose this thesis. Both OGTT and ITT require fasting the animals. Since the plant extracts or 
active principle were incorporated into the HFD, dietary interruption would result in 
concomitantly removing the treatment. Moreover, the mouse model used is primarily an obesity 
model resulting in T2D. Thus fasting the animals can result in a disruption of the metabolic 
alterations of the model, creating false positives when looking at overall weight gain and food 
intake.  
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Throughout the course of these studies, we discovered that the longer the animals were 
being administered a HFD, i.e. those in the treatment protocol, the more variability existed 
amongst them. This was confirmed in the studies of Peyot and collaborators (Peyot et al. 2010), 
which stated that pooling animals with different characteristics, such as low weight gain, weak IR 
and near-normal glycemia, with animals with high weight gain, frank IR, and hyperglycemia, can 
yield misleading results. Therefore in order to correct for this variability, animals administered a 
HFD were stratified into two groups according to the effect of the high-fat diet on body weight: 
low responders (LR) and high responders (HR). This stratification was based on body weight 
after 8 weeks of administration of a HFD, and allowed for analysis and comparison of the effect 
of P. balsamifera, salicortin, and L. laricina on mice fed a HFD (treatment protocol), in response 
to varying levels of obesity and insulin resistance. LR mice exhibited a much more normal 
metabolic profile. Treatment with the plant extracts or the active principle essentially had little if 
any effect. This confirms the validity of the segregation. However this decreased by half our 
number of animals per group, compromising the statistical power of many of the assays. This can 
be corrected in the future by starting off with twice the amount of animals.  
In order to simulate the traditional CEI preparations of the plant extracts, prepared mostly 
as infusions, the ethanolic plant extracts used in this thesis were compared to their aqueous 
extracts. The data pertaining to this study was not presented within the thesis. However it is 
important to mention that the effects produced by the aqueous extracts of P. balsamifera on 
physiological and systemic parameters associated to obesity and diabetes were similar to its 
ethanolic extract, but of lesser magnitude (approximately ! of the effect observed with its 
ethanolic counterpart). Solvents such as ethanol are able to extract more phenolic phytochemical 
compounds than water for example. It is these compounds that have been associated with 
beneficial effects against a wide range of diseases, including obesity, diabetes, cardiovascular 
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disease, and cancer (King and Young 1999; Dai and Mumper 2010). At this time, we cannot 
conclude that the traditional method of preparation and usage is not efficient. Firstly, the dosage 
used for the aqueous extracts was identical to the ethanolic one and, as mentioned, phenolic 
compounds are less concentrated in water extracts. Secondly, the traditional method of 
preparation remains confidential but boiling times and temperatures have been shown to be 
crucial in preparations since they can affect the amount of phenolics that are extracted with water 
(Dai and Mumper 2010). Further studies are required in order to properly evaluate the potential 
of water extracts at preventing or treating obesity, and to identify their signaling pathways, by 
using higher doses and by preparing water extracts that more closely resemble traditional 
preparations.   
Although basic in vitro screening studies were carried out on some of the mechanisms of 
action of P. balsamifera and L. laricina, more detailed analysis of the effects of these plant 
extracts and the active salicortin on pathways involved in glucose and lipid metabolism need to 
be conducted. The best and most cost-efficient approach would be to screen these pathways in 
vitro, since it will help orient the experiments in an in vivo context. Furthermore, it would be 
pertinent to identify the active components of L. laricina through in vitro bioassay guided 
fractionation in the adipogenesis and glucose uptake assays. Thereafter, an evaluation of the 
active principles’ potential as an antiobesity and antidiabetic agent in an in vivo context would be 
of great importance. Such studies are currently underway within our research team. Identification 
of an active principle is crucial, being a marker of quality control, as such allowing to correlate 
the temporal and geographical variations in traditional preparations with variations in 
phytochemical profile (and even biological activity in bioassays), thus paving the way to more 
uniform efficacy.  
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One of the limitations of natural product research is that information is scant or simply 
lacks as pertains to the stability, solubility, absorption, metabolism, as well as mechanism and 
duration of action of the plant extracts. There is a wide range of components found within each 
plant extract, each acting on various targets. This can lead to complications when trying to 
identify signaling pathways implicated in the observed effects of the plant species.  
It remains that the best prevention or even treatment for obesity and diabetes is diet and 
exercise. However when these prove to be insufficient, bariatric surgery and medications are 
available to treat either one of these diseases (Figure 53).  
 
Figure 53: Examples of complications associated with adult obesity and to what degree bariatric 
surgery improves them (taken from: http://www.hippocrateon.com/index.php?pageid=59). 
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5.7 General knowledge on natural products identified as antidiabetic 
and antiobesity agents, their mechanisms of action, and how P. 
balsamifera, salicortin, and L. laricina compare to them 
As reported, the use of complementary or alternative medicine to respond to one’s 
primary health care needs has been growing in popularity on a worldwide scale (Tilburt and 
Kaptchuk 2008). As stated, the CEI have a low compliance to modern therapies, wherefrom the 
need to identify and validate alternative and more culturally acceptable treatments stemming 
from their own traditional pharmacopoeia. This will help them prevent (predisposition due to 
genetics and lifestyle) or even treat (high incidence of already existing cases) both obesity and 
T2D. In addition, the high costs and undesirable, sometimes hazardous side-effects, observed 
with obesity and diabetes treatments has prompted research in the field of natural products, in 
order to develop and identify treatments, to be used as substitutes or alone, for both these 
diseases.  
These natural products, whether they are under the form of crude extracts or isolated 
compounds, can be arranged into different categories based on their antidiabetic or antiobesity 
effects.  
5.7.1 Natural products as antidiabetic agents 
Targets for antidiabetic medications include stimulating insulin secretion, increasing 
insulin sensitization (i.e. increasing glucose uptake, decreasing hepatic glucose production, and 
improving circulating TG by promoting adipogenesis), inhibiting intestinal carbohydrate 
digestion and absorption, and mimicking incretin-based therapies (incretin mimetics and DPPIV 
inhibitors). More specifically, there is evidence that a variety of plants possess antidiabetic 
properties by inhibiting hepatic glucose production through normalization of glucose-6-
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phosphatase activity. Examples are Momordica charantia (Singh et al. 1989; Shibib et al. 1993), 
Allium sativum (garlic) and Allium cepa (onion)(Sheela et al. 1995). Others such as Gymnema 
sylvestre, Momordica charantia, Nigella sativa have been shown to inhibit glucose absorption in 
the small intestine (Matsuda et al. 1999; Persaud et al. 1999; Meddah et al. 2009). There have 
also been some plants that have been associated with enhancing insulin signaling or secretion, 
such as Cinnamomum zeylanicum (cinnamon) (Kahn 2003), Nigella sativa (Benhaddou-
Andaloussi 2008), Aloe vera (Ajabnoor 1990), and Trigonella foenum graecum (also known as 
fenugreek) (Vats et al. 2003).  
5.7.2 Natural products as antiobesity agents 
Concerning plant extracts with antiobesity potential, they can be separated into 5 
categories depending on their site of action: lipid absorption, energy intake, energy expenditure, 
pre-adipocyte proliferation and differentiation, lipogenesis and lipolysis.  
5.7.2.1 Natural products as antiobesity agents acting on lipid absorption 
Natural products that act on pancreatic lipase, inhibit this key enzyme. The latter is 
implicated in TG absorption by hydrolyzing TG into monoglycerides (MG) and fatty acids. 
Inhibition of pancreatic lipase leads to decreased fat absorption and possibly increased fat 
excretion in stool, as observed with the antiobesity medication Orlistat. Some examples of plants 
inhibiting pancreatic lipase include Panax japonicus, Juniper communis, Trigonella foenum 
graecum (Yun 2010).  
The effects of P. balsamifera, salicortin, and L. laricina on inhibiting pancreatic lipase 
remain to be determined. Such an action would help explain, in part, the improvement in body 
weight and insulin sensitivity. An attempt was made to answer this hypothesis by collecting a 
sample of feces over a period of a week from mice of both the prevention and treatment protocols 
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and analyzing them in a bomb calorimetry assay (looking at differential energy release). However 
this assay was inconclusive due to unknown daily fecal matter excreted. This can be corrected by 
using metabolic chambers to measure total daily fecal excretion per mouse in future assays, 
allowing for proper analysis and conclusions.  
5.7.2.2 Natural products as antiobesity agents acting on energy intake 
Body weight regulation through appetite control is multifactorial, involving neurological 
and hormonal interrelationships. These take into account the physiological and psychological 
experience and behavioral expression of appetite, metabolism and peripheral physiology, and the 
central nervous system (CNS) neural pathway’s functioning (Yun 2010). Neurotransmitters such 
as serotonin, histamine, and dopamine, along with their receptors, are associated with satiety 
regulation, and represent potential targets for drugs geared towards reducing energy intake. 
Appetite suppressants usually affect hunger control centers in the brain, creating a sense of 
fullness. However this decrease in food intake can lead to increased ghrelin, which stimulates 
appetite (Yun 2010). Therefore, in the quest to find antiobesity treatments, it may be of interest to 
look at products that blunt this response, i.e. ghrelin antagonism, as well as those acting as 
melanin-concentrating hormone (MCH; orexigenic hypothalamic peptide) receptor antagonists 
(Yun 2010). A few examples of natural products acting as appetite suppressants include, Hoodia 
gordonii, a leafless spiny succulent plant from South African countries. It increases ATP content 
in hypothalamic neurons, decreasing AMPK activity and increasing malonyl-CoA. This signals 
the anorexigenic/orexigenic neuropeptide system to suppress food intake.  
Based on this information, the effect of P. balsamifera on satiety needs to be looked at in 
more detail. One hypothesis may be that it inhibits AMPK in the brain, leading to decreased food 
intake (proposed reason for anorexic effect of metformin). It could also act centrally in the 
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arcuate nucleus of the hypothalamus, ex. neuropeptide Y and agouti-related peptide (orexigenic), 
which regulate melanocortin system responsible for feeding behavior.  
Other targets for appetite control and modulating eating behavior include increasing the 
release of 5-hydroxytryptamine and serotonin. This was observed with hydroxycitric acid 
prepared from Garcinia cambogia. Alternatively, treatment can amplify signaling in the basal 
hypothalamus’ energy-sensing function, as occurs with the Korean red ginseng. Supplementing 
the diet with certain dietary fats, such as conjugated linoleic acid, lauric acid, and salatrim can 
also suppress energy intake, by slowing down gastric emptying and modulating gastrointestinal 
hormone secretion (Yun 2010).  
5.7.2.3 Natural products as antiobesity agents acting on energy expenditure 
Obesity results when there is an imbalance between energy intake and energy 
expenditure. Energy expenditure encompasses physical activity, obligatory energy expenditure, 
and adaptive thermogenesis. In that context, cellular targets for antiobesity (even for antidiabetic) 
medications include the mitochondria. For example, metformin and thiazolidinediones are said to 
inhibit complex I of the electron transport chain, activating AMPK in the process and leading to 
increased glucose and lipid metabolism, as well as energy expenditure.   
Several of the plant species belonging to the CEI traditional pharmacopoeia have been 
found to interfere with the normal functioning of mitochondrial respiration. Among them is L. 
laricina, which was identified as a mitochondrial uncoupler in vitro and confirmed in an in vivo 
context in this thesis, by measuring mitochondrial respiratory control ratio and heat expenditure 
(surface skin temperature). Its ability to activate the AMPK pathway, as observed in vitro, 
remains to be determined in an in vivo context.  
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Concerning P. balsamifera, it also exhibits increased heat expenditure, which correlated 
with an increase in UCP-1 expression in brown adipose tissue (associated with non-shivering 
thermogenesis). However there are non-pleasant side effects that have been associated with 
mitochondrial uncoupling agents, such as increased sweating, cataracts, and fatal hyperthermia.  
There are key players involved in energy expenditure as heat. These include UCP-1 found 
in brown adipose tissue. Another example is acquisition of BAT features, i.e. rich in 
mitochondria with increased capacity for FA oxidation, within white adipose tissue. More recent 
evidence suggests the implication of UCP-3, found in various tissues including skeletal muscle, 
in mediating thermogenesis regulated by thyroid hormone, !3-adrenergic agonists and leptin 
(induction of AMPK and skeletal muscle thermogenesis)(Solinas et al. 2004; Cline 2006; Yun 
2010; Henry et al. 2011)(Figure 54).  
 
 
Figure 54: Thyroid hormone upregulates UCP-3 activity (Lanni et al. 2003).  
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In any case, the putative hyperthermia observed in animals treated with P. balsamifera 
and L. laricina needs to be looked at more closely. It can be done by implanting microchips and 
looking at daily variations in temperature. Another possibility is by determining whether 
hyperthermia is exercise-induced by placing animals in metabolic chambers (to measure physical 
activity). It can also be hormonally induced (ex. thyroid hormone), in which case looking at their 
plasma levels is crucial. It is also important to analyze UCP (UCP-1 to 3) proteins expression in 
various tissues (liver, skeletal muscle, BAT and WAT) (Figure 55).   
 
 
Figure 55: Summary of the distribution of UCP 1 to 3, and how a proton leak leads to decrease 
ATP production and increased heat production (Fleury and Sanchis 1999).  
Natural products that cause energy expenditure through heat are useful in the treatment of 
obesity. Some examples include Pinellia ternate (Korean medicinal herb upregulating UCP1 
expression in BAT), Solanum tuberosum (increases UCP3 expression in BAT and liver), and 
naturally occurring n-3 polyunsaturated fatty acids and fucoxanthin (marine origin) (increases 
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BAT features in WAT deposits) (Yun 2010). Other compounds that have exhibited weight loss 
properties through increased energy expenditure include extracts of Pinellia ternate and Panax 
ginseng berries, caffeine, capsaicin, as well as green tea and its extracts (catechins, epicatechin 
gallate/EGC, epigallocatechin gallate/EGCG). Caffeine is reported to inhibit phosphodiesterase 
degradation of cAMP thereby increasing energy expenditure. Capsaicin upregulates 
catecholamine secretion from adrenal medulla (thermogenic properties) (Rayalam et al. 2008) 
(Figure 56). Finally, EGCG is said to stimulate thermogenesis by inhibiting the o-
methyltransferase involved in the degradation of norepinephrine (Yun 2010).  
 
Figure 56: !3-agonists and PKA upregulate UCP-1 expression and lead to thermogenesis (Lowell 
and Spiegelman 2000).  
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5.7.2.4 Natural products as antiobesity agents acting on adipose tissue (adipocyte 
proliferation and differentiation) 
Adipocytes play a central role in the maintenance of lipid homeostasis and energy 
balance. They do so by storing TG or releasing FA in response to changing energy demands. 
Adipose tissue growth can occur as a result of hyperplasia (proliferation) and hypertrophy 
(differentiation). Therefore natural products that act either to inhibit pre-adipocyte proliferation, 
to increase apoptosis of maturing adipocytes, or to inhibit adipocyte differentiation are being 
investigated with regards to potential antiobesity treatments. The latter mechanism of action is 
the case of P. balsamifera and its active principle salicortin. Some examples of phytochemicals 
exhibiting the abovementioned properties include resveratrol, quercetin, genistein, EGCG, and 
capsaicin. Pathways of interest in the adipocyte include ERK (cell proliferation, differentiation, 
apoptosis), AMPK (fatty acid oxidation), and sirtuin1 (Sirt1; decreases adipogenesis by 
promoting fat mobilization and suppressing PPAR!). The inhibition of adipogenesis or adipose 
tissue expansion can nonetheless have unhealthy consequences, by increasing ectopic fat storage, 
and as such promoting the development of T2D and other metabolic diseases.  
5.7.2.5 Natural products as antiobesity agents acting on lipid metabolism 
Antiobesity treatments can also target lipid metabolism by increasing TG hydrolysis 
(adipose tissue triglyceride lipase/ATGL, HSL, monoglyceride lipase lipoprotein lipase) and the 
oxidation of those newly released FA (Langin 2006). Due to the fact that excessive lipolysis can 
result in high circulating FA levels and the development of dyslipidemia, blocking FA release 
and promoting fatty acid oxidation can be of therapeutic interest (Langin 2006; Yun 2010). Fatty 
acid oxidation can occur through AMPK and PPAR" activation, as can be seen with Panax 
ginseng and Salacia oblonga root (Yun 2010). 
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As mentioned, the AMPK pathway is also involved in improving obesity by enhancing 
the !-oxidation of FA (increasing energy expenditure). Some examples of plant extracts that 
stimulate the AMPK pathway include the majority of plant extracts from the CEI traditional 
pharmacopoeia (Eid et al. 2010a; Martineau et al. 2010), including L. laricina. Other plants 
originating from Southern Brazil, such as Ilex paraguariensis (Yun 2010), do the same.  
In addition, treatments can inhibit lipogenesis by using for example PPAR" antagonists, 
such as resveratrol and quercetin. Alternatively, they can target fat absorption through inhibition 
of pancreatic lipase, as is the case for instance with peanut shell extract (Arachis hypogaea), 
green tea, and pomegranate. Active ingredients identified in this context include ellagic acid and 
tannic acid.  
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Chapter 6: Conclusion 
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The results of this thesis confirm in an in vivo context of diet-induced obesity in C57BL/6 
mice that P. balsamifera, its active salicortin, and L. laricina possess antiobesity and antidiabetic 
activity. These plant species were evaluated in two varying degrees of the metabolic syndrome, 
what were termed as prevention (mild state) and treatment (advanced state) protocols.  
Both balsam poplar and the active principle were effective in altering obesity and diabetes 
parameters in each one of the protocols. In the prevention protocol, P. balsamifera produced an 
immediate and sustained effect on the measured parameters, effectively reducing body weight 
gain, retroperitoneal fat pad weight, liver and muscle lipid content, as well as circulating glucose, 
insulin and leptin levels. It also activated (or strong tendencies) glucose and lipid oxidation 
pathways, as well as thermoregulation. In the treatment protocol balsam poplar increased in 
effectiveness throughout the study, while salicortin’s activity waned with time. P. balsamifera 
and its active salicortin mostly improved obesity parameters, with a consequent enhancement of 
insulin sensitivity (improving glycemia, insulinemia, adipokine, and hepatic TG levels). They 
also activated (or strong tendencies) pathways involved in lipid and glucose metabolism.  
L. laricina in both protocols effectively decreased glycemia levels, improved insulin 
resistance and slightly decreased abdominal fat pad and body weights. It also increased energy 
expenditure as demonstrated by elevated skin temperature in the prevention study, and showed 
strong tendencies to improve mitochondrial function and ATP synthesis in the treatment. 
Concerning L. laricina, in the prevention study its efficiency increased with time. In the 
treatment study, L. laricina’s effect was maintained when looking at glycemia and insulinemia 
levels, but tapered off when looking at body weight. L. laricina was therefore primarily 
antidiabetic, and indirectly altered body weight parameters, similarly to the mode of action of 
Metformin (AMPK activation, mitochondrial uncoupling, indirect body weight modulation). 
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In summary, both obesity and diabetes parameters were more efficiently altered in a less 
advanced state of the metabolic syndrome. This confirms how crucial weight loss is in 
reestablishing insulin sensitivity, and improving diabetes.  
Overall the results presented within this thesis demonstrate that P. balsamifera and its 
active salicortin, as well as L. laricina represent valuable culturally adapted alternative 
therapeutic agents in attenuating the development of obesity and insulin resistance (prevention), 
or improving the established state of both these diseases (treatment). Although salicortin’s 
activity waned with time at the dose used for this treatment study, it nevertheless represents an 
important marker for quality control, ensuring safety, characterizing composition and optimizing 
antiobesity biological activity of traditional preparations of P. balsamifera. It can also serve as a 
template for the development of new therapeutic agents for the treatment of obesity and T2D. It is 
to note, that salicortin was identified as the most potent phytochemical constituent of P. 
balsamifera in inhibiting adipogenesis in 3T3-L1 cells. This however does not preclude the 
possibility of identifying, through bio-assay guided fractionation, other constituents responsible 
for additional beneficial effects. The latter include improving other aspects of obesity or T2D and 
their associated secondary complications, such as peripheral neuropathy, inflammation, oxidative 
stress, and so on. This reinforces the importance in identifying the active principle(s) of L. 
laricina, through a bioassay guided-fractionation approach in the glucose uptake and 
adipogenesis assays, and testing them in an in vivo context of diet-induced obesity. As 
mentioned, L. laricina closely resembles, in its mechanism of action, the commonly prescribed 
antidiabetic medication Metformin. Therefore identifying active principles and evaluating their 
pleiotropic effects in an in vivo context, can potentially lead to the development of new 
pharmaceutical agents with great potential at improving diabetes and body weight parameters.  
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In conclusion, P. balsamifera, salicortin, and L. laricina modulated body weight and 
insulin resistance parameters in a manner comparable to modern day pharmaceuticals used in the 
treatment and management of both obesity and diabetes. Therefore, notwithstanding the work 
still necessary (for ex. more detailed signaling pathways in insulin-sensitive tissues as reported in 
section 5.5 Perspectives), the present thesis represents a major contribution to the validation and 
understanding of the antiobesity and antidiabetic potential of P. balsamifera, salicortin, and L. 
laricina. Indeed, we have identified properties that had not yet been ascribed to these plants or 
their phytochemical constituents. These thus represent valuable alternative and culturally-adapted 
therapies stemming from the CEI traditional pharmacopoeia. They provide a strong impetus for 
their integration in culturally-adapted clinical studies among the CEI, alongside lifestyle changes 
such as healthy diet and exercise, including culturally relevant traditional foods and activities 
(fishing, hunting, trapping). 
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i 
Appendix A: Diet composition and preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
Figure 1:  
Diet composition of standard laboratory chow diet used in all experimental protocols that 
compose this thesis (sent to the authors from a representative at Charles River Labs.). 
 
 
 
 
 
 
 
 
iii 
Figure 2:  
Diet composition of high-fat diet used in all experimental protocols that compose this thesis 
(taken from: http://www.bio-serv.com/pdf/F3282_S3282.pdf). 
 
 
 
 
 
iv 
Figure 3:  
Example of the calculation used for plant extracts or active principle dosing. It is based on 
assessment of average food consumption and body weight.  
 
If for example we are administering 125 mg/kg of body weight of either balsam poplar or 
tamarack to mice weighing on average 33 g:  
 
! 
125 mg of plant extract"1000 g (1kg) of body weight
x mg of plant extract" 33 g of body weight
x = 4.125 mg  
 
In other words, 4.125 mg of plant extract needs to be ingested by the mice in order for them to be 
receiving 125 mg/kg. Since the plant extracts or the active principle are incorporated into the 
high-fat diet consumed by the mice, this implies that 4.125 mg of plant extract needs to be 
incorporated into 2.6 g of average daily food consumed by each mouse. Therefore, if we prepare 
around 230 g of food (enough for 1 week of administration to a group of 12 mice):  
 
! 
4.125 mg of plant extract" 2.6 g of average daily food consumption
x mg of plant extract" 230 g of weekly food consumption for a group of 12 mice
x = 365 mg of plant extract to incorporate in 230 g of high fat diet
 
 
It is to note that the incorporation of the plant extract or the active principle into the high fat diet 
did not alter its texture. In addition, although the preparation was made for 1 week of 
administration, it was maintained in the refrigerator (4°C) in individual containers for each dose 
and each treatment. The control high-fat diet was also kept in the refrigerator (4°C). Each one of 
these diets was periodically administered to the animals throughout the week. Body weight, food 
and water intake, as well as glycemia were measured every second day. This close monitoring of 
the animals allowed for proper assessment of dose administration, based on variations in body 
weight, and if any on food intake as well.   
